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Abstract 
 
Defects in metabolism result in various diseases, with neurodegeneration being one of the most 
prevalent consequences. Mitochondria and lysosomes are long known to be fundamental for 
cellular metabolism. In addition to being energy ‘factories’, mitochondria are key cellular 
signaling platforms, contributing to cellular stress responses like autophagy, apoptosis or cell 
proliferation. Lysosomes have evolved beyond their ‘waste management’ roles and are now 
understood to coordinate major processes such as autophagy and nutrient sensing. Although 
for many years, these organelles were seen as independent functional entities in the cell, recent 
evidence suggests the existence of functional interdependent networks between lysosomes 
and mitochondria. In this study, we elucidate mechanisms beyond autophagy of crosstalk 
between lysosomes and mitochondria, and show that lysosomal defects affect mitochondrial 
function. 
To identify mechanisms regulating lysosomal and mitochondrial crosstalk, we employed two 
distinct models of lysosomal storage disorders (LSDs): Niemann-Pick disease and Pompe’s 
disease. We evaluated the effects of chronic lysosomal malfunction in these models on 
mitochondrial fitness and function.  
We showed in patient cells of Niemann-Pick disease that impaired S1P signaling engages 
transcriptional programs, via KLF2 and ETV1, to repress mitochondrial biogenesis and 
function. In support of these findings, in silico analyses on microarray datasets of brain and 
liver samples of NPC1-/- mice confirmed the repression of mitochondrial biogenesis and the 
induction of KLF2 and ETV1. Interestingly, mechanisms of KLF2 and ETV1 downregulation, 
including siRNA-mediated silencing and enhanced S1P signaling, are sufficient to promote 
mitochondrial biogenesis in Niemann-Pick disease. These findings uncover the involvement of 
a transcriptional network in the regulation of lysosomal and mitochondrial crosstalk and the 
therapeutic potential of modulating S1P signaling in Niemann-Pick disease. 
In the acid alpha-glucosidase (GAA) knockout mouse model, a model for the human Pompe’s 
disease, we showed extensive mtDNA defects in various tissues and cells. Interestingly, loss 
of mtDNA was independent of mitochondrial biogenesis. Rather, we demonstrated that mtDNA 
depletion was dependent on reduced nucleotide bioavailability. Strikingly, mtDNA depletion 
could be reversed by enhanced nucleotide biosynthesis through folate supplementation. 
Furthermore, this study demonstrated that impaired iron homeostasis, which affected the 
activity of iron-containing proteins including respiratory chain complex IV and ribonucleotide 
Abstract 
 
2 
 
reductases among others, was culpable for reduced nucleotide bioavailability and mtDNA 
depletion. In addition, mtDNA defects were associated with induction of the innate immune 
response via TLR9-mediated signaling in GAA-/- mouse tissues, which culminates in gliosis in 
the cortex. Strikingly, iron supplementation reverses mtDNA defects in MEFs and in the cortex 
of GAA knockout mice and dampens pro-inflammatory signaling in the cortex.  
Altogether, the findings of this study demonstrate that lysosomal malfunction has detrimental 
consequences for mitochondrial fitness and function, both in vitro and in vivo, and elucidate 
novel mechanisms of lysosomal and mitochondrial interplay. In addition, this study shows that 
the mechanisms of organelle crosstalk could provide therapeutic avenues for LSDs and even 
for neurodegenerative diseases (e.g., Parkinson’s disease).
 3 
 
1 Introduction 
1.1 Evolution of the eukaryotic cell: membrane-bound organelles 
Cellular efficiency underlay the evolutionary success of eukaryotes which was based on the 
symbiotic acquisition of subcellular compartments thereby enabling essential functions in 
metabolism and signaling (Douglas, 2014). These subcellular compartments were restricted to 
the mediation of processes involved in energy production. As such, eukaryotic cells 
unequivocally became larger without compromising energy production (Figure 1A). Bacterial 
cells, on the other hand, which retained energy production machinery in the cell membrane, 
are restricted to relatively small sizes (Figure 1B) although they can attain larger cell sizes 
through a variety of adaptations (Lane and Martin, 2010; Schulz and Jørgensen, 2001). 
Furthermore, the membranes of these subcellular compartments provided platforms for several 
cellular processes while restricting different metabolic processes in separate compartments. 
 
Figure 1| Main features of eukaryotic and prokaryotic cells –A A schematic 
representation of a simple eukaryotic cell, which is bound by a cell membrane showing 
intracellular components. Phototrophic eukaryotes contain plastids, which are not indicated. B 
A hypothetical flagellated prokaryote bound by a cell wall enclosing a cell membrane and 
defined by the lack of intracellular membrane-bound compartments. (original illustration, KF 
Yambire) 
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For instance, lysosomes (or vacuoles) evolved in eukaryotes to assume most of the catabolic 
processes in the cell while mitochondria retained the energy production machinery of the cell. 
Undeniably, the acquisition of some of these organelles defined the evolution of eukaryotes, 
with the increased cellular efficiency shaping evolutionary diversification. It is unimaginable 
how specialized cells like myocytes and neurons would have been acquired without the 
dimension of lifeform ushered in by subcellular organelles. 
It is widely accepted that eukaryotes of today evolved from an ancestor that already possessed 
a mitochondrion (Müller et al., 2012), the acquisition of which underlay the important events in 
the path to evolutionary success and diversification. In addition, a widely accepted mechanism 
of how the mitochondrion was acquired is solely based on phagocytosis. This is further 
supported by evidence of the existence of basic phagocytic and endocytic machinery prior to 
the endosymbiotic acquisition of the mitochondrion (Poole et al., 2014) suggesting an ancient 
interaction between the mitochondrion and the primitive lysosome. This study, which seeks to 
characterize such crosstalk between lysosomes and mitochondria, will also deepen our 
understanding of these two subcellular compartments in the succeeding sections. 
 
1.2 Biology of the lysosome 
In the early 1950s, while characterizing the role of glucose 6-phosphatase in the mechanism 
of insulin action by tissue fractionation studies, Christian de Duve came across acid 
phosphatase-containing cytoplasmic granules which were entirely distinct from microsomal and 
mitochondrial fractions. These cytoplasmic granules, later termed lysosomes, were found to be 
rich in hydrolytic enzymes (De Duve et al., 1955). More than 50 of such acid hydrolytic enzymes 
have been discovered, making the lysosome the primary catabolic sub-compartment of the cell, 
where cellular components are broken down and recycled. These acid hydrolases are known 
to function optimally at acidic lysosomal luminal pH ranging between 4.5 and 5.0. The highly 
acidic lumen of the lysosome is maintained by the vacuolar H+ ATPase (v-ATPase), which 
pumps protons into the lumen while providing the gradient for the counter flux of other ions like 
Na+, K+, and Cl- (Forgac, 2007; Mindell, 2012).  The degradative role of the lysosome ultimately 
depends on the cargo that is delivered to it, of which multiple pathways of cargo delivery have 
been described. Endocytosis, including the primitive phagocytosis and micropinocytosis, 
deliver cargo from the extracellular space to the lysosome while the self-catabolic pathway of 
autophagy mediates the delivery of subcellular macromolecules or whole compartments 
sequestered in autophagosomes to the lysosome (Di Fiore and von Zastrow, 2014; Mizushima 
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and Komatsu, 2011). Given the essential role of lysosomes in the maintenance of metabolic 
homeostasis, it is not surprising that gene mutations that affect key lysosomal components lead 
to a heterogeneous group of heritable disorders known as lysosomal storage disorders, which 
are often associated with neurodegenerative phenotypes (Platt et al., 2012; Sambri et al., 
2017).  
 
1.3 Structure, biogenesis, and function of the lysosome 
1.3.1 Structure of the lysosome 
Lysosomes are membrane-bound compartments of the eukaryotic cell, which contain several 
hydrolytic enzymes, thereby making them sites of intracellular digestion of macromolecules. As 
acid hydrolases, these enzymes require an acidic environment for their activation by proteolytic 
processing and for optimal activity. Although given this arrangement, lysosomal hydrolases are 
virtually inactive in the cytosol with pH of about 7.2, lysosomes are delimited by a phospholipid 
bilayer about 7–10nm thick, whose components allow for luminal acidification. Morphologically, 
lysosomes are a heterogeneous group of organelles with diverse shapes, sizes and numbers 
in a species-, cell type- and context-dependent manner. Several transmembrane proteins span 
the length of the lysosomal membrane, the most abundant of which are the lysosomal-
associated membrane protein (LAMP) 1 and LAMP2, the lysosomal integral protein, LIMP2 
and tetraspanin, CD63 (Perera and Zoncu, 2016; Saftig and Klumperman, 2009) as illustrated 
in Figure 2. These transmembrane proteins are unusually highly glycosylated on the luminal 
side, thus forming a glycocalyx, which serves to protect against self-digestion of the limiting 
lysosomal membrane. In addition to the v-ATPase which maintains the luminal pH, several 
other transmembrane proteins, although less abundant, span the entire length of the lysosomal 
membrane and mediate processes which include transport of digestive end-products such as 
amino acids, sugars, lipids and nucleotides into the cytosol, and membrane fusion (Saftig and 
Klumperman, 2009).  
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Figure 2| Structure of the lysosome – Lysosomes are membrane-bound organelles with 
several transmembrane proteins, some of which, LAMP1 and LAMP2 are indicated. The 
vATPases, which ensure luminal acidification, are also displayed. Different types of ion channels 
and nutrient exporters span the lysosomal membrane. The lumen contains hydrolases which 
degrade lysosomal cargo. (original illustration, KF Yambire) 
 
1.3.2 Lysosomal biogenesis 
Lysosomes arise from the integration of endocytic vesicles and those from the biosynthetic 
pathway of the cell through the trans-Golgi network. After budding from the plasma membrane 
and prior to reaching the lysosomes, cargo-containing endocytic vesicles pass through 
endosomal intermediates, notably, the early and late endosomes which are distinct from each 
other based on their content, morphology, pH and molecular make-up. The biosynthetic 
pathway targets newly synthesized lysosomal proteins through vesicles from the trans-Golgi 
network which eventually merge with the late endosome in a direct fashion or indirectly through 
delivery to the plasma membrane and subsequent endocytosis (Figure 3). The most well 
characterized direct pathway involves mannose 6-phosphate receptor-mediated transport of 
lysosomal hydrolases (Kornfeld and Mellman, 1989). Lysosomes are by no means just the 
terminal point of the endocytic pathway. Several trafficking routes deliver cargo to the 
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lysosome. In addition, some specialized lysosomes have the machinery to fuse with the plasma 
membrane and are thus capable of secreting undigested contents. To mediate some of these 
processes, lysosomes must traffic to merge with the cargo-containing vesicles or with the 
plasma membrane. These trafficking processes are made possible by microtubule-associated 
mobility of lysosomes. For instance, Pu et al. (2015) recently described a multi-subunit complex 
BLOC-1-related complex (BORC), which promotes movement of lysosomes to the cell 
periphery by recruiting the GTPase Arl8 to the lysosomal membrane. Arl8 then, in turn, initiates 
the coupling of lysosomes to the microtubule plus-end-directed kinesin motors. Centripetal and 
centrifugal lysosomal movements have also been described. Their respective GTPases and 
effectors were shown to be Rab7 and Rab-interacting lysosomal protein (RILP), and Arl8 and 
SKIP. These effectors respectively recruit minus-end-directed microtubule motor Dynein-
Dynactin to lysosomes for centripetal movement or plus-end-directed microtubule kinesin 
motors for centrifugal movement (Cantalupo et al., 2001; Rosa-Ferreira and Munro, 2011). 
TRPLM1 activity, which results in Ca2+ release from lysosomes, was recently reported to 
regulate lysosomal motility, positioning and tubulation while the cholesterol sensor ORPIL 
controls the association of late endosomes with motor proteins and their positioning in cells (Li 
et al., 2016; Rocha et al., 2009). Undoubtedly, these processes are more complex than 
previously envisaged. 
Beyond motility, subsequent fusion with cargo-containing vesicles and degradation of cargo, 
lysosomes are restored through lysosomal reformation mechanisms. Reactivation of mTORC1 
signaling following prolonged starvation was shown to trigger tubulation from autolysosomes 
(fused autophagosomes and lysosomes). Vesicles which matured into functional lysosomes 
budded from such tubules (Chen and Yu, 2017; Yu et al., 2010). Furthermore, a mutation in 
Spinster, a putative lysosomal permease, and sugar transporter, which ablated mTORC1 
reactivation following protracted starvation, resulted in enlarged autolysosomes, which could 
not bud proto-lysosomal tubules (Rong et al., 2011). To complete lysosomal reformation 
following autophagy, various factors have been reported to mediate scission of lysosomes from 
proto-lysosomal tubules of autolysosomes including PIP5K1A and the GTPase, dynamin 2 
(Rong et al., 2012; Schulze et al., 2013). The relevance of lysosomal reformation is further 
emphasized by the motor neuron disease, spastic paraplegia, whose gene products, Spastizin 
and Spatacsin are unable to mediate lysosomal reformation (Chang et al., 2014). 
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Figure 3| Pathways of lysosomal biogenesis – The biosynthetic pathway interacts with 
the endocytic (and autophagy) pathways during lysosomal biogenesis. Newly synthesized 
lysosomal proteins in the ER are processed and transported via the Golgi network directly to 
endocytic pathway or indirectly through secretion and subsequent endocytosis from the plasma 
membrane. Through the endocytic pathway, cargo reaches the lysosome via maturation and 
fusion events. Cargo that is sequestered by the autophagosome is delivered via autophagy to the 
lysosome, with a subsequent budding of new lysosomes from the autolysosome. (original 
illustration, KF Yambire) 
 
Lysosomal function ultimately depends on the coordinated action of several mechanisms 
including their trafficking towards cargo, integration of biosynthetic pathways of lysosomal 
proteins and endocytosis. It was thus rational to postulate the presence of a concerted program 
of regulation of lysosomal biogenesis and function. This led to the discovery, by Andrea 
Ballabio and colleagues, in 2009, of a transcriptional program, which coordinated the 
expression of lysosomal genes including those of lysosomal hydrolases and lysosomal-
associated membrane proteins (Sardiello et al., 2009). Employing a bioinformatic approach, 
these authors identified that most lysosomal genes shared a palindromic 10–base pair 
GTCACGTGAC motif in their promoters. They would later term this motif the coordinated 
lysosomal expression and regulation (CLEAR) element and find that its sequence overlaps that 
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of the E-box which is targeted by basic helix-loop-helix (bHLH) transcription factors (Sardiello 
et al., 2009).  
In addition, they described members of the microphthalmia-transcription factor E (MiT/TFE) 
subfamily to bind to the CLEAR element and demonstrated that overexpression of TFEB, a 
member of this subfamily in humans, was sufficient to drive expression of lysosomal genes and 
significantly increase the number of lysosomes per cell (Sardiello et al., 2009). Subsequently, 
it was demonstrated that, in addition to regulating lysosomal biogenesis, TFEB mediated the 
expression of autophagy genes, thereby coupling these two fundamental processes of 
lysosomal function (Palmieri et al., 2011; Settembre et al., 2011). It is noteworthy that following 
the discovery of TFEB and its role in regulating lysosomal biogenesis and function, several 
investigations focused on the other members of MiT/TFE subfamily. These studies 
demonstrated that MITF and TFE3 in particular mediated lysosomal biogenesis and function 
similar to TFEB in a context or cell type-specific manner, thus illustrating the redundancy 
between these transcription factors (Martina et al., 2014; Nezich et al., 2015; Ploper and De 
Robertis, 2015).  
Conversely, the postulation of a coordinated program of regulation of lysosomal biogenesis 
and function is certainly not restricted to transcriptional activation. Indeed, a zinc finger family 
DNA-binding protein with a SCAN and a KRAB domain, ZKSCAN3 was shown to regulate 
autophagy and lysosomal biogenesis (Chauhan et al., 2013). ZKSCAN bound to promoter 
regions of several lysosomal and autophagy-related genes; however, unlike TFEB, ZKSCAN 
repressed expression of lysosomal and autophagy genes. Consistently, silencing ZKSCAN 
resulted in an increase in the number of lysosomes as well as the induction of autophagy 
(Chauhan et al., 2013). More recently, the bromodomain-containing protein 4 (BRD4) was also 
found to negatively regulate lysosomal and autophagy functions through RNAi screening and 
transcriptome analyses. BRD4 was shown to bind to acetylated histones in the promoter 
regions of lysosomal and autophagy genes and suppress their expression. Consistently, it was 
demonstrated that nutrient deprivation via AMPK activated the histone deacetylase SIRT1 
through its dissociation from the inhibitory molecule DBC1. Histone deacetylation by SIRT1 
prompted BRD4 dissociation from the promoters of lysosomal and autophagy genes thereby 
inducing their expression (Sakamaki et al., 2017). Despite this progress, discovering more 
transcriptional networks of lysosomal-autophagic function regulation is still the subject of 
several ongoing investigations.  
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Following the striking discovery of the role of MiT/TFE factors in lysosomal-autophagic function, 
the lysosomal and signaling fields were interested in elucidating the mechanisms that controlled 
the activity of these transcription factors. In the initial report of TFEB as a regulator of lysosomal  
 
Figure 4| Transcriptional regulation of lysosomal biogenesis – A TFEB is 
phosphorylated by mTORC1 under nutrient-replete condition thereby blocking its nuclear 
translocation and activity. B Under starvation conditions, mTORC1 inactivity and calcineurin-
mediated dephosphorylation of TFEB allow its nuclear translocation and transcriptional 
activation of lysosomal and autophagy genes. (original illustration, KF Yambire) 
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biogenesis, amino acid starvation was found to promote nuclear translocation of TFEB, a 
required step for its transcriptional function (Sardiello et al., 2009). Nuclear-cytoplasmic 
relocation of TFEB was found subsequently to be under the control of mTORC1 (Martina et al., 
2012; Roczniak-Ferguson et al., 2012; Settembre et al., 2012). These studies found that 
nutrient withdrawal, which led to mTORC1 inhibition, as well as mTORC1 catalytic inhibitors, 
led to the rapid relocation of TFEB into the nucleus (Figure 4B). On the contrary, under nutrient- 
replete conditions, TFEB was phosphorylated by mTORC1 on Serine 142 and Serine 211, 
leading to its binding to 14-3-3 proteins and cytoplasmic retention (Figure 4A). This mechanism 
of regulation was found to be shared between members of the MiT/TFE family, especially MITF 
and TFE3 ((Martina et al., 2012; Roczniak-Ferguson et al., 2012). In addition, MEK/ERK and 
AKT have also been shown to regulate the nuclear-cytoplasmic translocation of MiT/TFE family 
members (Palmieri et al., 2017; Settembre et al., 2011). While the activity of these kinases 
negatively regulates TFEB by phosphorylation leading to its cytoplasmic retention, lysosomal 
calcium signaling has been shown to positively mediate TFEB activity through its 
dephosphorylation and subsequent nuclear translocation (Medina et al., 2015). Like the 
endoplasmic reticulum, the lysosomal lumen is a storage site for Ca2+. Following nutrient 
withdrawal, activation of the lysosomal TRPML1 channel releases Ca2+ into the cytosol, which 
activates calcineurin, a serine-threonine phosphatase. Calcineurin dephosphorylates TFEB 
prompting its rapid nuclear relocation. Consistent with this mechanism, calcium chelation or 
TRPML1 silencing blocked nuclear translocation of TFEB under starvation conditions (Medina 
et al., 2015). 
 
1.3.3 Lysosomal function 
1.3.3.1 Lysosomes as major cellular catabolic centers 
Although lysosomes have evolved to play other pivotal roles in metabolism such as nutrient 
sensing, serving as reservoirs of amino acids and ions, and transcriptional regulation, they 
remain the principal sites of intracellular digestion of macromolecules. Cargo destined for 
degradation is delivered to the lysosome through endocytic (including pinocytic and phagocytic) 
and autophagic pathways. These pathways terminate in the lysosome where its hydrolytic 
enzymes mediate the degradation of diverse macromolecules. 
The endocytic pathway targets extracellular cargo to the lysosome through budding of vesicles 
from the plasma membrane. The endocytic pathway is also reached by biosynthetic cargo from 
the Golgi network directly or indirectly following secretion and subsequent retrieval from the 
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plasma membrane (Figure 3). The endocytic pathway begins with the budding of coated 
vesicles of about 60 to 100nm in diameter from the plasma membrane. The vesicles undergo 
multiple rounds of interaction and fusion events with early endosomes near the plasma 
membrane resulting in the gradual remodeling and maturation of these early endosomes 
(Klumperman and Raposo, 2014). These fusion and maturation events are pivotal for the 
acquisition of functional and biological markers. One of such markers is Rab5, which has been 
shown to be necessary for the biogenesis of the endolysosomal system (Zeigerer et al., 2012). 
In this study, liver-specific silencing of Rab5 was reported to lead to a striking decrease in the 
number of early endosomes and, as a consequence, a decrease in the number of late 
endosomes, further illustrating the dynamic interplay between these endosomal subtypes 
(Zeigerer et al., 2012).  
Not all contents of early endosomes are destined for degradation given the variety of cargo that 
they receive. As such, functionally, endosomes sort cargo for degradation or recycling. 
Endosomes extend tubules which contain materials to be recycled while cargo targeted to the 
lysosomes remain in the sorting endosomal vacuole. Another characteristic distinction of the 
vacuoles is the presence of intraluminal vesicles which are absent in tubules (Saftig and 
Klumperman, 2009). These sorting endosomal vacuoles fuse with and mature into late 
endosomes while exchanging biological markers like Rab5 for Rab7 (Rink et al., 2005). Multiple 
fusion events result in an increase in the number of intraluminal vesicles in the late endosomes, 
thus giving them the characteristic appearance which is commonly referred to as multivesicular 
bodies. Late endosomes, when formed, are typically competent to fuse with the lysosome 
where the contents are either degraded or resident lysosomal proteins are retained 
(Klumperman and Raposo, 2014). 
Autophagy is a conserved and highly regulated pathway that targets intracellular cargo and 
even organelles to the lysosome for degradation. Although the concept existed for a long time, 
since the lysosomes were considered to be the ‘garbage bags’ of the cell, the mechanisms 
governing the autophagic process were not appreciated. This was probably due to the 
unavailability of technologies to study such dynamic processes in the cell. Genetic studies in 
yeast, in the early 1990s, led to the discovery of a series of autophagy-related (ATG) genes 
(Klionsky et al., 2003). Since then, the autophagy field has expanded exponentially. Most 
autophagy events are categorized into either one of three classes: macroautophagy, 
microautophagy, or chaperone-mediated autophagy (CMA) (Figures 5 and 6). Macroautophagy 
is the most broadly studied class of autophagy since it is thought to be the most predominant 
type. 
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During macroautophagy, an isolation membrane (phagophore), whose origin is still the subject 
of considerable debate and investigation, sequesters a portion of the cytoplasm into a double 
membrane-bound dynamic organelle termed the autophagosome (Mizushima and Komatsu, 
2011). After maturation of the autophagosome, it then fuses with the lysosome to become the 
autolysosome, whose contents are degraded by the lysosomal hydrolases (Figure 5). 
Autophagosomes may form amphisomes by fusing with late endosomes before finally fusing 
with the lysosome (Shen and Mizushima, 2014).  
Microautophagy and CMA, by contrast, target intracellular material to the lysosome in an 
autophagosome-independent manner (Figure 6). For instance, in microautophagy, the 
lysosome engulfs small cytoplasmic material via inward invagination of its membrane (Figure 
6A). In CMA, as illustrated in Figure 6B, proteins containing a pentapeptide motif in their amino 
acid sequence, KFERQ, are translocated across the lysosomal membrane via a multimeric 
translocation complex with LAMP2A as receptor and HSC70 as a chaperone (Kaushik and 
Cuervo, 2012). 
 
 
Figure 5| Macroautophagy pathway degrades cellular contents within lysosomes 
– During Macroautophagy, cytoplasmic portions or whole organelles are sequestered by an 
isolation membrane, which elongates and eventually encloses the cargo in an autophagosome. 
The autophagosome delivers its content via fusion with lysosome to form dynamic structures 
called autolysosomes, whose contents are degraded by lysosomal hydrolases. (original 
illustration, KF Yambire) 
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Figure 6| Microautophagy and chaperone-mediated autophagy pathways mediate 
direct lysosomal engulfment of cytoplasmic cargo – A During microautophagy, 
lysosomal membrane invagination engulfs small cytoplasmic material, which is then degraded 
by the lysosomal hydrolases. B In chaperone-mediated autophagy, pentapeptide motifs in the 
amino acid sequence of substrate proteins are recognized by Hsc70 chaperone, which targets 
these proteins to the lysosome via a multimeric translocation complex with LAMP2A as the 
receptor. (original illustration, KF Yambire) 
 
1.3.3.2 The lysosome as a signaling hub 
Lysosomes have emerged as key regulators of metabolism due to their physical and functional 
interaction with mTORC1, the master growth regulator (Laplante and Sabatini, 2012; Perera 
and Zoncu, 2016). The evolutionary success of this role stems from the primitive function of 
lysosomes as catabolic centers of the cell and hence reservoirs of nutrients. It would seem 
logical to couple the master growth regulator to the source of nutrients which drive growth 
(Chantranupong et al., 2015). Intriguingly, mTORC1 modulates mass accumulation via control 
of anabolic and catabolic processes by integrating cues from lysosomes such as nutrients and 
growth factors (Laplante and Sabatini, 2012; Ma and Blenis, 2009). This is the same signaling 
route, which is targeted during nutrient scarcity, where mTORC1 is inactivated leading to TFEB 
nuclear translocation and transcriptional activation of catabolic processes to restore nutrient 
levels (Martina et al., 2012; Roczniak-Ferguson et al., 2012; Settembre et al., 2012). Notably, 
the mechanism of mTORC1 recruitment to the lysosomal surface by amino acids is well 
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characterized (for a recent review see Perera and Zoncu, 2016). The lysosomal lumen is also 
a reservoir for Ca2+, whose signaling role as a ubiquitous second messenger is widely 
appreciated. Lysosomal Ca2+ concentration is about one thousand-fold higher than cytosolic 
Ca2+ levels (Christensen et al., 2002). The role of lysosomal calcium in calcineurin-dependent 
activation of TFEB was only recently demonstrated (Medina et al., 2015). However, it remains 
to be elucidated which other cellular processes require lysosomal calcium release. 
 
1.3.3.3 Lysosomes and the immune response pathways 
There is now ample evidence in support of the essential role of lysosomes in immune response 
pathways. Indeed, the function of various immune cell types like macrophages and microglia 
stems from the unique lysosomes they possess to degrade and inactivate pathogens. In 
addition, lysosomes are equipped with the machinery to drive the innate immune response 
(Kawai and Akira, 2010). Although the plasma membrane is the cell’s first point of contact with 
invading pathogens, these pathogens ultimately reach the lysosome via the endocytic pathway. 
Various pattern recognition receptors including TLR7 and TLR9 have been known to localize 
to the endolysosomal system following stimulation. TLR9 for example has been identified as 
the receptor for the unmethylated CpG-rich DNA motifs, which are present in bacteria and 
mitochondrial DNA (O’Neill et al., 2013; West and Shadel, 2017). Upon sensing these motifs in 
the late endosome or lysosome, TLR9 recruits its signaling molecule, myeloid differentiation 
primary-response protein 88 (MYD88). MYD88 signaling drives the transcriptional activity of 
interferon-regulatory factor 7 (IRF7) leading to the induction of type I interferon genes, which 
initiate the immune response as well as the production of cytokines (Barbalat et al., 2011). In 
addition, the lysosome plays a pivotal role in adaptive immunity through antigen presentation. 
The lysosomal and endoplasmic reticulum systems have been shown to degrade, process and 
load antigen peptides onto major histocompatibility complex (MHC) molecules which are then 
trafficked to the cell surface for presentation (Gao et al., 2017; Hsing and Rudensky, 2005). 
Although the exact relationships between altered lysosomal malunction and immune response 
induction are currently under intense investigation, there is already a substantial body of data 
that links LSDs and irregularities in the immune system (reviewed in Kawai and Akira, 2010; 
Platt et al., 2016; Rigante et al., 2017). 
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1.3.3.4 Lysosomes: regulators of iron homeostasis 
Iron is an essential trace element that is required as a functional component of many proteins, 
including the formation of heme and iron-sulfur clusters. As a cofactor in several metabolic 
processes, iron participates in oxidative phosphorylation as well as in the regulation of the 
activity of ribonucleotide reductases, which are central to nucleotide synthesis (Bourdon et al., 
2007; Guittet et al., 2001; Rouault, 2013). In addition, iron was recently found to play a crucial 
role in mitochondrial biogenesis. It was demonstrated in mouse myotubes that iron chelation 
results in a marked decrease in mitochondrial transcripts and proteins, which could be reversed 
by iron repletion (Rensvold et al., 2013). 
Given the essential role of iron as illustrated before, its bioavailability is pivotal even for cell 
survival. To this end, iron homeostasis is maintained via a tightly regulated process. The 
endolysosomal system is involved in the two main pathways that make iron available to the cell 
for metabolic and other processes. For instance, ferric iron (Fe3+) from the bloodstream is 
endocytosed when it binds to transferrin which in turn binds to transferrin receptors at the cell 
surface. The transferrin receptor-transferrin-Fe3+ complex is endocytosed via a clathrin-
mediated process. The endocytic vesicles ultimately reach the late endosome/lysosome where 
the activity of the metalloreductase STEAP3 reduces Fe3+ to ferrous iron (Fe2+). Fe2+, released 
from transferrin, is then transported by the divalent metal transporter 1 (DMT1) into the cytosol 
(Lane et al., 2015; Rouault, 2013) as illustrated in Figure 7 
Owing to the reactive and damaging nature of free iron via the Fenton reaction, excess amounts 
are sequestered by the cytosolic 24-subunit heteropolymer protein, ferritin (Kurz et al., 2008). 
Access to iron sequestered by ferritin is mediated by ferritinophagy where ferritin is targeted to 
the autophagosome via its receptor NCOA4 (Biasiotto et al., 2016; Mancias et al., 2014). 
Following autolysosome formation, ferritin is degraded and the iron is released, reduced and 
transported to the cytosol via DMT1 (Figure 7) 
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Figure 7| Maintenance of iron homeostasis – Lysosomes are central to the process of 
maintaining cellular iron homeostasis. Transferrin-dependent and –independent pathways 
deliver ferrous iron via endocytosis to the lysosome, where it is reduced and exported as free 
iron into the cytoplasm. In addition, cytoplasmic iron, which is sequestered by ferritin, is 
delivered via autophagy to the lysosome. Lysosomal hydrolases degrade ferritin and make iron 
available to the cell. (original illustration, KF Yambire) 
 
Intriguingly, the transferrin-independent and cell-type specific pathway of iron delivery via the 
Scavenger Receptor Class A Member 5 (SCARA5) protein also requires the endolysosomal 
system. SCARA5 acts as a ferritin receptor mediating endocytosis of iron-bound ferritin directly 
from the bloodstream. The SCARA5-Ferritin complex is delivered to the lysosome where it is 
degraded and iron is once again released, reduced and transported into the cytosol (Li et al., 
2009). This pathway is also depicted in Figure 7. 
Maintenance of iron homeostasis depends on the activity of several proteins, whose post-
transcriptional regulation by iron regulatory protein (IRP)1 and IRP2 provides another 
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mechanism of cellular iron regulation. IRP1 and IRP2 sense iron levels in the cytosol and 
regulate the transcripts of genes encoding for key proteins required for iron homeostasis (Lane 
et al., 2015; Rouault, 2013). When cytosolic iron levels are low, IRPs bind iron-responsive 
elements (IREs) in the transcripts of these genes and interfere with translation by preventing 
the assembly of the translational machinery leading to decreased levels of ferritin for instance. 
Conversely, IRP binding to transferrin receptor 1 (TFRC) mRNA stabilizes it, leading to 
increased transferrin receptor synthesis. However, under conditions of iron overload, iron binds 
to IRPs resulting in their dissociation from IREs. Consequently, translation of ferritin is 
enhanced while TFRC is degraded by endonucleases (Biasiotto et al., 2016; Rouault, 2013).  
 
1.4 Lysosomal storage disorders 
The crucial role that lysosomes play in cellular metabolism implies that altered lysosomal 
function would contribute greatly to the pathogenesis of several metabolic diseases. Indeed, 
the inability of the lysosome to degrade cargo, resulting in their accumulation, or export 
nutrients underlies lysosomal storage disorders (LSDs). LSDs are inborn errors of metabolism 
with an approximate combined incidence of 1 in 5000 live births (Platt et al., 2012). LSDs are 
caused mainly by heritable mutations in genes that encode lysosomal hydrolases (e.g., GBA 
in Gaucher’s diseases and GAA in Pompe’s disease) and permeases (e.g., NPC1/2 in 
Niemann-Pick type C and MCOLN1 in Mucolipidosis type IV). Neurodegeneration is a hallmark 
of most LSDs, probably because neurons have limited regenerative capacity and may be 
particularly dependent on lysosomal function to maintain neuronal health (Perera and Zoncu, 
2016). Increasingly, mutations leading to LSDs are emerging as risk factors for late-onset 
neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease (Osellame and 
Duchen, 2014). Although around 70 LSDs have been described, in the context of this study, 
only two kinds of LSDs will be discussed in the following sections. 
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1.4.1 Niemann-Pick disease 
Niemann-Pick diseases (NP) are a group of sphingolipid storage disorders, which are 
characterized by the accumulation of different lipid species in lysosomes (Platt, 2014). Three 
distinct forms of NP have been described: Types A, B and C. Types A and B are caused by a 
deficiency in the lysosomal enzyme, acid sphingomyelinase (ASM), while Type C is caused by 
defects in two distinct lysosomal cholesterol efflux proteins, NPC1 and NPC2. Though the 
etiologies may differ, these diseases display common biochemical and clinical features 
(Schuchman and Desnick, 2017). 
In NP types A and B (NPA and NPB), ASM deficiency, caused by mutations in SMPD1, leads 
to the accumulation of sphingomyelin (ASM substrate) in the lysosome. The hallmark of NPA 
is hepatosplenomegaly and progressive neurodegeneration, with most patients unable to thrive 
beyond 3 years of age mostly due to respiratory failure (Schuchman and Desnick, 2017). NPB 
is phenotypically variable; although patients also display hepatosplenomegaly, they typically 
do not show central nervous system (CNS) pathologies. Defects in NPA and NPB are modeled 
by the ASM-/- mice with liver fibrosis and brain deficits consistent with clinical findings in patients  
(Schuchman and Desnick, 2017). 
In NPC, deficiency of the lysosomal cholesterol efflux proteins NPC1 and NPC2 result in 
impaired lipid trafficking and accumulation of unesterified cholesterol in the liver, spleen, and 
CNS. As a result, NPC is characterized by progressive neurological deficits (Patterson et al., 
2012). NPC1 is a lysosomal transmembrane protein while NPC2 resides in the lysosomal 
lumen. NPC1 and NPC2 are thought to cooperate in cholesterol efflux from the lysosome, 
where NPC2 binds cholesterol and transfers it to NPC1, which shuttles it through the glycocalyx 
to the lysosomal membrane where it is released (Davies and Ioannou, 2000; Friedland et al., 
2003). The NPC1-/- mice closely model defects in NPC with progressive neural deficits and 
ataxia. In addition, impaired lysosomal calcium homeostasis in NPC has been shown to result 
in reduced calcium release, which blocks late endolysosomal fusion events. This results in 
glycosphingolipid deposition in late endosomes and lysosomes (Lloyd-Evans et al., 2008). 
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1.4.2 Glycogen storage disease type II (Pompe’s disease) 
The concept of LSDs was established based on studies of Pompe’s disease, which incidentally 
was the first LSD to be described. Pompe’s disease is caused by mutations in acid alpha-
glucosidase (GAA) leading to a deficiency of its gene product, the lysosomal glycogen-
metabolizing enzyme. Pompe’s disease is an inherited metabolic myopathy, which is 
characterized by striated muscle accumulation of intralysosomal glycogen (Raben et al., 2012). 
Cardiac hypertrophy, progressive muscle weakness, and respiratory dysfunction are hallmarks 
of Pompe’s disease, and patients with severe forms of infantile Pompe’s disease fail to thrive 
beyond 1 year of age (DeRuisseau et al., 2009; van der Ploeg and Reuser, 2008). The GAA-/- 
mouse model mimics the classical infantile form of human Pompe’s disease. These animals 
develop generalized intralysosomal glycogen accumulation with progressive skeletal and 
cardiac myopathy as disease manifestations (Raben et al., 2002). Although earlier studies in 
patient and mouse models ruled out nervous system dysfunction in Pompe’s disease, recent 
investigations have demonstrated central and peripheral nervous system pathology in GAA-/- 
mice (DeRuisseau et al., 2009; Falk et al., 2015; Turner et al., 2016). 
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1.5 Mitochondrial biology 
Aerobic respiration takes place in a membrane-enclosed sub-compartment of the eukaryotic 
cell. This membrane-enclosed organelle, which uses oxygen to generate energy, is now known 
as the mitochondrion. The word ‘mitochondrion’ crudely translates as thread-like granule owing 
to its initial description as ‘granules’ in insect muscles by Rudolf Albert von Koelliker around 
the mid-1800s. The subsequent discovery of DNA in mitochondria strongly emphasized their 
close relationship with bacteria, which are thought to have been phagocytosed by a proto-
eukaryote more than 2 billion years ago (Lane and Martin, 2010; Müller et al., 2012).  
Although mitochondria have evolved to accommodate several roles in cellular metabolism, they 
are still referred to, in text today, as ‘energy factories’ of the cell. This designation originates 
from their crucial role in the generation of ATP, ‘the energy currency of the cell’ (Scheffler, 
2007). Beyond ATP synthesis, mitochondria mediate a wide range of cellular functions 
including amino acid and fatty acid metabolism, iron-sulfur cluster biogenesis, heme and steroid 
synthesis, and calcium homeostasis (Nunnari and Suomalainen, 2012). In addition, 
mitochondria play diverse roles in the regulation of cellular processes such as autophagy and 
apoptosis, and cell proliferation and differentiation (Nunnari and Suomalainen, 2012; 
Raimundo, 2014). The important role of mitochondria in cellular physiology is further highlighted 
by pathologies that arise following mitochondrial malfunction (DiMauro, 2004). Mitochondrial 
dysfunction, with etiologies stemming from defects in genes from both genomes encoding 
mitochondrial proteins, has been shown to result in several diseases including myopathies and 
neurodegenerative disorders (DiMauro, 2004).  
 
1.5.1 Structure and morphology of mitochondria 
Mitochondria were usually depicted as sausage-like-shaped, static organelles in the cell with a 
diameter of 0.5–1.0µM, a notion which has since been challenged by recent evidence that 
mitochondria constantly undergo fusion and fission in response to cellular cues (Pernas and 
Scorrano, 2016). Two specialized membranes with different functions enclose mitochondria, 
making them distinct from all other organelles within the cell (Figure 8). 
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Figure 8| Ultrastructure of the mitochondrion – The outer mitochondrial membrane 
(OMM) surrounds the intermembrane space (IMS) and inner mitochondrial membrane (IMM). 
The IMM, which is folded into the cristae, encloses the mtDNA-containing matrix. The cristae 
house the respiratory chain complexes and ATP synthase. (original illustration, KF Yambire) 
 
The outer mitochondrial membrane (OMM) serves as the barrier between the cytoplasm and 
the intermembrane space (IMS), preventing small molecule diffusion while protecting the cell 
from deleterious mitochondrial products like death cues (pro-apoptotic factors) or even the 
mitochondrial genome (mtDNA). However, the OMM contains the β-barrel protein, porin, also 
known as voltage-dependent anion channel (VDAC), which confers membrane permeability to 
ions, small metabolites and non-electrolytes of less than 8kDa (Colombini, 1980; Zalman et al., 
1980). In addition, mitochondrial motility along microtubules and cytoskeletal filaments is due 
to interaction with proteins of the OMM. Mitochondria also engage other sub-cellular 
compartments like the nucleus and endoplasmic reticulum through the OMM (Pernas and 
Scorrano, 2016). 
The cardiolipin-rich inner mitochondrial membrane (IMM), which creates the two 
subcompartments, IMS and matrix (Figure 8), is further divided into two subdomains. One of 
the domains, the inner boundary membrane (IBM) forms contacts with the OMM at sites where 
the protein import machinery is localized (Reichert and Neupert, 2002).  
The other domain of the IMM is highly convoluted forming a series of invaginations known as 
the cristae (Figure 8). The IBM and cristae membrane join at narrow necks referred to as cristae 
junctions. The cristae house the assembled respiratory chain complexes and supercomplexes 
as well as the proteins involved in iron-sulfur cluster biogenesis and mtDNA maintenance and 
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transcription (Krauss, 2001; Pernas and Scorrano, 2016). Due to the high number of protein 
machinery for several processes localized to the IMM, it has an unusually high protein to lipid 
ratio of about 80:20, compared to that of the OMM which is 50:50. Another key feature of the 
IMM is optic atrophy 1(OPA1)-mediated remodeling of the cristae. Indeed, the number and 
morphology of the cristae may reflect a response of mitochondria to energy demands of the 
cell. For example, under high energy requirements, or in cells with greater respiratory rates like 
myocytes and neurons, the cristae are usually presented as highly folded and lamellary with a 
large surface area (Patten et al., 2014; Pernas and Scorrano, 2016; Rossignol et al., 2004). 
The two aqueous compartments, IMS (more specifically the intra-cristae space) and matrix, 
respectively delimited by the OMM and IMM, are important for oxidative phosphorylation. The 
IMS usually has a low pH due to the protons that are pumped from the matrix into the IMS. The 
net effect is the maintenance of chemical and electrical gradients which are necessary for ATP 
synthesis. Some enzymes localized to the IMS are involved in heme synthesis  or creatine 
phosphorylation. The most abundant IMS protein, cytochrome c, represents the electron shuttle 
connecting complexes III and IV of the respiratory chain (Herrmann and Riemer, 2010). The 
metabolic center of the mitochondrion is the matrix, which houses enzymes of the citric acid 
cycle, oxidative phosphorylation, urea cycle and beta-oxidation of fatty acids. It contains the 
mtDNA and the protein machinery necessary for its replication and expression (Scalettar et al., 
1991).  
Contrary to the depiction of mitochondria as static, rod-shaped organelles, evidence 
challenging this notion existed more than a century ago, even before they were referred to as 
‘power plants’ of the cell. Indeed, in the words of Lewis and Lewis (1914), “…there are to be 
found in single stained preparations all gradations of size and shape from the small and large 
granules to short rods and long rods, to threads of varying length, to anastomosing threads and 
networks, which extend throughout the cytoplasm and to rings and loops of various shapes”. 
These observations of mitochondrial fusion and fission were made from chick embryo cells in 
culture (Lewis and Lewis, 1914). It is intriguing that with the tools available to biologists in the 
early 20th century, a report that accurately describes the modern day micrograph of 
mitochondria depicted in Figure 9 could be made. Nonetheless, it would take close to a century 
to understand the molecular basis of mitochondrial dynamics and its role in mitochondrial 
function.   
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Figure 9| Mitochondrial network in mouse embryonic fibroblasts – A micrograph of 
MEFs transfected with a mitochondrial-targeted cyan fluorescent protein illustrates the 
mitochondrial network with diverse shapes and lengths of mitochondria. Scale bar : 5µM. 
 
Generally mitchondrial morphology and number vary depending on cell type and context-
specific demands, and the balance between mitochondrial fusion or fission regulates 
mitochondrial morphology, distribution and function (Chan, 2012). Mitochondrial dynamics 
plays a crucial role in mitochondrial quality control and its altered shape affects several 
processes including respiration, apoptosis, mtDNA stability or cellular stress responses (Chan, 
2012; Pernas and Scorrano, 2016).  
Mitochondrial fission is mediated by a member of the dynamin superfamily of GTPases, the 
dynamin-related protein 1 (DRP1) (Smirnova et al., 2001). DRP1 is a cytosolic protein, which 
is recruited to mitochondria by either adaptor proteins, Fission 1 (FIS1), mitochondrial fission 
factor (MFF), mitochondrial dynamics proteins (MiD) of 49kDa (MiD49) or 51kDa (MiD51) 
(Gandre-Babbe and van der Bliek, 2008; Loson et al., 2013; Palmer et al., 2013). Following the 
marking of a fission site, recruited DRP1 oligomerizes into a coil-shaped structure around the 
marked fission site, which constricts and fissions mitochondria following GTP hydrolysis. 
Mitochondrial fission is involved in apoptosis as well as in mitochondrial proliferation during cell 
division (Chan, 2012; Pernas and Scorrano, 2016). 
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Mitochondrial fusion requires two distinct fusion events each for either OMM or IMM, which are 
also mediated by distinct fusion machinery. Fusion of the OMM is mediated by the  OMM-
localized transmembrane GTPases Mitofusins 1 and 2 (MFN1 and MFN2). OPA1, the dynamin-
related GTPase, mediates IMM fusion. During fusion, MFN1 and MFN2 tether two closely 
apposed mitochondria by forming homotypic or heterotypic complexes in trans between them, 
thereby promoting fusion (Chen et al., 2003; Koshiba, 2004). OPA1 is however not required on 
adjacent membranes for IMM fusion (Song et al., 2009). Mitochondrial fusion is thought to be 
relevant for maintaining a healthy population of mitochondria where toxic mitochondrial 
products or mutant mtDNA is diluted among mitochondria. (Pernas and Scorrano, 2016) 
 
1.5.2 Mitochondrial genome 
Except for the nucleus, mitochondria are the only organelles in animal cells to possess their 
own genetic material. The origin of mtDNA has been the subject of debate since its discovery 
in 1963 as DNAse-sensitive threads inside mitochondria (Nass and Nass, 1963), although its 
presence is consistent with the endosymbiotic theory of mitochondrial acquisition as a whole. 
It is thought that most genes of the α-protobacterium were lost or transferred to the nucleus 
during evolution (Gray et al., 1999), leaving only the circular, compact and double-stranded 
mtDNA molecule with 16,569 nucleotides in humans for example as depicted in Figure 10. 
Each human mtDNA molecule (mostly 103–104 copies/ cell in mammals) codes for 37 genes, 
comprising 13 polypeptides of the respiratory chain, 2 ribosomal RNAs (rRNAs) and 22 transfer 
RNAs (tRNAs). All mammalian mtDNA genes lack introns and there is only one non-coding 
region, which is also referred to as the control region because it contains the heavy strand and 
light strand promoters (HSP and LSP) for mtDNA transcription and replication (Anderson et al., 
1981). Due to uneven guanidine content, the mtDNA strands can be separated into a heavy 
(H) and a light (L) strand using alkaline CsCl density gradient centrifugation (Berk and Clayton, 
1974). The H strand encodes both rRNAs, 12 of the 13 mRNAs and 14 of the 22 tRNAs. The 
rest are encoded by the light strand (Figure 10). 
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Figure 10| Human mtDNA map – Respiratory chain subunits are color-coded for each 
complex; ribosomal RNAs, 12S and 16S have been depicted in red. Mitochondrial transfer RNAs 
and their corresponding single-letter amino acid codes have been indicated as black bars 
(original illustration, KF Yambire) 
 
mtDNA is organized into compact ovoid structures called nucleoids, which are diverse in size 
with an average diameter of about 100nm (Brown et al., 2011; Kukat et al., 2011). The 
mitochondrial transcription factor A (TFAM), which binds to mtDNA promoters and acts a 
transcription factor, is also the principal core protein of the nucleoid. As a packaging factor, 
there are about 450 TFAM binding sites on the 16kb mammalian mtDNA where it localizes 
exclusively (Kaufman et al., 2007). Interestingly, when not bound to mtDNA, TFAM is unstable 
and is usually targeted for degradation by the LON proteases (Matsushima et al., 2010). 
Since defects in mtDNA result in various human pathologies, understanding its maintenance 
has garnered a lot of interest over the years. Indeed, the machinery for mtDNA replication is 
known to consist of the DNA polymerase γ (PolG), the mtDNA helicase (TWINKLE), the 
mitochondrial single-stranded binding protein (mtSSB), and mtDNA topoisomerases 
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(Gustafsson et al., 2016). A minimal replisome is however designated as PolG, mtSSB and 
TWINKLE owing to its ability to replicate mtDNA in vitro (Korhonen et al., 2004). Although the 
mtDNA replisome is known, it is rather the mode of replication that has proved controversial 
over the years. Three models of mtDNA replication have been proposed: the original strand-
asynchronous model, the alternative strand-synchronous model, and the unidirectional 
replication model. The strand-asynchronous model suggests an L-strand transcript, which is 
processed by the mtDNA replisome into primers for the H-strand, primes mtDNA replication. 
Following about 70% of H-strand replication and H-strand displacement, the origin of L-strand 
(OL, see Figure 10) is exposed and L strand replication begins and proceeds in the opposite 
direction (Shadel and Clayton, 1997; Wong and Clayton, 1985). The strand-synchronous model 
posits that both H and L strands are synthesized bidirectionally from within an area in the non-
coding region beyond the displacement loop (D-loop, see Figure 10) (Holt et al., 2000). The 
third model proposes that mtDNA replication starts at either one of the two sites (consistent 
with the asynchronous model). DNA synthesis progresses in the leading strand with 
simultaneous RNA incorporation throughout the lagging strand (RITOLS) (Yasukawa et al., 
2006). 
 
1.5.3 Mitochondrial biogenesis 
1.5.3.1 Transcriptional regulation of mitochondrial biogenesis 
Mitochondrial biogenesis, which serves to increase the mass and copy number of mitochondria, 
and increase mitochondrial metabolic capacity, is a process that requires the coordinated and 
regulated expression of nuclear and mitochondrial genomes. Although only 13 of such proteins 
are encoded by the mtDNA, they are nevertheless essential because they form the core of 
most complexes of the respiratory chain, and oxidative phosphorylation (OXPHOS) collapses 
when they are not expressed  (Larsson et al., 1998). Most mitochondrial proteins (about 99%), 
including the factors that drive mtDNA expression, are encoded by nuclear genes, synthesized 
on cytosolic ribosomes and imported into mitochondria. Nuclear control of mitochondrial 
biogenesis was originally found to be driven by nuclear respiratory factors, NRF1 and NRF2 
(Evans and Scarpullas, 1989; Virbasius et al., 1993b). NRF1 and NRF2 regulate the expression 
of distinct classes of mitochondrial proteins. These include proteins, which drive mtDNA 
transcription and replication, several subunits of the respiratory chain complexes, cytosolic 
enzymes of heme synthesis and mitochondrial protein import components (Virbasius et al., 
1993a, 1993b). In addition to the NRFs, several other factors, including the peroxisome 
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proliferator-activated receptor (PPAR)α and δ and estrogen-related receptor α (ERRα), target 
mitochondrial function by mediating the expression genes of the β-oxidation of fatty acids 
pathway (Gulick et al., 1994; Schreiber et al., 2004).  
Several transcriptional regulators have been shown to mediate mitochondrial biogenesis (see 
review in (Scarpulla, 2008)). Integrating the actions of these multiple regulators suggests the 
activity of an overarching control factor. This was provided by the discovery of the PPARγ 
coactivator 1α (PGC1α) (Puigserver et al., 1998). PGC1α integrates cellular physiological cues 
like thermogenesis, cell growth, and gluconeogenesis in its coordination of the activity of 
several transcriptional regulators of mitochondrial biogenesis (Lin et al., 2005). Subsequently, 
another PGC1 family of coactivators, PGC1β and PGC1-related coactivator (PRC) has been 
discovered. These factors, just like PGC1α, mediate gene expression through transcriptional 
regulators or directly through the targets of these transcription factors (Lin et al., 2005; 
Scarpulla, 2008). 
 
1.5.3.1 Mitochondrial protein import 
Nuclear-encoded mitochondrial transcripts, whose expression is induced by the transcriptional 
regulators described above, are translated on cytosolic ribosomes into precursor proteins with 
targeting sequences directing them to the mitochondrion. The precursor proteins are stabilized 
by Hsp90 and Hsp70 and delivered to the import receptor Tom70 (Young et al., 2003). The 
protein import machinery of mitochondria imports and sorts the precursor proteins via at least 
four distinct pathways (Chacinska et al., 2009). Almost all precursor proteins destined for the 
mitochondria are imported through the translocase of the outer membrane (TOM complex), 
which consists of Tom20, Tom22 and Tom70 (receptor subunits), which recognize precursor 
proteins and translocate them through the channel-forming Tom40 subunit. The other subunits 
of the TOM complex are Tom5, Tom6, and Tom7 (small subunits), which are involved in 
assembly, stability and dynamics of the TOM complex (Rapaport, 2005; Sherman et al., 2005).  
Following translocation through the TOM complex, depending on the structure and final 
destination, each precursor protein is sorted via one of at least four pathways. The TOM 
complex assists in the insertion of the simplest of outer membrane proteins into the OMM 
(Rapaport, 2005). OMM proteins typified by complex topology such as porins are initially 
delivered into the IMS. These proteins transiently associate with the Tim9-Tim10 chaperone 
complex and are delivered to the sorting and assembly machinery (SAM), which mediates their 
insertion into the OMM (Paschen et al., 2003; Wiedemann et al., 2003). Import of precursor 
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proteins targeted to the IMS, IMM, and matrix involves the translocase of inner membrane (TIM 
complex), which includes two distinct complexes TIM23 and TIM22. From the TOM complex, 
precursor proteins are directed to the TIM23 complex, which comprises Tim23, Tim50, Tim17, 
Tim21, and Tim44. Tim50 recognizes the precursor proteins and translocates them through the 
channel-forming Tim23 subunit (Mokranjac and Neupert, 2005).  
Translocation through the TIM23 complex into the matrix or insertion into the inner membrane 
requires membrane potential. IMM-destined precursor proteins are arrested by their 
hydrophobic stop signals and are laterally released into the IMM (Wiedemann et al., 2004). In 
addition, the TIM23 complex associates with the presequence translocase-associated motor 
(PAM), while Tim44 recruits ATP-bound mtHSP70 from the matrix. Import motor-driven ATP 
hydrolysis stabilizes mtHSP70 interactions with Tim44 and with matrix precursor proteins thus 
preventing their retrograde movement into the IMS. ADP exchange by a new ATP, mediated 
by nucleotide exchange factor Mge1, facilitates precursor protein release into the matrix 
(Chacinska et al., 2009; Mokranjac and Neupert, 2005; Wiedemann et al., 2004). 
The second TIM complex, TIM22 mediates the insertion of carrier proteins into the IMM. TIM22 
complex is composed of Tim22 (shares homology with Tim23), Tim54, Tim18 and small Tims. 
The Tim9-Tim10 chaperone complex in the IMS binds precursor carrier proteins, following their 
translocation through the TOM complex and delivers them to the TIM22 complex by directly 
docking to it. The precursor proteins are translocated through the channel-forming protein 
Tim22 and laterally released into the lipid phase of the IMM in a membrane potential-dependent 
manner (Rehling et al., 2003; Wiedemann et al., 2004).  
Mitochondrial proteins targeted to the IMS including the small Tims, which act as chaperone 
complexes for nascent mitochondrial proteins, are mostly small.A dedicated import pathway for 
these proteins has been described: the mitochondrial IMS import and assembly (MIA) pathway. 
The import mechanisms in this pathway have been reviewed excellently in Chatzi et al. (2016) 
and Stojanovski et al. (2008). 
While these pathways mediate the import of nuclear-encoded mitochondrial proteins, the 
oxidase assembly (OXA) translocase exports mtDNA-encoded respiratory chain proteins into 
the IMM. In addition, the OXA translocase mediates the export of a small fraction of nuclear- 
encoded mitochondrial proteins, which are initially targeted into the matrix via the TIM23 
complex (Hell et al., 1998; Stiller et al., 2016).   
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1.6 Mitochondrial metabolism 
The oxidation of glucose via glycolysis releases only a small fraction of the potential free energy 
contained in glucose. Most of the energy in eukaryotic cells is derived from complete oxidation 
of carbohydrates and fatty acids in mitochondria. The mitochondrion houses several metabolic 
pathways, whose enzymes are distinctly localized to the IMM or to the matrix. The enzymatic 
machinery of oxidative phosphorylation is found in the IMM while those of carbohydrate, lipid 
and amino acid oxidation are localized to the matrix. In addition, enzymes of the heme 
biosynthetic pathway and some enzymes of the urea cycle are found in the matrix. 
 
1.6.1 Generation of ATP 
1.6.1.1 Glycolysis 
ATP is generated via a series of redox reactions and involves the transport of energy from 
chemical bonds to high-energy compounds. Glucides, especially glucose, and fatty acid 
oxidation serve as the main source of energy, although amino acids and ketone bodies can 
also be oxidized for ATP generation under starvation conditions. The process of glucose 
oxidation to pyruvate, termed glycolysis, is catalyzed by cytosolic enzymes. The 10 reactions 
of the glycolytic pathway generate pyruvate and NADH in the cytosol with a net gain of two 
ATP molecules per glucose molecule. In the absence of oxygen (O2), pyruvate oxidizes NADH, 
yielding lactate in mammalian cells. However, under aerobic conditions, pyruvate is transported 
into the mitochondrial matrix, where it is decarboxylated to acetyl-Coenzyme A (CoA) with 
simultaneous generation of NADH. Acetyl-CoA enters the tricarboxylic acid cycle. 
1.6.1.2 The tricarboxylic acid cycle 
The enzymes, which catalyze the reactions of the tricarboxylic acid (TCA) cycle, are localized 
to the mitochondrial matrix or to the matrix side of the IMM (succinate dehydrogenase). 
Following the demonstration by Franz Koop and Carl Martinus of a series of reactions that 
yielded oxaloacetate from citrate, Hans Krebs and William Johnson discovered the cyclical 
nature of the reactions from citrate oxidation to oxaloacetate.  
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They also filled the gaps in the cycle while proposing a two-carbon donor, which allowed the 
conversion of oxaloacetate to citrate (Krebs and Johnson, 1937). It would take more than a 
decade until the two-carbon donor was discovered to be acetyl-CoA (Lipmann et al., 1950). 
The TCA cycle, as illustrated in Figure 11, completely oxidizes acetyl-CoA into two molecules 
of CO2 while concurrently conserving the liberated energy as high-energy compounds, three 
molecules of NADH and one molecule of FADH2 per molecule of acetyl-CoA oxidized. These 
high-energy compounds are subsequently used as substrates for mitochondrial oxidative 
phosphorylation to generate ATP. 
 
Figure 11| Schematic representation of the TCA cycle – The TCA cycle as illustrated 
above also depicts points of entry of Acetyl-CoA and amino acids into the cycle. Enzymes that 
catalyze each step of the reactions, as well as the reverse reactions in the TCA cycle, are not 
indicated. (original illustration, KF Yambire) 
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1.6.1.3 Respiratory chain and oxidative phosphorylation 
The process of ATP synthesis via oxidative phosphorylation requires the generation of an 
electrochemical gradient across the IMM, which is used by the ATP synthase to catalyze the 
reaction, ADP + Pi → ATP. The electrochemical gradient is generated and maintained by the 
mitochondrial respiratory chain, which consists of four enzyme complexes, denoted complexes 
I, II, III and IV. These complexes, in addition to the ATP synthase (complex V), are localized to 
the IMM. Peter Mitchell proposed and demonstrated this process of coupling respiration to ATP 
synthesis in mitochondria, referred to as the chemiosmotic theory (Mitchell, 1961), which is 
widely accepted today. 
The operation of the enzyme complexes of the respiratory chain is well characterized. Complex 
I catalyzes the transfer of two electrons from NADH to ubiquinone to form ubiquinol while 
simultaneously pumping four protons into the IMS. Several iron-sulphur clusters mediate the 
electron transfer by complex I. Electron transfer from succinate through iron-sulfur clusters and 
heme to FAD and then to ubiquinone is mediated by complex II, which lacks proton-pumping 
activity. Complex III then catalyzes the transfer of electrons from ubiquinol to cytochrome c via 
the Q cycle. Four protons are concurrently pumped into the IMS by complex III for every pair 
of electrons transferred. The terminal enzyme complex of the respiratory chain, complex IV, 
catalyzes the transfer of electrons from reduced cytochrome c to oxygen to generate water. 
Translocation of four protons by complex IV into the IMS is coupled to every pair of electrons 
transferred. Finally, the ATP synthase utilizes the proton motive force generated by the 
respiratory chain complexes I, III and IV to catalyze ATP synthesis. This process is also coupled 
to proton translocation from the IMS into the matrix. Details of the mechanisms of electron 
transfer and oxidative phosphorylation are described in Scheffler (2007). 
1.7 Mitochondria in metabolic signaling 
The nucleus is typically viewed as the ‘control center’ of the cell, the compartment where 
physiological cues are integrated to command diverse cellular processes including directing 
mitochondrial function through mitochondrial biogenesis. Given the crucial role of mitochondria 
in driving several metabolic processes especially in ATP production, it is rational to think that 
optimal cellular function would require the integration of functional cues from mitochondria to 
the rest of the cell. This is further highlighted by the diverse nature of mitochondrial diseases, 
which seem to be of multiple etiologies other than just a decline in ATP levels. Mitochondrial 
signaling has been coined to describe such mechanisms of communication between 
mitochondria and the rest of the cell. 
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Reactive oxygen species (ROS) are generated by complexes I and III of the respiratory chain. 
Several lines of evidence suggest that mitochondrial ROS (mROS) regulate signaling pathways 
in the rest of the cell. For instance, mROS have been shown to regulate cellular adaptation to 
hypoxia. Because oxygen is required for ATP synthesis by mitochondria, hypoxic conditions 
trigger hypoxia-inducible factors, which induce the expression of EPO and VEGF and several 
glycolytic enzymes. This response serves to boost oxygen availability and maintain ATP levels. 
Bell et al. (2007) demonstrated in cells lacking complex III subunit, cytochrome b, that HIF-1α 
stabilization under hypoxic conditions was dependent on mROS and not on oxidative 
phosphorylation. mROS have been implicated in the regulation of proliferation and 
differentiation (Nunnari and Suomalainen, 2012). Furthermore, Raimundo et al. (2012) showed 
that mROS-dependent activation of AMPK in transgenic-mtTFB1 mice induced E2F1-mediated 
loss of inner ear ganglion neurons.  
For a very long time, metabolites used to be considered just by-products of metabolic reactions 
mostly driven by mitochondrial enzymes. This view has been challenged by increasing reports 
of their role in modulating several cellular processes. The TCA cycle intermediate, α-
ketoglutarate, for example, has been shown to increase lifespan in C. elegans, in a similar way 
to caloric restriction, by inhibiting ATP synthase and TOR while inducing autophagy (Chin et 
al., 2014). In addition, succinate and fumarate, two TCA cycle metabolites, induce oncogenesis 
by facilitating angiogenesis, metastasis, and glycolysis (Pollard et al., 2005; Selak et al., 2005). 
A detailed description of metabolites and other signaling molecules from mitochondria is 
discussed in several excellent reviews (Hamanaka and Chandel, 2010; Nunnari and 
Suomalainen, 2012; Raimundo, 2014; Raimundo et al., 2011).  
The electrochemical gradient, which provides the driving force for ATP synthesis is also 
coupled to the handling of ions with signaling functions by mitochondria. The most 
characterized of these ions is Ca2+. Mitochondrial Ca2+ handling is based on three cooperating 
modules: Ca2+ uptake from the non-mitochondrial compartments by the mitochondrial uniporter 
(MCU), its buffering in the mitochondrion and its efflux into the cytosol through the Na+/Ca2+ 
exchanger to drive cellular processes. All these processes are dependent on the 
electrochemical gradient generated by the respiratory chain (Rizzuto et al., 2012). Although 
mitochondrial Ca2+ uptake is known to drive local metabolic processes such as increasing ATP 
production (Jouaville et al., 1999) or regulating mitochondrial fission through DRP1 
phosphorylation (Cribbs and Strack, 2007), its role in regulating diverse extramitochondrial 
cellular processes has also been established. Mitochondrial Ca2+ uptake, for example, has 
been shown to affect cell death pathways such as necrosis and apoptosis. In excitatory 
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neurons, NMDA receptor activation, for instance, results in increased Ca2+ conductance 
through the NMDA receptor, as well as through voltage-gated Ca2+ channels, which open 
following depolarization. Mitochondria have been shown to accumulate Ca2+ under these 
conditions thereby buffering the cytosolic load. However, prolonged influx of Ca2+ coupled with 
decreased mitochondrial buffering capacity and decreased cytoplasmic Ca2+ clearance 
mechanisms initiate necrosis (Bano et al., 2005). In addition, the electrochemical gradient 
dissipates following mitochondrial Ca2+ overload resulting in necrosis induction.  
The release of pro-apoptotic factors such as cytochrome c by mitochondria is implicated in 
apoptosis. Mitochondrial Ca2+ mediates the activity of the permeability transition pore, whose 
prolonged opening results in cytochrome c release and apoptosis initiation (Rasola and 
Bernardi, 2011). Furthermore, mitochondrial Ca2+ handling affects autophagy, a pathway that 
modulates cell survival. Increased inositol 1,4,5-triphosphate (IP3) receptor-mediated 
mitochondrial Ca2+ signaling was shown to regulate AMP-activated protein kinase (AMPK) 
activity, a positive regulator of autophagy (Cárdenas et al., 2010).  
 
1.8 Mitochondria in immune response pathways 
Induction of the innate immune response is initiated by pattern recognition receptors (PRRs), 
which recognize pathogen-associated molecular patterns (PAMPs) on invading pathogens. 
Ligation of PRRs triggers downstream signaling mediated by nuclear factor kB (NFkB), 
mitogen-activated protein kinases (MAPKs) and interferon regulatory factors (IRFs), which 
induce the expression of cytokines and chemokines and type I interferons to contain the 
pathological insult while triggering the adaptive immune response (West et al., 2011). Following 
the discovery of Toll-like receptors (TLRs), several families of cytosolic PRRs were found, 
including retinoic acid-inducible gene I (RIG-I)-like receptor (RLRs), nucleotide oligomerization 
domain (NOD)-like receptors (NLRs), and C-type lectin receptors (CLRs) (Kawai and Akira, 
2010; West et al., 2011). 
Mitochondria were previously known to play a role in immune response through the induction 
of apoptosis following infection. However, multiple lines of evidence suggest that mitochondrial 
involvement in the immune response goes beyond apoptosis induction. The discovery of the 
mitochondrial antiviral signaling protein (MAVS) as an adaptor protein for RLRs provided 
evidence of mitochondrial involvement in immune response induction (Kawai et al., 2005; 
Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005). Interestingly, MAVS was found to localize 
to the OMM where it recruits RLRs following viral infection (Seth et al., 2005). In addition, MAVS 
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was found to mediate downstream signaling by interacting with tissue necrosis factor (TNF) 
receptor-associated factor (TRAF) family members. Strikingly, MAVS loses its signaling 
capacity when mislocalized to the cytosol (Seth et al., 2005). 
Furthermore, mROS has been shown to promote antibacterial innate immune response and 
bactericidal activity. Evidence of the role of mROS in immunity was first reported in mice lacking 
the mitochondrial uncoupler protein 2 (UCP2). These mice were challenged with Toxoplasma 
gondii and were found to be more resistant to Toxoplasma-induced lethality when compared to 
their wild-type littermates (Arsenijevic et al., 2000). Macrophages from these mice showed 
increased bactericidal activity and higher basal and Toxoplasma-induced mROS levels 
(Arsenijevic et al., 2000). Conversely, macrophages overexpressing UCP2 produced lower 
levels of cellular ROS when stimulated with TLR4 agonist lipopolysaccharide (Kizaki et al., 
2002), thus demonstrating that mROS contribute to the proper induction of the innate immune 
response. 
Lastly, sterile immune responses, unlike infections, are triggered by PRR-dependent sensing 
of damage-associated molecular patterns (DAMPs) following cellular injury. TLRs and NLRs 
mediate the sensing of DAMPs and the subsequent induction of the immune response. A well 
characterized mitochondrial DAMP is the hypomethylated CpG motifs of mtDNA, which 
resemble bacterial CpG DNA. mtDNA is thus a potent agonist of TLR9- mediated induction of 
the innate immune system (discussed earlier, see section 1.3.3.3).  
 
1.9 Lysosomal and mitochondrial crosstalk 
The endosymbiotic theory of organelle acquisition has been widely accepted as defining the 
evolution of eukaryotes. Although this theory is consistent with the first kind of organelle 
crosstalk between the primitive lysosome (phagosome) and the ancestral mitochondrion, a 
more entrenched position by some endosymbiont proponents was the view that modern 
organelles should be as autonomous as their ancestors (Bogorad, 1975). This view is certainly 
challenged by mounting evidence, which suggests that organelles exist as interdependent units 
in the eukaryotic cell.  
We have recently reviewed the communication between mitochondria and other membrane-
bound compartments of the cell (Diogo et al., 2017; Raimundo et al., 2016). Nevertheless, in 
the context of this study, recent evidence, which pertains to the crosstalk between lysosomes 
and mitochondria, which may involve physical interactions or via signaling pathways 
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(Raimundo, 2014), will be discussed. The most notable of cellular processes that link 
lysosomes and mitochondria, is the selective degradation of damaged mitochondria by 
lysosomes, known as mitophagy (Youle and Narendra, 2011). Classical mitophagy is mediated 
by PINK1 and Parkin (whose genes are mutated in autosomal recessive Parkinson’s disease). 
Several mechanisms involved in mitophagy have been characterized and discussed in several 
reviews (Pickrell and Youle, 2015; Whitworth and Pallanck, 2017; Youle and Narendra, 2011). 
One of the most hotly discussed mechanisms involves PINK and Parkin. Briefly, in healthy, TIM 
import-competent mitochondria, the kinase PINK1 is targeted to the mitochondrial matrix for 
processing and degradation. Following IMM depolarization in damaged mitochondria, PINK1 
import is blocked and it accumulates on the OMM where it recruits the cytosolic E3 ubiquitin 
ligase Parkin to the mitochondrial surface. Parkin ubiquitinates several target proteins on the 
OMM. Ubiquitination of OMM proteins results in the recruitment of ubiquitin adaptor proteins, 
which promote the engulfment and sequestration of damaged mitochondria into 
autophagosomes and targeted to the lysosome for degradation. 
Furthermore, contact sites between mitochondria and vacuole were recently reported in yeast 
(Elbaz-Alon et al., 2015), although evidence of such interactions in mammalian cells is still 
lacking. Another striking finding pertaining to mitochondrial and lysosomal crosstalk was 
recently reported by Heidi McBride and colleagues. In this report, the authors showed in 
mammalian cells that under subtoxic doses of ROS, cargo-containing mitochondrial-derived 
vesicles (MDVs) budded from mitochondria and delivered their cargo to lysosomes 
(Soubannier et al., 2012). Although this work illustrates an essential mitochondrial quality 
control pathway, it remains unclear whether it applies in vivo.  
In addition, we and others have demonstrated recently that mitochondria and lysosomes 
communicate via signaling pathways (Baixauli et al., 2015; Fernández-Mosquera et al., 2017). 
We showed in cells that acute mitochondrial malfunction, induced by mitochondrial poisons, 
triggered TFEB/MITF-dependent lysosomal biogenesis via AMPK (Fernández-Mosquera et al., 
2017). The existence of an interdependent network between these compartments is further 
highlighted by several reports of mitochondrial defects in LSDs and of lysosomal malfunction 
in mitochondrial disorders (reviewed in Diogo et al., 2017; Ordonez, 2012; Osellame and 
Duchen, 2014; Raimundo et al., 2016). For example, mitochondrial defects including impaired 
respiration, reduced respiratory chain enzyme activities, decreased membrane potential, and 
fragmentation were reported in a mouse model of Gaucher’s disease, the most common LSD 
(Osellame et al., 2013). Interestingly, Gaucher’s disease is associated with increased risk of 
Parkinson’s disease. Finally, chronic mitochondrial malfunction, akin to most mitochondrial 
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diseases, was shown to result in the accumulation of swollen and dysfunctional lysosomes in 
fibroblasts from mice lacking OPA1, PINK1 or AIF (Demers-Lamarche et al., 2016). The 
crosstalk between lysosomes and mitochondria likely plays a crucial role in the pathogenesis 
of metabolic diseases and understanding the mechanisms involved should be of utmost priority. 
1.10 Aims of the study 
Mitochondrial malfunction has been shown in several lysosomal storage disorders (LSDs). 
However, the mechanism(s) underlying mitochondrial defects in LSDs remain virtually 
unknown. The aims of this study were to identify the mechanistic links between LSDs and 
mitochondrial malfunction. Given that distinct etiologies including mutations in different groups 
of hydrolases or permeases underlie the different LSDs, it is anticipated that different 
mechanisms might mediate mitochondrial dysfunction in different LSDs. That notwithstanding, 
it is also expected that common mechanisms linking different LSDs to mitochondrial 
malfunction may exist due to secondary lysosomal enzyme deficiencies that have been 
reported in several LSDs. In addition, it was interesting to know the role that the identified 
mechanisms of lysosomal and mitochondrial crosstalk played in the pathogenesis of lysosomal 
storage disorders. Importantly, this study also sought to harness the therapeutic potential of 
mechanistic links between lysosomes and mitochondria to mitigate disease consequences. To 
this end, the specific goals of this study were to:  
 Identify the mechanism(s) of mitochondrial malfunction in cellular and mouse models of 
Niemann-Pick disease Types A/B/C (lipid storage disorders). 
 Demonstrate central nervous system pathology in mouse models of Pompe’s disease 
(glycogen storage disorder) and elucidate the mechanism(s) that links lysosomal 
malfunction in Pompe’s disease to mitochondrial dysfunction. 
 Show whether the identified mechanism(s) could be modulated pharmacologically to 
ameliorate disease outcomes.
  
 
2. Materials and methods 
2.1 Materials 
2.1.1 Reagents 
Several chemicals and reagents were used in this study. The respective lists of reagents and 
their suppliers are provided in the table below. 
Table 1: List of reagents and their suppliers and catalog numbers 
Product Supplier Catalog number 
Absolute ethanol BD Bioscience 354052 
Acrylamide solution 40% AppliChem A0385 
Agarose Carl Roth 3810.3 
Ammonium Persulfate (APS) AMRESCO 0486 
Antimycin Sigma Aldrich A8674 
Bovine serum albumin (BSA) Sigma Aldrich A7906 
Bromophenol blue Carl Roth T116.1 
CaCl2 Alfa Aesar L13191 
CCCP Fluka 857815 
Chloral hydrate Sigma Aldrich C8383 
Chloroquine disphosphate Sigma Aldrich C6628 
Cold fish gelatin Sigma Aldrich G7765 
Coomassie Brilliant Blue G Carl Roth 9598.2 
Cryo-OCT compound Fisher Scientific 14-373-65 
Cytochrome c (from bovine heart) Sigma Aldrich C2037 
D(+)-Glucose  Carl Roth 275227941 
DAPI Carl Roth C6335.1 
Deferoxamine mesylate Sigma Aldrich D9533 
Desipramine Biotrend BG0162 
Diaminobenzidine Sigma Aldrich D8001 
Isoflurane Sigma 792632 
Digitonin Merck 11024-24-1 
Continue on next page 
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Table 1: Continued from previous page 
Product Supplier Catalog number 
DMEM High glucose  Gibco 41965-062 
DMSO Sigma Aldrich D8418 
DTT AppliChem A2948 
Dulbecco´s Modified Eagle´s Medium  
(DMEM) Base 8.3g/L 
Sigma Aldrich D5030-1L 
ε-Amino n-caproic acid Merck CAS6032-2 
EDTA Carl Roth 8043.2 
Ethanol 70% VWR 84858.440 
Ethidium bromide VWR E406 
FCCP Sigma Aldrich C2920 
Ferric citrate Sigma Aldrich F3388 
Folic acid Sigma Aldrich F8758 
GlutaMax-1 (100X) Gibco 35050-061 
Glycerol Carl Roth 7530.1 
Glycine VWR 0167 
Goat Serum Life Technologies  10000C 
H2O Nuclease-free  VWR E476 
HaltTM Protease & Phosphatase single use 
Inhibitor Cocktail 
Thermo Scientific 78442 
HCl Sigma Aldrich H1758 
Heparin Sigma Aldrich H3393 
HEPES Carl Roth HN77.2 
K2HPO4 Carl Roth P749.2 
KCl Volu-Sol 83608.26 
KH2PO4 Carl Roth 3904.1 
2-Mercaptoethanol Carl Roth 4227.3 
Methanol VWR 20903.368 
MgCl2 VWR 8.14733.0100 
MgSO4 – 7H2O Sigma Aldrich 63138 
Continue on next page 
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Table 1: Continued from previous page 
Product Supplier Catalog number 
Mowiol 4-88 AppliChem A9011  
NaCl AppliChem A1430,0010 
NaH2PO4.H2O  Carl Roth K300.1 
NaHCO3 Carl Roth P029.3 
NaN3 Sigma Aldrich 52002-1006 
N-dodecylmaltoside Carl Roth CN26.2 
NH4Cl Carl Roth K298.1 
Nonidet®P-40 Substitute AMRESCO E109-50ML 
Oligomycin Sigma Aldrich O4876 
Paraformaldehyde (PFA) AppliChem A3813 
PMSF Sigma P7626 
Polybrene Sigma 28728-55-4 
Proteinase K Amresco 0706 
Puromycin 100mg Fisher Scientific BP2956-100 
Ribonuclease A Amresco 0675 
Rotipherose Gel 40 (37.5:1) Carl Roth T802.1 
SDS Sigma Aldrich L4509-500G 
Sew2871 Cayman 10006440 
Skim Milk Powder Fluka 70166 
Sodium deoxycholate Sigma Aldrich 30970 
TEMED Sigma Aldrich T7024 
Torin-1 BioVision 2273  
Trehalose Carl Roth 5151.3 
TRI Reagent Sigma T9424 
Tris Base Sigma Aldrich T1503 
Tris-HCl Carl Roth 9090.2 
Triton X-100 AMRESCO 0694 
Tween 20  AMRESCO 0777-1L 
U0126  Millipore 662005 
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2.1.2 Kits and consumables 
The kits and consumables used in this thesis are listed in Table 2 below. The corresponding 
suppliers and catalog numbers of the kits are also provided. 
Table 2: List of kits and consumablesables used in the study 
Product Supplier Catalog number 
Amersham Hybond PO45 PVDF GE Healthcare 10600023 
Centrifuge tubes 15 mL Corning 
CentriStar 
Corning 430791 
Centrifuge tubes 50 mL Corning 
CentriStar 
Corning  430829 
Cryomold (tissue tek) Fisher Scientific NC9511236 
CRYSTAL RNA Mini Kit New England Biolabs 31-010-404 
Cuvettes PMMA VWR-International 634-0678 
DQTM Red BSA  Life Technologies D12051 
FACS Tubes Polystyrene Round-Bottom 
5 mL 
Corning 352052 
Fetal Bovine Serum Heat-Inactivated Gibco 10500-064 
Fugene R 6 Transfection Reagent Promega E2691 
GoTaq Flexi DNA polymerase kit Promega M8291 
High-Performance chemiluminescence 
film 
GE Healthcare 28906837 
iScrip cDNA Synthesis Kit Bio-Rad 170-8891 
iTaqTM Universal SYBR Green Supermix Bio-Rad 172-5124 
Lenti X concentrator Clontech 631231 
Lipofectamine 2000 Reagent Invitrogen 11668-019 
Continue on next page 
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Table 2: Continued from previous page 
Product Supplier Catalog number 
LuminataTM Classico Western HRP 
Substrate 
Millipore WBLUC0500 
LuminataTM Crescendo Western HRP 
Substrate 
Millipore WBLUC0500 
LuminataTM Forte Western HRP 
Substrate 
Millipore WBLUF0500 
Medical X-Ray Film Foma -----  
Microscope slides Carl Roth 2111 
Microseal B seal Bio-Rad MSB1001 
MitoSOXTM Red  Life Technologies M36008 
Mitotracker Deep Red Life Technologies L7526 
Mitotracker Deep Red FM Life Technologies M22426 
Mitotracker Green FM Life Technologies M7514 
Native Gel marker GE Healthcare 17-0445-01 
PageRuler Plus Prestained Protein 
Ladder 
Thermo Scientific 26619 
PBS  tablets Sigma Aldrich P44177-100TAB 
PCR plate 384-well skirted ABI-Type 
(Universal) 
StarLab E1042-3840 
Penicillin/Streptomycin Gibco 15140-062 
Pierce BCA Protein Assay Kit Thermo Scientific 23225 
Protein Assay Dye Reagent Concentrate Bio-Rad 500-0006 
Serological Pipette 10 mL StarLab E4860-1011 
Serological Pipette 25 mL StarLab E4860-2511 
Continue on next page 
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Table 2: Continued from previous page 
Product Supplier Catalog number 
Serological Pipette 5 mL StarLab E4860-0511 
Sodium Pyruvate Sigma S8636 
Test Tube Soda Glass VWR-International 212-003 
Tips 10 µL TipOne StarLab S111-3210 
Tips 1000 µL TipOne StarLab S1111-6001 
Tips 20 µL TipOne StarLab S120-1810 
Tips 200 µL TipOne StarLab S1120-8800 
Triplet Express (1X) Gibco 12605-010 
Trypan Blue 0.4% Life Technologies T10282 
Tubes 0.5 mL molecular probes Life Technologies Q33856 
Tubes 1.5 mL StarLab E1415-1500 
Tubes 2 mL StarLab S1620-2700 
Tubes 8 Twin Strip Start PCR  StarLab 11402-3700 
Western Blot Paper TH-Geyer 4-01-60-0041 
XFe 96 extracellular flux assay kit 
Seahorse 
BD Bioscience 102416-100 
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2.1.3 Buffers and solutions 
All buffers and solutions that were used in this study are listed in Table 3 below. Unless 
otherwise stated, all buffers and solutions were prepared in ddH2O and concentrated buffers 
were further diluted to 1X in ddH2O also.  
Table 3: List of buffers and solutions 
Buffer/solution Composition 
Anode buffer 10x 500mM Tris-HCl, pH 7.0 
BN-loading dye 10X 5% Coomassie blue, 500mM ε-Amino n-caproic acid, 
100mM Tris, pH 7.0 
Blocking buffer  5% (w/v) Skimmed milk or BSA in TBST 
Blocking buffer 
(Immunohistochemistry)  
0.1% Cold fish gelatin , 0.1% Triton X-100, 3% BSA,   1% 
Goat serum and 0.05% Tween-20 in PBS 
Cathode Buffer 500mM Tricine, 150mM Tris, 0.2% Coomassie G 
Complex IV activity 
staining buffer 
50mM KPi, pH 7.4, 2.33mM 3, 3-diaminobenzidine, 80µM 
reduced cytochrome c (bovine heart) 
DNA extraction buffer 50mM Tris-HCl pH 8.5, 0.25%SDS, 1mM EDTA and 
5mM DTT 
Digitonin solubilization 
buffer 
1% Digitonin, 20mM Tris-HCl, pH 7.4, 0.1mM EDTA, pH 
8.0, 50mM NaCl, 10% glycerol, 1mM PMSF (freshly 
added) 
EBSS medium 1.8mM CaCl2,  5.3mM KCl, 117mM NaCl, 5.6mM 
Glucose, 26mM NaHCO3, 0.8mM MgSO4 and  
1mM NaH2PO4.H2O 
Freezing medium 10%(v/v) DMSO, 20%(v/v) FBS in DMEM high glucose                                         
Gel Buffer 3X 0.2M ε-Amino n-caproic acid, 150mM Tris-HCl, pH 7.0 
Homogenization buffer A 300mM Trehalose, 10mM KCl, 10mM HEPES pH 7.4 
before use add freshly 0.2% BSA  and 1X protease/ 
phosphatase inhibitor cocktail 
Homogenization buffer B As Homogenization buffer A without 0.2% BSA and 1X 
protease/ phosphatase inhibitor cocktail 
Hypertonic buffer, pH 7.9 20mM Tris, 0.42M KCl, 1.5mM MgCl2, 20% Glycerol                   
Hypotonic buffer, pH 7.9 10mM Tris, 10mM KCl and 1.5mM MgCl2  
Imaging buffer, pH 7.4 120mM NaCl, 2.5mM KCl, 2mM CaCl2, 1mM MgCl2 and                                                                                                        
10mM HEPES   
Buffers and solutions continued on next page 
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Table 3: Continuation of list of buffers and solutions 
Buffer/solution Composition 
Mowiol® 4-88 6.4mM Mowiol 4-88, 5.4M Glycerol, 0.1M Tris pH 8.5                                            
NaN3  10% NaN3 
PBS Dissolve 5 PBS tablets in 1L ddH2O. Autoclave 
Resolving gel 12%  
 
0.375M Tris, pH 8.8, 0.1%SDS, 12% Polyacrylamide, 
0.1% APS, 0.04% TEMED   
RIPA buffer 50mM Tris pH 8.0, 150mM NaCl, 1% Triton X-100, 0.1% 
SDS and 0.5% Sodium deoxycholate supplemented with 
fresh 1X protease/phosphatase inhibitor 
Running buffer 5X 125mM Tris Base, .96M Glycine, .5% SDS 
SDS loading buffer 62.5mM Tris, pH 6.8, 50 %( v/v) Glycerol, 12 %( w/v) 
SDS, 0.06 %( w/v) Bromophenol blue. Add 5% 2-
Mercaptoetanol freshly prior to use        
SNET buffer 20mM Tris pH 8.0, 5mM EDTA pH 8.0, 40mM NaCl, 0.5% 
SDS 
Stacking gel 5%  
 
62.5mM Tris pH 6.8, 0.1% SDS, 5% Polyacrylamide,                        
0.1% APS, 0.1% TEMED                                      
TAE buffer 50X 2mM Tris, 50mM EDTA, 1M Glacial acetic acid pH 8.0 
TBST 10X 200mM Tris, 1.5M NaCl, 1% Tween 20, pH 7.4  
TE buffer 10mM Tris-HCl, 0.2mM EDTA pH 7.5 
Transfer buffer 10X 250mM Tris, 1.92M Glycine. 1X dilution includes 
20%(v/v) Methanol                                      
Whole cell extraction 
buffer 
1.5% N-dodecylmaltoside in PBS supplemented with  
fresh 1X protease/phosphatase inhibitor  
XF Seahorse assay 
 media 
8.3g DMEM base, 10mL Glutamax, 10mL Sodium 
pyruvate, 1.85g NaCl made up to 1L  with ddH2O. Sterile 
filtered                                            
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2.1.4 Primers 
All primers used for qPCR in this thesis were found in the Primer Bank repository of the Harvard 
Medical School and ordered from Integrated DNA Technologies. These primers are listed in 
Tables 4 and 5 below 
Table 4: Human primers used for qPCR experiments in this study 
Primer Sequence (5’3’)-Forward Sequence (5’3’)-Reverse 
Atp6v0d1 GAGGAACCATGCCTATGAGCC GGATCACGTTGTCGATCATGTAA 
Atp6v0e1 GTCCTAACCGGGGAGTTATCA AAAGAGAGGGTTGAGTTGGGC 
Atp6v1a GGGTGCAGCCATGTATGAG TGCGAAGTACAGGATCTCCAA 
Atp6v1h GCTGCTGTCCCCACCAATAT GCTTCTCTTCAGGGCTTCGT 
Cox1 AACCCAATACCAAACGCCCCT GAAGGTGGTGTTGAGGTTGCG 
Cox10 CACCGCCCAGCCTATCTTTG TCATCTCTTTCCACCGCTTTTC 
Cox5a ATCCAGTCAGTTCGCTGCTAT CCAGGCATCTATATCTGGCTTG 
Ctsa TCCCAGCATGAACCTTCAGG AGTAGGCAAAGTAGACCAGGG 
Ctsb ACAACGTGGACATGAGCTACT TCGGTAAACATAACTCTCTGGGG 
Ctsc CGATGTCAACTGCTCGGTTAT AAGGCAAACCACTTGTAGTCATT 
Ctsd ATTCAGGGCGAGTACATGATCC CGACACCTTGAGCGTGTAG 
Ctsf AGAGAGGCCCAATCTCCGT GCATGGTCAATGAGCCAAGG 
Cytb TACTCACCAGACGCCTCAACC ATTGGCGTGAAGGTAGCGGAT 
Elk1 AATCGGAAGAGCTTAATGTGGAG CTTGGTGGTTTCTGGCACAAA 
Etv1 TGGCAGTTTTTGGTAGCTCTTC CGGAGTGAACGGCTAAGTTTATC 
Gaa TGCCCTCGCAGTATATCACAG GAGACCCGTAGAGGTTCGC 
Gapdh GGAGTCAACGGATTTGGTCG GACAAGCTTCCCGTTCTCAG 
Gba ATGGAGCGGTGAATGGGAAG GTGCTCAGCATAGGCATCCAG 
Hexa ACGTCCTTTACCCGAACAACT CGAAAAGCAGGTCACGATAGC 
Hprt ACCAGTCAACAGGGGACATAA CTTCGTGGGGTCCTTTTCACC 
Klf2 TTCGGTCTCTTCGACGACG TGCGAACTCTTGGTGTAGGTC 
Lamp1 CAGATGTGTTAGTGGCACCCA TTGGAAAGGTACGCCTGGATG 
Mitf GCCTCCAAGCCTCCGATAAG GCACTCTCTGTTGCATGAACT 
Continue on next page 
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Table 4: Continued from previous page 
Primer Sequence (5’3’)-Forward Sequence (5’3’)-Reverse 
Nd1 CAAAGGCCCCAACGTTGTAGG AGGGTGATGGTAGATGTGGCG 
Nd6 AGGATTGGTGCTGTGGGTGA ACCCTGACCCCTCTCCTTCAT 
Ndufs3 TGTGGCTGAAATCTTGCCCAA AGTTGAAGCGCAGAGACAACA 
Npc1 GCACCTTTTACCATCACTCCTG GGCCACAGACAATAGAGCAGT 
Npc2 CAAAGGACAGTCTTACAGCGT GGATAGGGCAGTTAATTCCACTC 
Nrf1 AGGAACACGGAGTGACCCAA TATGCTCGGTGTAAGTAGCCA 
Nrf2 TTAAACCTGCGGACACTGTTG GTATCCCAAGGCGTTCTTGTT 
Polg GCTGCACGAGCAAATCTTCG GTCCAGGTTGTCCCCGTAGA 
Polrmt GGACTCCCCGGCAAAGAAG CGCCACATCCACCCTGTTC 
S1pr1 TTCCACCGACCCATGTACTAT GCGAGGAGACTGAACACGG 
S1pr2 CATCGTCATCCTCTGTTGCG GCCTGCCAGTAGATCGGAG 
S1pr3 CGGCATCGCTTACAAGGTCAA GCCACGAACATACTGCCCT 
Sdha CAGCATGTGTTACCAAGCTGT GGTGTCGTAGAAATGCCACCT 
Sdhd CATCTCTCCACTGGACTAGCG TCCATCGCAGAGCAAGGATTC 
Sgpl1 CCTAGCACAGACCTTCTGATGT ACTCCATGCAATTAGCTGCCA 
Sgpp1 GCAACTGGCCGCTCTACTG AGAAGACCTCCAACTTGACCA 
Sphk1 GCTCTGGTGGTCATGTCTGG CACAGCAATAGCGTGCAGT 
Sphk2 ATGGCATCGTCACGGTCTC CTCCCAGTCAGGGCGATCTA 
Tfam ATGGCGTTTCTCCGAAGCAT TCCGCCCTATAAGCATCTTGA 
Tfb2m CCAAGGAAGGCGTCTAAGGC CTTTCGAGCGCAACCACTTTG 
Tfeb ACCTGTCCGAGACCTATGGG CGTCCAGACGCATAATGTTGTC 
Tpp1 CCTCCACACGGTGCAAAAATG CTCTGCTTGTCGGATGCTCAG 
Uqcrc1 GGGGCACAAGTGCTATTGC GTTGTCCAGCAGGCTAACC 
Uqcrfs1 CTGAATACCGCCGCCTTGAA ATGCGACACCCACAGTAGTTA 
mtDNA CGAAAGGACAAGAGAAATAAGG CTGTAAAGTTTTAAGTTTTATGCG 
B-globin CAACTTCATCCACGTTCACC GAAGAGCCAAGGACAGGTAC 
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Table 5: Mouse Primers used for qPCR in this study 
Primer Sequence (5’3’)-Forward Sequence (5’3’)-Reverse 
12S AGACACCTTGCCTAGCCACAC CGGTGGCTGGCACGAAATTTA 
Atg5 ATGCGGTTGAGGCTCACTTTA GGTTGATGGCCCAAAACTGG 
Atp6v0d1 GCTACTTGGAGGGATTAGTGCG GCGGAACTCTACTACCATCTTCT 
Atp6v1a CCGTACTCCGCACTGGTAAAC TGGGGATGTAGATACTTTGGGT 
CAD GCAAGTGGTTTGAATCCTCGG CATTGGGGTCCACGAATGG 
Cox5a ATGCCTGGGAATTGCGTAAAG TGCGAACAGCACTAGCAAAAT 
Creb CAGTGGGCAGTACATTGCCAT CTGCTGTCCATCAGTGGTCTG 
Ctsb TTGCGTTCGGTGAGGACATAG GCAGGAGCCCTGGTCTCTA 
Cxcl10 CCAAGTGCTGCCGTCATTTTC GGCTCGCAGGGATGATTTCAA 
Cytb GCTTTCCACTTCATCTTACCATTTA TGTTGGGTTGTTTGATCCTG 
Dguok CGTCTCCGAGCGTCTTTCC CACAGCGATGTTGCCTTCA 
Fpn TGGAACTCTATGGAAACAGCCT TGGCATTCTTATCCACCCAGT 
Fth1 CAAGTGCGCCAGAACTACCA ACAGATAGACGTAGGAGGCATAC 
Ftl1 AGGGCGTAGGCCACTTCTT CTGGGTTTTACCCCATTCATCTT 
Gaa GGGCCTGCACCCTTATCTC GGTCGGTACGTCTTCCACAG 
Gapdh TGTGTCCGTCGTTCTGA CCTGCTTCACCACCTTCTTGA 
Hprt CCTCCTCAGACCGCTTTTT AACCTGGTTCATCATCGCTAA 
Ifi44 ATGCTCCAACTGACTGCTCG ACAGCAATGCCTCTTGTCTTT 
Ifit1 GCCTATCGCCAAGATTTAGATGA TTCTGGATTTAACCGGACAGC 
Ifit3 CCTACATAAAGCACCTAGATGGC ATGTGATAGTAGATCCAGGCGT 
Irf3 GAGAGCCGAACGAGGTTCAG CTTCCAGGTTGACACGTCCG 
Irf7 GCGTACCCTGGAAGCATTTC GCACAGCGGAAGTTGGTCT 
Irp1 ACTCAAGATACGGACGCTTACC GTTGCATGACATTCCAATTCAGG 
Irp2 TTCTGCCTTACTCAATACGGGT AGGGCACTTCAACATTGCTCT 
Isg15 GGTGTCCGTGACTAACTCCAT CTGTACCACTAGCATCACTGTG 
Lamp1 GACGGTGACCAGAGCGTTC GTGGGCACTAGGGCATCAG 
Mthfd1 GGGAATCCTGAACGGGAAACT TGAGTGGCTTTGATCCCAATC 
List of Mouse primers continued on next page 
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Table 5: Continued from previous page 
Primer Sequence (5’3’)-Forward Sequence (5’3’)-Reverse 
Mthfd1l GCATGGCCTTACCCTTCAGAT GTACGAGCTTCCCCAGATTGA 
Mthfd2 AGTGCGAAATGAAGCCGTTG GACTGGCGGGATTGTCACC 
Mthfd2l ACGAAGCCGTTATCATCTCAGG TGTTCCCGAGAGCGATCCA 
Myd88 AGGACAAACGCCGGAACTTTT GCCGATAGTCTGTCTGTTCTAGT 
Nd1 AGGCCCTAACATTGTTGGTCCA TGTGAGTGATAGGGTAGGTGCA 
Nd6 ATTAAACAACCAACAAACCCAC TTTGGTGGTTGTCTGGGTT 
Ndufs3 TGGCAGCACGTAAGAAGGG CTTGGGTAAGATTTCAGCCACAT 
Nrf1 CCCCCGAGGACACTTCTTATGATG GGCCGTTTCCGTTTCTTCCCTGTT 
Nrf2 AGAAATTGAGATCGACGGGACT GCTGGGGTATAGGTTTGTTCCA 
Polg GAGCCTGCCTTACTTGGAGG GGCTGCACCAGGAATACCAG 
Polrmt AGAAGGCTCCAGTAATGTCCA CCTGCATCAGTATGCTCACAA 
Pparg GGAAGACCACTCGCATTCCTT GTAATCAGCAACCATTGGGTCA 
Rrm2b GAGCCACTCCTAAGAAAGAGTTC CAGGGAGGTCCTTTGACAAGT 
Samhd1 CTGAGTCAGTCTCGGATTGATCT AGCTGCTTGATATAGCGAAGTC 
Slc11a2 TTTAGCTTTCGTAAACTCTGGGC GTTTCCTGGGTCTAGGTAGGC 
Stat1 TCACAGTGGTTCGAGCTTCAG CGAGACATCATAGGCAGCGTG 
Stat2 GTTACACCAGGTCTACTCACAGA TGGTCTTCAATCCAGGTAGCC 
Steap3 CTCAGCGAGGGAGGTAGAAG TCGGATGAAGTTGTAGGTGTAGA 
Sting TCGCACGAACTTGGACTACTG CCAACTGAGGTATATGTCAGCAG 
Tfam GCTCTACACGCCCCTGGTTTCTGG TCGCTGTAGTGCCTGCTGCTCCTG 
Tfb2m TATAGAGCCGTTGCCTGATTCT GCCGCTTTCTTACATGCTATGTG 
Tfeb CCACCCCAGCCATCAACAC CAGACAGATACTCCCGAACCTT 
Tfrc GTTTCTGCCAGCCCCTTATTAT GCAAGGAAAGGATATGCAGCA 
Tk2 AGCAGTGGTTTGTATTGAGGG ACATGAGGCTCAGAGGGTTATG 
Tlr9 ACAACTCTGACTTCGTCCACC TCTGGGCTCAATGGTCATGTG 
Tsc2 TGAATGCGGCCTCAACAATC GACAGCCTTCCAAAGTGCCT 
mtDNA CCTATCACCCTTGCCATCAT GAGGCTGTTGCTTGTGTGAC 
nDNA ATGGAAAGCCTGCCATCATG TCCTTGTTGTTCAGCATCAC 
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2.1.5 Cell culture devices 
The following materials and devices were used specifically for cell culture experiments carried 
out in this study. 
Table 6: Cell culture materials and devices 
Product Supplier Catalog number 
60 x 20 mm TC dish CytoOne CC7682-3354 
100 x 20 mm TC dish CytoOne CC7682-3394 
150 x 20 mm TC dish CytoOne CC7682-3617 
6-well TC plate CytoOne CC7682-7506 
12-well TC plate CytoOne CC7682-7512 
96-well TC plate CytoOne CC7682-7596 
96-well TC plate black Thermo Scientific 137104 
Cell scraper StarLab CC7600-0202 
Countess cell counting chamber slides Invitrogen C10283 
Coverslips Marienfeld 017580 
Cryogenic vial 2 mL Fisher Brand 1050026 
Filter syringe 0.22 Ø Rotilabo CME Carl Roth SE2M35I07 
Syringe Inject  Becton. Dickinson and 
company 
4606205 
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2.1.6 Plasmids 
Transfections were carried out with pcDNA, shRNA, and siRNA listed below (Table 7). 
Table 7: Plasmids used in this study 
Plasmid Supplier Catalog number 
PLP1, PLP2, PLP-VSVG Kind gift from Prof. D Katschinski 
pLKO.1-blast-scrambled Addgene 26701 
Scrambled negative control Integrated DNA Technologies 51-01-19-09 
shRNA-human GAA GE Dharmacon RHS3979-9616754 
siRNA-human ETV1  Integrated DNA Technologies 72688375 
siRNA-human ETV1 Integrated DNA Technologies 72688384 
siRNA-human KLF2 Integrated DNA Technologies 72688381 
siRNA-human KLF2 Integrated DNA Technologies 72688378 
siRNA-human TFEB Integrated DNA Technologies 73459471 
siRNA-human TFEB Integrated DNA Technologies 73459474 
siRNA-mouse ATG5 Integrated DNA Technologies 69223127 
siRNA-mouse ATG5 Integrated DNA Technologies 69223130 
siRNA-mouse SLC11A2 Integrated DNA Technologies 72093245 
siRNA-mouse SLC11A2 Integrated DNA Technologies 72093248 
siRNA-mouse TMEM173 Integrated DNA Technologies 70933800 
siRNA-mouse TMEM173 Integrated DNA Technologies 70933803 
siRNA-mouse TSC2  Integrated DNA Technologies 71074023 
siRNA-mouse TSC2 Integrated DNA Technologies 71074026 
siRNA-mouse TSC2 Integrated DNA Technologies 71074029 
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2.1.7 Antibodies 
Different primary and secondary antibodies were used for Immunoblotting (IB) and 
immunocytochemistry (IHC) experiments in this thesis. These antibodies are listed below.  
Table 8: Primary antibodies for immunoblotting and immunocytochemistry 
Antibody Supplier Catalog number Application Dilution 
ACC Cell signaling 3676 IB 1:1000 
ACC pSer79 Cell signaling 3661 IB 1:1000 
AKT pan Cell signaling 4691 IB 1:1000 
AKT pSer473 Cell signaling 4060 IB 1:1000 
ATG5 Cell signaling 12994 IB 1:1000 
CAD Cell signaling 9392 IB 1:1000 
CAD pSer1859 Cell signaling 1266 IB 1:1000 
DGUOK Sigma Aldrich HPA034766 IB 1:1000 
ERK Cell signaling 4695 IB 1:1000 
ERK pThr204 Cell signaling 4376 IB 1:1000 
ETV1 Abcam ab184120 IB 1:1000 
MTHFD1 Sigma Aldrich HPA000704 IB 1:1000 
MTHFD2 Abcam ab151447 IB 1:1000 
P70S6K1 Cell signaling 2708 IB 1:1000 
P70S6K1 pThr389 Cell signaling 9234 IB 1:1000 
SAMHD1 Abcam ab128107 IB 1:1000 
SAMHD1 pThr592 Cell signaling 15038 IB 1:1000 
SQSTM1 Abcam ab110252 IB 1:8000 
TSC2 Cell signaling 4308 IB 1:1000 
List of primary antibodies continued on next page 
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Table 8: Continued from previous page 
Antibody Supplier Catalog number Application Dilution 
FTH1 Cell signaling 3998 IB 1:2000 
FTL1 Abcam ab69090 IB 1:2000 
GAPDH Sigma Aldrich G9545 IB 1:10000 
GFAP Kind gift from Prof. K-A Nave IB/ IHC 1:1000 
HPRT Abcam ab10479 IB 1:4000 
KLF2 Abcam ab203591 IB 1:1000 
LAMP1 Abcam ab24170 IB 1:2000 
LC3B (D11) Cell Signaling 3868 IB 1:2000 
MBP Kind gift from Prof. K-A Nave IB/ IHC 1:1000 
NDUFS3 Invitrogen 459130 IB 1:1000 
NRF1 Abcam ab175932 IB 1:1000 
NRF2 ProteinTech 21542-1-AP IB 1:1000 
OXPHOS Abcam ab110413 IB 1:2000 
PLP Kind gift from Prof. K-A Nave IB/ IHC 1:1000 
S1PR1 Abcam ab125074 IB 1:5000 
S6 Cell signaling 2217 IB 1:2000 
S6 pSer235/236 Cell signaling 4858 IB 1:2000 
TFAM Abcam ab138351 IB 1:1000 
TFEB Novus NBP1-67872 IB 1:1000 
TFRC Abcam ab84036 IB 1:1000 
UQCRC1 Abcam ab110252 IB 1:1000 
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Table 9: Secondary antibodies for immunoblotting and immunocytochemistry 
 
 
 
2.1.8 Cell lines 
HeLa and DU145 cells used in this work were purchased from ATCC. In addition, HEK293T 
cells, obtained from Prof. Katschinki’s Lab, were used as lentiviral packaging cells for the 
generation of stable GAA knock-downs. Niemann-Pick Type A/B patient and age-matched 
control fibroblasts were obtained from the University of Goettingen Medical Center (Prof. 
Robert Steinfeld) and maintained under the UMG’s ethical guidelines. 
 
2.1.9 Instruments 
All instruments and equipment used in this study are listed in Table 10 below. 
Table 10: List of instruments and equipment 
Instrument Manufacturer 
Ace Block Digital Dry Bath Labnet 
Amaxa 4D-Nucleofector Lonza 
Bio-Rad Power Pack HC Mini-Protean Tetra System Bio-Rad 
CAWOMAT 2000 CAWO 
Centrifuge 5415R Eppendorf 
Centrifuge 5810R Eppendorf 
Centrifuge Allegra X-15R Beckman Coulter 
Continue on next page 
Antibody Supplier Code Applications 
Goat anti-mouse IgG Dianova 115-035-146 IB 
Goat anti-mouse Alexa 488 Life Technologies A-11001 IHC 
Goat anti-rabbit IgG Dianova 115-035-144 IB 
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Table 10: Continued from previous page 
Instrument Manufacturer 
Countess C10281 Invitrogen 
Cryogrider tool kit 230V OPS Diagnostics 
FACS CantoTMII BD Biosciences 
Gene Quant 1300 GE Healthcare 
Hood Herasafe Thermo Scientific 
Incubator Heracell 150i Thermo Scientific 
Leica CM 1850 Cryostat Leica Biosystems 
Microscope Zeiss Axio Vert A1 Zeiss 
Multichannel pipette Eppendorf Research 
Nanodrop 2000C Peqlab 
Pipettes Eppendorf Research 
Pipette gun accu-jet pro BrandTech Scientific Inc. 
pH meter pH7110 WTW Inolab 
Potter S (Dounce homogenizer) Sartorius 
Precision balance Explorer OHAUS 
Quant Studio 6 Flex Life Technologies 
Revolver wheel Labnet 
Scanner Epson Perfection V850 Pro Epson 
Seahorse XF96 Extracellular Flux Analyzer Agilent 
SE600 Ruby system GE Healthcare 
Spinning disk confocal microscope  Perkin Elmer 
Continue on next page 
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Table 10: Continued from previous page 
Instrument Manufacturer 
SYNERGYM1 microplate reader BioTek 
Thermocycler UNO II Biometra 
Vortex RS-VA10 Phoenix Instrument 
LSM 880 Airyscan Zeiss 
 
2.1.10 Software 
Several software programs were used to analyze most of the data obtained from experiments 
carried out in this study. The table below lists these software packages and their manufacturers. 
Table 11: List of software programs 
Software Manufacturer City/State Country 
Adobe Illustrator CS6 Adobe Systems Inc. San Jose, CA USA 
FACS DIVATM software BD Biosciences Heidelberg Germany 
FlowJo FlowJo LLC Ashland, OR USA 
GraphPad Prism 6 & 7 GraphPad Software Inc.  La Jolla, CA USA 
GeneSpring 13.0 Agilent Santa Clara, CA USA 
Genomatix Suite Genomatix GmbH Munich Germany 
ImageJ NIH  Bethesda, MD USA 
IPA Ingenuity Qiagen  Redwood City, CA USA 
Mendeley Mendeley Ltd London UK 
MetaboAnalyst 3.0 McGill University Montreal Canada 
Microsoft Oﬃce Microsoft Corporation Redmond, WA USA 
  
 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Fibroblast culture growth conditions 
 
All fibroblasts used in this study were cultured in sterile Dulbecco's Modified Eagle Medium 
high glucose medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
Penicillin/Streptomycin (P/S), hereafter referred to as growth medium, in a humidified incubator 
at 37°C and 5% CO2 unless otherwise noted. In all experiments, cells were harvested at 70-80 
% confluence except for mtDNA copy number experiments, in which case cells were always 
confluent prior to harvesting. Cells were usually seeded at least 24 hours before experiments 
at the following densities: 
Table 12: Seeding density and application for cell culture experiments 
Type of cell culture plate Seeding density Application 
15cm plate 2.5 x 106 cells Cell lysates, nucleic acid isolation 
6cm plate 2.0 x 105 cells Flow cytometry 
6-well plate 1.2 x 105 cells Flow cytometry 
12-well plate 3.5 x 104 cells Microscopy 
96-well plate 1.2 x 104 cells Microplate reader assays, respirometry 
 
2.2.1.2 Drug and chemical treatment of adherent cells 
For each application, human dermal fibroblasts or mouse embryonic fibroblasts were seeded 
in the appropriate plate and at the corresponding density at least 24 hours prior to chemical 
treatments. The following chemicals and their concentrations (unless stated otherwise) were 
used for cell treatments: 50µM Chloroquine, 1µM Oligomycin, 2µM Carbonyl cyanide 3-
fluorophenylhydrazone (FCCP), 1µM Rotenone, 1µM Antimycin, 40µM Desipramine, 5µM 
Sew2871, 20µM U0126, 50µM Folic acid, 100µM Ferric citrate. The diluent for each chemical 
was used as the corresponding control for treatments. Unless otherwise noted, cells were 
treated with these drugs for 72 hours by briefly washing cells in warm PBS and replacing the 
growth medium with growth medium supplemented with the corresponding drug or its diluent 
as a control. 
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2.2.1.3 Generation of stable GAA knockdown cell lines 
Lentiviral suspensions were obtained by lipofectamine-mediated transfection of HEK293T 
packaging cells with an optimized mix of packaging plasmids (PLP1, PLP2, and PLP/VSVG) 
and either of GAA shRNAs targeting five different regions of GAA coding gene or scrambled 
non-targeting negative control shRNA. Following manufacturer’s instructions, lentiviral vectors 
were concentrated using the Lenti-X concentrator. HeLa and DU145 cell lines were transduced 
with concentrated viral suspension supplemented with 8ug/ml Polybrene and cells with 
puromycin resistance were selected and polyclonally expanded. Knockdown efficiency was 
confirmed by Western blot and qPCR. The best two knockdowns were selected for subsequent 
experiments. 
 
2.2.1.4 Transfection of dermal and mouse embryonic fibroblasts 
Control and patient dermal fibroblasts or MEFs were transfected with siRNAs for target genes 
or scrambled negative control using electroporation, following manufacturer’s instructions. 
Briefly, after collecting cells as described in section 2.2.1.5, the cell pellet was resuspended in 
warm growth medium and 20µL of the suspension was applied to an improved Neubauer cell 
counting chamber. The cell density was determined by the formula: 
𝑁 × 104 where N is the average cell number in the four corner squares 
Following cell density determinations, 1.5 × 106 cells were pelleted and the excess medium 
was aspirated. 100µL of Amaxa transfection working reagent (made of 263µL of buffer and 
62.5µL of supplement) was added to the cell pellet. siRNA vectors were added to a final 
concentration of 10nM and the cell pellet was resuspended by gently pipetting up and down. 
The cell suspension was transferred to labeled electroporation cuvettes and electroporated 
with the appropriate program for dermal fibroblasts or MEFs using the Amaxa 4D Nucleofector. 
The electroporated cells were then incubated at RT for 10 minutes, resuspended in warm 
growth medium and passed into appropriate plates depending on further applications. The 
transfected cells were cultured in normal growth conditions and harvested after 72 hours.  
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2.2.1.5 Harvesting of adherent fibroblasts 
For the preparation of whole cell lysates, nucleic acid isolation or cell iron measurements, 
adherent cells were harvested by aspirating the growth medium and washing once in warm 
PBS. Growth medium is then replaced with 10mL ice-cold PBS and the cells are scraped on 
ice. The cell suspension is then collected and distributed into appropriate tubes for cell lysate 
preparation and nucleic acid isolation. The cell suspension is then pelleted at 2500rpm, 40C for 
5minutes. The supernatant is discarded and the pellet is used for the required application or is 
snap frozen in liquid nitrogen and stored at -800C for later use. For all other determinations 
including flow cytometry, cryopreservation and transfection of fibroblasts adherent cells were 
collected by aspirating the growth medium, washing in warm PBS and detaching cells with 
TrypLE Express enzyme during 5 minutes incubation at 370C. Trypsin activity is blocked by 
adding twice the volume of growth medium. The cell suspension is then collected into labeled 
falcon tubes and centrifuged at centrifuged at 1500rpm, 40C for 5minutes. The supernatant is 
discarded and the cell pellet is used for subsequent applications. 
 
2.2.1.6 Cryopreservation and thawing of fibroblasts 
To freeze fibroblasts, cells were collected by trypsinization as described before and the cell 
pellet was resuspended in freezing medium. 1mL aliquots of the cell suspension were made 
into labeled cryotubes and transferred to Mr. Frosty freezing containers filled with isopropanol. 
The cells were frozen at -80°C overnight and then transferred to labeled cryo-boxes in a liquid 
nitrogen tank. On the other hand, to defrost cells, frozen cells were quickly thawed in a water 
bath set at 37°C and cultured with a suitable amount of warm growth medium at normal growth 
conditions. Following overnight incubation, the growth medium was aspirated, cells were 
washed with warm PBS and cultured in fresh warm growth medium. 
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2.2.2 Transgenic animal handling 
2.2.2.1 Mouse lines and genotyping 
All mouse lines used in this study were bred and housed under standard conditions at the 
animal facility of the European Neuroscience Institute with access to food and water ad libitum. 
All animal experiments were carried out in accordance with the European guidelines for animal 
welfare and were approved by the Lower Saxony Landesamt fur Verbraucherschutz and 
Lebensmittelsicherheit (LAVES), registration number 15-1883. Mouse lines used for 
experiments in this study included GAA-/- mice (Jackson’s lab, USA) and their wild-type 
littermate controls.  
 
2.2.2.1.1 Isolation of genomic DNA from mouse tails 
Genomic DNA (gDNA) was extracted by digesting 1cm of mouse tails in 300µL SNET buffer 
supplemented with 50µg/ml proteinase K at 55°C for 2 hours in a thermomixer. The lysed 
samples were centrifuged at 11000 x g for 20 minutes and the supernatant was collected. 
750µL of absolute ethanol was added to the supernatant and inverted 4-6 times to completely 
precipitate gDNA. The precipitated gDNA was pelleted at 11000 x g for 30 minutes, washed 
with 900µL of 70% ethanol and centrifuged again at 11000 x g for 20 minutes. The supernatant 
was removed and the isolated gDNA was air dried and resuspended by adding 50µL TE buffer 
and placing the samples in a thermomixer at 55°C for 30 minutes with vortexing. The 
concentration of DNA was measured using the Nanodrop and the gDNA was used for 
genotyping or stored at -20°C. 
 
2.2.2.1.2 Genotyping of GAA mice 
Following gDNA isolation from mouse tails, for the purpose of genotyping, gDNA was amplified 
using the GoTaq Flexi DNA polymerase kit according to manufacturer’s protocol. Briefly, each 
25µL reaction was made of 5µL of 5X reaction buffer, 2µL of 25mM MgCl2, 0.5µL of 10mM 
dNTPs, 0.5µL each of 10µM primers, 0.2µL of 5U/µL Taq polymerase, 12.8µL of nuclease-free 
water and 3µL of gDNA template. The following thermal cycling protocol was used for gDNA 
amplification: initial denaturation at 95°C for 10 minutes, 33 cycles of denaturation at 95°C for 
30 seconds, annealing at 58°C for 45 seconds and extension at 72°C 1 minute, followed by 7 
minutes of final extension at 72°C. The reaction was then held at 10°C indefinitely. 18µL of 
amplicons, mixed with 5X loading buffer along with a standard DNA marker were 
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electrophoresed in 1.5% agarose gels. The gels were previously poured by dissolving 1.5g of 
agarose in 100mL of 1X TAE buffer, boiled in a microwave to dissolve the agarose, allowed to 
cool to about 60°C and mixed with 3µL of 10mg/mL ethidium bromide and poured into a 
horizontal chamber. 1X TAE buffer was used as running buffer for the electrophoresis, which 
was run at a steady voltage of 120V. Following electrophoresis, the DNA was imaged with a 
UV gel documentation system and the size of DNA fragments was determined by comparing 
bands to the DNA marker. 
Table 13: Primers used for GAA mouse genotyping 
Primer Sequence 
IMR7067 TCC TGA GCC CAA ACA CTT CT 
IMR7077 ATT GTT GCA CAA CGC TCT TG 
IMR7297 CGT TGG CTA CCC GTG ATA TT 
 
2.2.2.2 Harvesting of mouse tissues 
For biochemical and molecular biology applications, mouse tissues were harvested, snap 
frozen in liquid nitrogen and stored at -80°C until usage. Briefly, GAA-/- mice and their wild-type 
littermates were anesthetized with isoflurane following which they were euthanized by cervical 
dislocation. Each mouse was decapitated and the head was sprayed with 70% Ethanol. The 
skull was opened after peeling off the skin of the scalp and the brain was removed and placed 
in a dish containing PBS. With the help of a light microscope, the brain was dissected into 
cortices, hippocampi, and rest of the brain. These were transferred into Eppendorf tubes and 
snap frozen in liquid nitrogen. For other tissues, the rest of the body of the mouse was placed 
in a dish and sprayed with 70% Ethanol. The abdomen was opened and a small piece of the 
liver was cut into an Eppendorf tube. The diaphragm was cut open and the heart was also 
removed, rinsed in PBS and placed in an Eppendorf tube. Quadriceps were also obtained from 
the mice after peeling off the thigh skin and placed in an Eppendorf tube. Similarly, these 
samples were also snap frozen in liquid nitrogen. All samples were then stored at -80°C. Prior 
to usage for other applications, tissues were powdered by grinding under liquid nitrogen using 
a cryogrinder toolkit. Aliquots of powdered tissue were then made and used immediately or 
stored at -80°C. 
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2.2.2.3 Perfusion and fixation of mouse tissues and immunohistochemistry 
Immunohistochemical assays provide reliable techniques to assess the localization and/or 
distribution of cellular components in tissues. The success of these approaches depends 
largely on adequate sample preparation, where cellular components of samples are preserved 
as closely as possible to their native states. To this end, mice were anesthetized with 40mg/mL 
chloral hydrate in PBS by abdominal peritoneal injection. Mice were then fixed to a surgical 
platform and the abdomen was cut open along both sides until the diaphragm, which was then 
cut to expose the beating heart. Cardiac perfusion was then carried out first with cold 100U/mL 
heparin in PBS followed by cold 4% Paraformaldehyde (PFA) in PBS. The whole brain was 
carefully harvested as described before (see previous section) and post-fixed in 5mL of 4% 
PFA in PBS overnight at 4°C. After slow dehydration in 12%, 15%, and 18% sucrose gradient 
solutions, the brain was embedded in OCT (Tissue Tek) in a cryomold, frozen in isopentane 
set in liquid nitrogen and stored at -80°C. For immunohistochemistry (IHC), 10µM thick sagittal 
sections of the cortex were cut with a cryostat and placed on microscope glass slides. Brain 
sections were then washed twice in PBS for a minute, incubated with 50mM NH4Cl in PBS for 
10 minutes and rinsed with PBS. Sections were blocked and permeabilized in IHC blocking 
buffer for 1 hour at RT, following which they were labeled with diluted primary antibodies in IHC 
blocking buffer by overnight incubation at 4°C. The sections were rinsed multiple times in PBS, 
washed for a further three times in PBS for 10 minutes and incubated in diluted fluorescently 
labeled secondary antibodies at RT for 1–2 hours. Sections were rinsed and washed once in 
PBS for 10 minutes, counterstained with DAPI (1:5000 in PBS) for 5 minutes at RT in the dark, 
washed once in PBS for 15 minutes (protected from light) and mounted with Mowiol® 4-88. 
Sections were left to dry overnight at RT in the dark and sealed. Slides were immediately 
imaged or stored in slide boxes at 4°C. 
 
2.2.2.4 Isolation of mitochondria from mouse tissue 
Fresh mouse cortices were harvested as described in section 2.2.2.2, washed twice in 3mL 
cold PBS and cut into smaller pieces. The pieces of tissue were transferred into a pre-chilled 
Dounce homogenizer on ice and 1mL of Homogenization buffer A was added to it. Dounce 
homogenization was performed by potting tissues on ice for 50 strokes. Samples were 
transferred into 1.5mL Eppendorf tubes and spun at 700 x g for 10 minutes at 4°C. The 
supernatant was transferred into new Eppendorf tubes. The pellet was resuspended in 1mL 
Homogenization buffer A and placed in the Dounce homogenizer. Homogenization was 
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performed again as before. The samples were collected into Eppendorf tubes and centrifuged 
again at 700 x g for 10 minutes at 4°C. The supernatant was collected, pooled with previously 
collected supernatant and centrifuged for a further 10 minutes at 700 x g, 4°C. The supernatant 
was again collected and further centrifuged at 11000 x g for 15 minutes at 4°C. The supernatant 
was collected into new Eppendorf tubes as the cytosolic fraction. The mitochondrial pellet was 
washed with 500µL of Homogenization buffer B and centrifuged again at 11000 x g for 5 
minutes at 4°C. The supernatant was discarded and the isolated mitochondria (pellet) were 
resuspended in 200uL of Homogenization buffer B. The mitochondrial protein concentration 
was determined using the Pierce BCA assay (described later see section 2.2.3.4). Purified 
mitochondria were used immediately for subsequent applications or aliquoted, snap frozen in 
liquid nitrogen and stored at -80°C.  
 
2.2.3 Biochemical procedures 
2.2.3.1 Preparation of whole cell lysates from adherent cells 
Whole cell lysates were prepared by resuspending previously harvested adherent cell pellets 
on ice in 50–150µL of lysis buffer (1.5% N-dodecyl β-D-maltoside in PBS supplemented with 
protease and phosphatase inhibitor), depending on pellet size. The cell suspension was 
transferred to 1.5ml Eppendorf tubes and lysed by rotation at 4°C for 30 minutes. The cell 
homogenate was then centrifuged at 16000rpm, 4°C for 20 minutes. The whole cell lysate 
(supernatant) was collected into new 1.5mL Eppendorf tubes and the protein concentration 
was determined by the Bradford Assay. In order to avoid freeze-thaw cycles, lysates were 
either used for further determinations or aliquoted and stored at -80°C. 
 
2.2.3.2 Preparation of whole tissue lysates 
For tissue lysates, previously cryoground tissue powder in 1.5mL Eppendorf tubes were 
resuspended in 250–400µL of RIPA buffer supplemented with protease and phosphatase 
inhibitor (depending on tissue size), vortexed briefly and lysed by rotation at 4°C for 1 hour. 
Following lysis, the tissue homogenate was centrifuged at 16000rpm, 4°C for 20 minutes. The 
tissue lysate (supernatant) was collected into new 1.5mL Eppendorf tubes and the protein 
concentration was determined by the Pierce Assay.  In order to avoid freeze-thaw cycles, 
lysates were used for further determinations or aliquoted, snap frozen in liquid nitrogen and 
stored at -80°C. 
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2.2.3.3 Protein concentration determination using Bradford assay 
Protein concentrations of whole cell lysates were determined using Protein Assay Dye Reagent 
Concentrate (Bio-Rad) following manufacturer’s protocol. Along with standards using bovine 
serum albumin (BSA), the protein concentration of cell lysates was determined by mixing, in 
duplicates, 800µL of ddH2O, 1µL of sample or standard and 200µL of protein assay dye reagent 
concentrate in a glass tube and vortexed briefly. The tubes containing mixtures were incubated 
at RT in the dark for 5 minutes and transferred into plastic cuvettes. The absorbance at 595 
nm was measured using a GeneQuant 1300 spectrophotometer. The protein concentration of 
the cell lysates was calculated based on the standard calibration curve using Microsoft Excel 
2013.  
 
2.2.3.4 Protein concentration determination using Pierce BCA assay 
Protein concentrations of tissue lysates and purified tissue mitochondria were determined using 
Pierce BCA Protein Assay Kit (Bio-Rad) according to manufacturer’s instructions. Along with 
albumin standards, the protein concentration of tissue lysates or purified mitochondria was 
determined by mixing, in duplicates, 1mL of Pierce BCA working reagent (reagents A and B, 
50:1) and 50µL of standards or 1:40 diluted samples in a glass tube and vortexed briefly. The 
tubes containing mixture were incubated at 37°C for 30 minutes in the dark and transferred into 
plastic cuvettes. The absorbance at 562 nm was measured using a GeneQuant 1300 
spectrophotometer. The protein concentration of the cell lysates was calculated based on the 
standard calibration curve while taking into consideration the sample dilution factor using 
Microsoft Excel 2013.  
 
2.2.3.5 SDS-PAGE 
SDS-PAGE is a widely used technique to separate denatured molecules according to their 
weight. Briefly, using the Bio-Rad Gel preparation system, 1mm thick 12% resolving gels were 
made with the composition described previously in section 2.1.3, poured between the gel glass 
plates and covered with isopropanol to prevent air bubbles. After the gels were set, the excess 
isopropanol was drained and the gels were rinsed with ddH2O. The excess water was also 
drained and the 4% stacking gel (composition previously described) was poured on top of the 
polymerized resolving gel. A desired multi-well comb was quickly inserted into the stacking gel 
and allowed to set. The polymerized gel was used immediately or stored in a container filled 
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with 1X running buffer at 4°C. To run the SDS-PAGE, the Mini-Protean Tetra System (Bio-Rad) 
was set up with gels without the combs and filled with 1X running buffer. An equal amount of 
protein from cell or tissue lysates was mixed with 4µL of 6X SDS loading buffer, made up to 
24µL with lysis buffer, boiled at 95°C for 5 minutes and loaded per well in a 10-well gel along 
with a molecular weight standard, the PageRuler plus Prestained ladder. For 15-well gels, an 
equal amount of protein and 3µL of 6X SDS made up to 18µL with lysis buffer instead was 
loaded per well after boiling at 95°C for 5 minutes. Within the stacking gel, the electrophoresis 
was run at an initial constant voltage of 80V and switched to constant 180V when samples 
were in the resolving gel and run until samples reached the bottom of the gel.  
 
2.2.3.6 Immunoblotting 
Following SDS-PAGE and in order to detect specific target proteins, Western blot was carried 
according to protocols described by (Gallagher et al 2011). Briefly, polyvinylidene fluoride 
(PVDF) membranes were rinsed for 15 sec in methanol to activate them and washed with ddH2O 
for 3 minutes. Previously run gels were disassembled from the gel glass plates, stacking gels 
were cut off and the gels along with activated PVDF membranes were equilibrated at RT in 1X 
transfer buffer (contains 20% methanol and cold at all times). The transfer sponges and sheets 
of Whatman paper were also soaked in 1X transfer buffer. Using the tank transfer system, the 
transfer sandwich was assembled on a plastic transfer cassette completely immersed in 1X 
transfer buffer to avoid trapping air bubbles. The order of the transfer assembly was as follows: 
place a soaked sponge on the bottom half of the plastic transfer cassette followed by two sheets 
of wet Whatman paper, place gel on top of the papers and remove any air bubbles by gently 
rolling a roller over the gel surface, place wet PVDF membrane on top of the gel and roll over 
membrane surface to remove any air bubbles and place again two sheets of wet Whatman 
paper followed by one wet transfer sponge. The top half of the transfer cassette was locked in 
place and the transfer sandwich was placed in the transfer apparatus in a tank filled with 1X 
transfer buffer while ensuring the correct orientation (bottom half towards cathode). A cold ice 
pack was also placed in the tank to avoid excessive heating of the transfer buffer. The proteins 
were transferred from gel to PVDF membrane at constant 100V for 1.5 hours in a cold room. 
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2.2.3.7 Immunodetection 
After complete electrotransfer of proteins onto PVDF membranes, the transfer sandwich was 
disassembled and the PVDF membranes were blocked in blocking buffer with mild shaking for 
1 hour at RT. The membranes were then washed three times in 1X TBST for 5 minutes and 
labeled with primary antibodies (diluted in blocking buffer) by overnight incubation at 4 °C. The 
membranes were washed three times in 1X TBST for 10 minutes and incubated with 
appropriate HRP-conjugated secondary antibodies diluted in blocking buffer at RT for 1 hour 
and washed three more times in 1X TBST for 10 minutes. Signals representing proteins by 
chemiluminescence were detected by draining excess 1X TBST on membranes, incubating 
membranes in Luminata Western HRP substrate for 3 minutes and developing signals on 
medical X-ray films using the AGFA Curix 60 processor. The films were scanned with the Epson 
Perfection V850 Pro Scanner and band densities were quantified with Image J software.  
 
2.2.3.8 BN-PAGE and respiratory chain complex activity staining 
BN-PAGE, unlike SDS-PAGE, resolves non-denatured proteins thereby also preserving their 
physiological interactions with other proteins. As a result, the electrophoretic mobility depends 
not only on the charge-to-mass ratio but also on the size and shape of proteins. As this 
technique was developed to separate mitochondrial proteins and complexes, under low 
detergent conditions, respiratory chain supercomplexes are preserved, allowing for further in-
gel staining of their activities (Schägger and Pfeiffer, 2000; Schägger and von Jagow, 1991). 
We took advantage of this technique to characterize the role of lysosomal malfunction in 
mitochondrial complex assembly and function.  
 
2.2.3.8.1 BN-PAGE: sample preparation 
50µg each of previously isolated mitochondria from mouse cortices was centrifuged at 
14000rpm, 2°C for 5 minutes. The supernatant was removed and the mitochondrial pellet was 
resuspended in 50µL of ice-cold digitonin solubilization buffer. The mitochondria were 
solubilized by pipetting up and down (10 times) without generating foam. The mitochondria 
were mixed on a shaker at RT for 10 seconds and put back on ice for 15 minutes to complete 
solubilization. To remove insoluble material, the samples were centrifuged at 14000rpm, 2°C 
for 5 minutes and the supernatant was transferred into new pre-cooled Eppendorf tubes. 5µL 
of 10X BN–loading dye was added to 45µL of the solubilized mitochondria and cleared by 
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spinning at 14000rpm, 2°C for 2 minutes. Each 50µL sample was loaded per well in a 6–16.5% 
gradient gel along with a molecular weight standard.   
 
2.2.3.8.2 BN-PAGE: casting gels and electrophoresis 
For native separation of mitochondrial protein complexes by BN-PAGE, the protocol described 
in Dekker et al. (1997) was used. The gels were cast and run using the SE600 Ruby system. 
Briefly, resolving gels were made from equal volumes of 6% and 16.5% acrylamide (stock: a 
mixture of 48% acrylamide and 1.5% bisacrylamide) in 1X BN–gel buffer supplemented with 
0.44% APS and TEMED and cast using a gradient gel maker with pump. The stacking gel 
contained 4% acrylamide solution in 1X BN-gel buffer, 0.08% APS and 0.133% TEMED. 
Following loading of samples in the gels, the cathode buffer was gently overlaid on the samples. 
The gel was then run in a cooled gel-chamber at 15mA per gel at 100V overnight at 4°C. The 
cathode buffer was replaced with the anode buffer when the electrophoresis was half-way 
through the gel. The electrophoresis was completed just prior to the blue loading dye running 
out of the gel into the anode buffer. 
 
2.2.3.8.3 BN-PAGE: enzyme activity staining 
To assess the activity of complex IV of the respiratory chain, we took advantage of the COX-
catalyzed reaction, which is coupled to the oxidation of 2, 2-diaminobenzidine (DAB). Briefly, 
electrophoresed gels were equilibrated in 50mM Potassium phosphate buffer (pH 7.4) for at 
least 15 minutes at RT. The gels were then incubated in 10mL of complex IV activity staining 
buffer (see section 2.1.3) at 30°C until the brown bands of oxidized DAB were visible. The gels 
were then rinsed briefly in equilibration buffer and scanned using the Epson Perfection V850 
Pro Scanner. The intensity of DAB stains was quantified using Image J software.  
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2.2.4 Molecular biology 
2.2.4.1 RNA isolation from cells 
Ribonucleic acid (RNA) was isolated from cells using the CRYSTAL RNA Mini Kit (BioLab) 
according to manufacturer’s protocol. Cell pellets were lysed by adding 400 µL of Lysis Solution 
RL supplemented with 1% 2-Mercaptoethanol (β-SH), incubated at RT for 2 minutes, 
resuspended and incubated for a further 3 minutes at RT. The lysed samples were transferred 
to Spin Filter D column placed in Receiver Tubes 2 mL and centrifuged for 2 minutes at 
12000rpm. The column was discarded and 400 µL of 70 % ethanol was added to the flow-
through, mixed gently by pipetting to precipitate RNA, transferred to Spin Filter R column in 
Receiver Tubes 2 mL and centrifuged again for 2 minutes at 12000rpm. The flow-through was 
discarded and the column was washed with 500 µL of Washing Solution HS, followed by 
washing with 700 µL of Washing Solution LS at 10000rpm centrifugation for 1 minute each. 
The RNA was dried by centrifuging columns in Receiver Tubes 2mL at 12000rpm for 2 minutes. 
The RNA was eluted into RNAse-free 1.5mL collection tubes by adding 20–50µL of nuclease-
free water, incubated at RT for 1 minute and centrifuged at 8000rpm for 1 minute. The RNA 
concentration was determined as described (see 2.2.4.4) and the RNA was either used 
immediately or frozen at -80°C. 
 
2.2.4.2 RNA isolation from tissues 
Isolating RNA from tissues was found to be impractical with the commercial kit we used for 
purifying RNA from cells. As a result, isolating RNA from tissues was carried using the TRI 
reagent (Sigma) according to protocols described by Rio et al. (2010) with slight modifications. 
Cryoground tissues were homogenized in 1mL of TRI reagent following 5 minutes incubation 
at RT in 1.5mL Eppendorf tubes. 0.2mL of chloroform was added per 1mL of TRI reagent. 
Tubes were securely capped, shaken vigorously by hand for 15 seconds and incubated at RT 
for 2–3 minutes. The samples were centrifuged at 12000 x g for 15 minutes at 4°C. The 
aqueous phase was removed and placed in new RNAse-free 1.5mL Eppendorf tubes. RNA 
was precipitated by adding 0.5mL of isopropanol per 1mL of TRI reagent used and incubating 
at RT for 10 minutes and pelleted by centrifugation at 12000 x g for 10 minutes at 4°C. The 
supernatant was removed and the RNA pellet was washed by adding 1mL 75% Ethanol per 
1mL of TRI reagent, vortexed briefly and centrifuged at 7500 x g at 5 minutes at 4°C. The 
supernatant was removed and the RNA pellet was air-dried at RT for 5–10 minutes, 
resuspended in 50µL of RNAse-free water and incubated in a heat block at 55°C for 10–15 
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minutes. The RNA concentration was determined as described (see 2.2.4.4) and the RNA was 
either used immediately or frozen at -80°C. 
2.2.4.3 Total DNA isolation from cells and tissues 
For the purpose of mtDNA copy number determination, total DNA was isolated from cells and 
tissues as described in Cotney et al. (2007). Briefly, cells or tissues were lysed in 500µL of 
DNA extraction buffer (composition described, see Table 3) and boiled for 10 minutes at 95°C. 
After cell lysis, samples were cooled to RT and 100µg of RNAse A was added to each sample 
and incubated at 37°C for 3 hours. Following degradation of RNAs, 100µg of Proteinase K was 
added to each sample and incubated at 55°C overnight. Samples were then heated to 95°C 
and allowed to cool to RT. Total DNA concentration was determined as described (see 2.2.4.4) 
and the DNA was either used immediately or frozen at -20°C. 
 
2.2.4.4 Determination of nucleic acid concentrations 
To determine the concentration of isolated RNA or DNA, the Nanodrop (PeqLab) 
spectrophotometer was used. Sample absorbances against nuclease-free water blank were 
also measured 260nm and 280nm to check the quality of nucleic acids. Briefly, 1.5µL of blank 
or sample was applied to the Nanodrop pedestal, the arm was closed and the sample 
concentration and absorbances were measured. The results of nucleic acid concentration 
determinations were then exported as Microsoft Excel files. The samples were either stored as 
described previously or used immediately. 
 
2.2.4.5 cDNA synthesis 
For gene expression studies, isolated RNA was reverse transcribed into cDNA using the iScript 
cDNA synthesis kit (BioRad) according to manufacturer’s instructions. Briefly, all reaction 
components were thawed on ice and each reaction contained 1µg of RNA, 1µL of iScript 
reverse transcriptase, 4µL of 5X iScript reaction mix and made to a final volume of 20µL with 
nuclease-free water in PCR strips. The reaction mix was vortexed and spun down briefly. The 
reaction mix was then incubated in a thermal cycler using the following protocol: priming at 
25°C for 5 minutes, reverse transcription at 46°C for 20 minutes, reverse transcriptase 
inactivation at 95°C for 1 minute and holding at 4°C indefinitely. The synthesized cDNA was 
diluted a 100 fold in nuclease-free water and stored at -20°C until used for qPCR.  
Methods 
 
 
2.2.4.6 qPCR 
To measure the expression of various genes in this study, quantitative real time PCR was 
carried out using previously synthesized cDNA. Reactions were carried out as at least technical 
triplicates using the iTaq Universal Sybr Green Supermix (BioRad). Each 8µl reaction per well 
in a 384-well plate contained 3.6µl of Sybr Green supermix, 0.2µl each of forward and reverse 
primers for each gene and 4µl of diluted cDNA template. The plate was sealed with adhesive 
seal, spun briefly at 2000rpm for 1 minute and incubated in the QuantStudio™ 6 Flex Real-
Time PCR system (Life Technologies) using the fast thermal cycling protocol described as 
follows: polymerase activation at 95°C for 30s, amplification for 40 cycles with steps of 
denaturation at 95°C for 3 seconds, annealing at 56°C for 30 seconds and extension at 60°C 
for 30 seconds. Melt-curve analyses were carried out at steps of 85°C for 15 seconds, 52°C for 
30 seconds and 95°C for 15 seconds. Data analyses were carried out using the QuantStudio™ 
Real-Time PCR Software and exported as Microsoft Excel files for further analyses using the 
ΔΔCT method.  
 
2.2.4.7 Relative mtDNA copy number determination 
Relative mtDNA copy numbers were determined using the protocol described in Cotney et al. 
(2007). The quantitative real time PCR for mtDNA was carried out similarly to qPCR described 
above (see 2.2.4.6) with some modifications. Instead of cDNA, total DNA was used for this 
purpose. Previously isolated total DNA was diluted to 2.0ng/µL in nuclease-free H2O. Reactions 
were carried out as at least technical quadruplicates using the iTaq Universal Sybr Green 
Supermix. Each 10µl reaction per well in a 384-well plate contained 5.0µl of Sybr Green 
supermix, 0.25µl each of forward and reverse primers for each gene and 4.5µl of diluted total 
DNA template. The following fast thermal cycling protocol was used: hold stage and 
polymerase activation at 95°C for 10 minutes, amplification for 40 cycles with steps of 
denaturation at 95°C for 15 seconds, annealing/extension at 60°C for 1minute. Melt-curve 
analyses were carried out with a temperature step gradient in 0.5°C increments from 55 to 
80°C. Fluorescence was measured at each temperature following 10 seconds incubation. Data 
analyses were carried out using the QuantStudio™ Real-Time PCR Software and exported as 
Microsoft Excel files for further analyses using the ΔΔCT method.  
2.2.5 Flow cytometry 
Flow cytometry is a powerful laser-based technique for characterizing intracellular and cell 
surface molecules from cell populations. This approach was used to measure fluorescence 
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intensities of markers, which we previously labeled in cells or ligands that associated with 
molecules of interest in this study. Experimental conditions were carried out as at least four 
technical replicates. 
 
2.2.5.1 Apoptosis analyses by Annexin V and Propidium Iodide staining assay 
Previously seeded cells and cells with induced apoptosis (4µM Staurosporine treatment for 2 
hours at 37°C) were harvested in culture medium as described before (see 2.2.1.5). The cells 
were washed twice with ice-cold PBS and centrifuged at 1500rpm for 5 minutes, resuspended 
in 400µL of 1X binding buffer and transferred to FACS tubes on ice. The cells were double dye-
stained in suspension by adding 5μL of Annexin V-FITC and 5μL of 50 μg/mL Propidium iodide, 
vortexed briefly and incubated in the dark at RT for 15 minutes. Along with unstained controls, 
single dye-stained controls, and Staurosporine positive controls, the apoptotic cell population 
of the samples was analyzed by flow cytometry. The results were analyzed using FlowJo v10 
software. 
 
2.2.5.2 Measurement of mitochondrial superoxide levels 
Mitochondrial superoxide levels were measured by flow cytometry using the MitoSOX Red 
Mitochondrial superoxide indicator according to manufacturer’s protocol. Briefly, 5mM MitoSOX 
indicator stock was prepared by resuspending each 50µg dye in 13µl DMSO. The MitoSOX 
working reagent was made by adding the 13µl of indicator stock to 13mL of warm PBS, which 
contained 0.5µM glucose at all times for MitoSOX experiments to yield a final dye concentration 
of 5µM. Previously cultured cells were washed with warm PBS and stained by adding MitoSOX 
working reagent to cells and incubating at 37°C for 15 minutes. Following staining, the excess 
indicator was washed off cells with warm PBS and cells were harvested by trypsinization as 
described before (see 2.2.1.5). The cells were washed twice with PBS, centrifuged at 1500rpm 
for 5 minutes and resuspended in 0.5mL PBS. The cell suspension was transferred to FACS 
tubes and along with unstained cells, stained test samples and positive controls (treated with 
100µM H2O2 or 100µM Antimycin for 20 minutes at 37°C) mitochondrial superoxide levels were 
determined by flow cytometry. The results were analyzed using FlowJo v10 software.  
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2.2.6 Microplate reader assays 
2.2.6.1 Measurement of lysosomal proteolytic capacity 
Lysosomal proteolytic capacity was measured using the DQ Red BSA Dye (Molecular Probes) 
following manufacturer’s protocol. 1mg of dye was resuspended in 1mL of PBS and 100ul of 
the resuspended dye was added to 10ml of warm DMEM medium. Previously seeded cells in 
a transparent 96 well-plate, cultured at least overnight after seeding, were loaded with 100ul 
per well each of the dye-containing medium and incubated at 37°C for 1 hour. Cells were then 
washed twice with warm PBS and the medium was replaced with 100 µL/well of warm EBSS 
medium. The kinetics of DQ Red BSA digestion were recorded at respective excitation and 
emission maxima of 590nm and 620nm in a microplate reader over a 4h period. The results 
were exported as Microsoft Excel files for further analyses. 
 
2.2.6.2 Measurement of total cell iron concentration 
Total cellular iron concentration was measured using the Iron Assay kit (Abcam) according to 
manufacturer’s instructions. MEFs were harvested as previously described (see 2.2.1.5) and 
homogenized in 1mL of assay buffer using a Dounce homogenizer sitting on ice. The 
homogenate was collected into 1.5mL Eppendorf tubes and centrifuged at 16000rpm for 10 
minutes at 4°C to remove insoluble materials. The supernatant was collected into new 1.5mL 
Eppendorf tubes and kept on ice always during the assay. All reagents were equilibrated to RT 
and serial dilutions of the standard were made in assay buffer. All standards, controls, and 
samples were assayed as duplicates in a transparent 96-well plate. The total iron assay’s initial 
205µl reaction per well contained 100µl standard, sample (at different dilutions) or assay buffer 
as control, 5µl iron reducer, and 100µl iron probe. For ferrous iron measurement, 5µl assay 
buffer was used instead of iron reducer. The reaction was mixed by pipetting and incubated at 
RT. Following 30 minutes of incubation, 100µl of the iron probe was added to each well-
containing standard, control, and samples, mixed and incubated at RT for a further 60 minutes. 
The absorbance at 593nm was measured immediately in a microplate reader. The results were 
exported as a Microsoft Excel file where a standard curve was made. The total, ferric and 
ferrous iron concentrations of the cell were calculated from the standard curve and normalized 
to the protein amount (determined by the Bradford assay, see 2.2.3.3). 
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2.2.6.3 Protein concentration determination using Pierce BCA microassay 
For all experiments carried out in 96-well plates except for iron measurements, protein 
concentration per well of samples was always determined for normalization purposes. To this 
end, immediately after an assay in a 96-well plate, the assay medium was always aspirated 
and the cells were lysed in 125µL of ddH2O for 1 hour with mild shaking. Following cell lysis, 
protein concentrations were determined using the Pierce BCA Protein Assay kit. Unlike in the 
tube method, 100µl of double concentrated Pierce BCA working reagent (reagents A and B, 
25:1) was added to each well-containing samples and blank, mixed by pipetting and incubated 
at 37°C for 30 minutes. The absorbance of the samples was measured at 562nm in a microplate 
reader and the protein concentration was calculated from a standard curve made from albumin 
standards. 
 
2.2.7 Real Time Respirometry 
The Seahorse XF96 Extracellular Flux Analyzer provides a robust tool for assessing cellular 
metabolic status. We assessed oxygen consumption and extracellular acidification rates in 
cultured cells as respective indicators of mitochondrial respiration and glycolytic capacity. 
These experiments were carried out using the XFe 96 extracellular flux assay kit and following 
manufacturer’s protocols. For a MitoStress Test, cells were seeded (12000 cells/well) in the 
XF96 cell culture plate in 200µL growth medium per well and cultured in normal growth 
conditions overnight. Furthermore, sensor cartridges were hydrated by adding 200µL of XF 
calibrant to the XFe 96 sensor cartridge plate and incubated in a non-CO2 incubator at 37°C 
overnight. On the day of the assay, XF medium was warmed, the pH was set to 7.4 and 
supplemented with 25mM glucose. The previously cultured cells in the XF96 cell culture plate 
were washed with warm PBS and the medium was replaced with 180µL of warm XF medium 
and incubated at 37°C for 1 hour without CO2. The following compounds were prepared in 
warm XF medium and loaded in the indicated ports in the sensor cartridge using the templates 
provided: 10µM Oligomycin (20µL per well loaded in Port A), 20µM FCCP (22µL per well loaded 
in Port B) and 10µM each of Rotenone and Antimycin (25µL per well loaded in Port C). The 
sensor cartridge plate was loaded and calibrated in the XF96 Extracellular Flux Analyzer, which 
was always switched on at least 5 hours prior to assay. Following calibration, the cell culture 
plate was loaded into the XF96 Extracellular Flux Analyzer and a MitoStress Test was run using 
the XFe analyzer software. Data were exported as a Microsoft Excel file for further analyses. 
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Protein amount was measured following assay completion using the Pierce BCA microassay 
as described (see 2.2.6.3) for normalization purposes. 
 
2.2.8 Confocal microscopy and image analyses 
Images of frozen brain sections were acquired using the LSM 800 with Airyscan setup (Zeiss). 
The same background and gain settings were maintained for all compared groups. Images 
were acquired with the 20X Plan Apochromat objective (Zeiss). All settings were saved and 
applied to subsequent imaging sessions for comparable groups. Post-acquisition image 
analyses were carried out with ZEN software (Zeiss) and Image J.  
 
2.2.9 Bioinformatics 
With the advent of large-scale multi-omics data, bioinformatics provides tools to accurately 
analyze biological data and thus make reliable predictions of the structure, networks, and 
function of macromolecules. These tools were extensively relevant in realizing the goals of this 
study. The next few sections describe some of these tools and how useful they were in this 
study. 
 
2.2.9.1 Microarray dataset mining and analyses 
In order to identify transcriptional signatures mediating organelle crosstalk in lysosomal 
malfunction, microarray data involving lysosomal malfunction were mined from transcriptome 
dataset repository, Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo). Criteria for 
dataset selection included datasets from several tissues with multiple replicates. The selected 
dataset was GSE39621, which included samples from brain, liver, and spleen of NPC1-/- mice 
and their wild-type littermates before and after 6 weeks of age, a relevant time point for the 
onset of disease manifestation (Alam et al., 2012). Splenic datasets were excluded from this 
study given the heterogeneous population of cells (e.g. immune cells) that invade the spleen 
in this disease (Patterson et al., 2012). It was, therefore, reasoned that wild-type and NPC1-/- 
splenic datasets were not directly comparable. As a result, brain and liver datasets were loaded 
into the microarray data analysis software GeneSpring 13.0 (Agilent Technologies) and 
datasets were normalized by robust multi-array averaging (Irizarry et al., 2003). Following 
normalization, differentially expressed genes (DEG) were determined as statistically significant 
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genes between conditions at a cut-off threshold of p-value < 0.05 using ANOVA with a 
Bonferroni post hoc correction. 
 
2.2.9.2 Pathway analyses and identification of transcriptional regulators 
The DEGs were imported into the comprehensive pathway analyses software Ingenuity 
Pathway Analysis (IPA, Qiagen) in order to identify signaling pathways responding to lysosomal 
malfunction. IPA determines statistically enriched transcriptional regulators and signaling 
pathways using the Fisher’s exact test. The statistical cut-off was set at p < 0.01. 
 
2.2.9.3 Organelle-specific gene expression analyses 
In order to determine the average expression of organelle-specific genes, which we showed 
previously to be a good indicator of the biogenesis of that organelle (Fernández-Mosquera et 
al., 2017), we obtained organelle proteomes from comprehensive databases for lysosomal, 
mitochondrial (and respiratory chain subunits), peroxisomal, endoplasmic reticulum and Golgi 
proteomes (see Table 14). The protein IDs were converted to NCBI gene symbols. These 
genes were translated to their corresponding probeset IDs in GeneSpring 13.0 and their 
expression levels in the GSE39621 datasets were obtained and exported as Microsoft Excel 
files. The average expression of organelle gene list was calculated as the average cumulative 
fold change of all genes that make up each organelle. Differences between wild-type and 
NPC1-/- organelle expression were considered significant if they passed a statistical threshold 
of p-value < 0.05 determined by Student’s t-test with Bonferroni post hoc correction.  
Table 14: Source of organelle-specific proteome database 
Dataset Number of genes Source 
Mitochondria 1049 (Calvo et al., 2016; Pagliarini et al., 2008) 
Respiratory chain subunits 108 (Calvo et al., 2016; Pagliarini et al., 2008) 
Lysosomes 435 (Brozzi et al., 2013) 
Peroxisomes 254 (Wiese et al., 2007) 
Endoplasmic reticulum 297 (Gilchrist et al., 2006) 
Golgi (COP I) vesicles 86 (Gilchrist et al., 2006) 
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2.2.9.4 Promoter analyses of Respiratory chain genes 
Promoter analyses were carried out to identify which transcription factors (TFs) mediated the 
expression of respiratory chain genes. This was performed using the software Genomatix Suite 
(http://www.genomatix.de), which provides a robust tool for predicting TFs that drive gene 
expression. Promoter regions of respiratory chain genes were first defined from 500 base pairs 
upstream (-500) until 100 base pairs downstream (+100) of the transcription start site (TSS). 
To locate these promoters, we used the Genomatix tool Gene2Promoter and subsequently 
identified the TFs which had binding sites on them. Only promoters that drive the expression 
of mRNAs which lead to fully functional respiratory chain proteins were selected for each gene. 
The promoter sequences were used to determine cis-elements and identify the corresponding 
TFs. TFs with binding sites in less than 85% of the promoters were excluded. In addition, a 
statistical threshold of p-value < 0.05 was set for significantly enriched TF families determined 
by the Fisher’s exact test within the software suite. Within the enriched TF families, only 
individual TFs with binding sites in at least 50% of promoters under analyses were selected as 
relevant. 
 
2.2.9.5 ChIP-Seq dataset mining and analyses 
In order to validate the role of ETV1 as a regulator of mitochondrial biogenesis, we obtained 
published ETV1 ChIP-Seq data (Baena et al., 2013). Genes with promoter regions bound 
exclusively by ETV1 and not its related transcription factor family member ERG were selected 
with a MAT score threshold of p < 0.0001. This gene list was crossed with our mitochondrial 
gene list (see section 2.2.9.3) to obtain mitochondrial genes under transcriptional regulation of 
ETV1. 
 
2.2.9.6 Metabolomics 
Lysosomes and mitochondria serve as distinct hubs for several metabolic processes in the cell 
and metabolite profiling provides unique fingerprints of such processes. To obtain such 
features, stable GAA knockdown cells and their scrambled controls were cultured under normal 
growth conditions until 100% confluence. The cells were washed with ice-cold PBS, and all 
metabolic process were quenched by harvesting cells in 500µL cold 50% MS-grade methanol 
with a scraper. The collected cells were transferred into an Eppendorf tube containing 500µL 
MS-grade chloroform on ice. The samples were snap-frozen in liquid nitrogen and sent to a 
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metabolomics facility at the Department of Plant Biochemistry, Goettingen Center for Molecular 
Biosciences. At the facility, briefly, the samples were dried under a nitrogen gas stream and 
the metabolites were extracted in extraction solvent (a mixture of methanol, chloroform, and 
water, 129:50:25 [v/v/v]). Following addition of internal standards, metabolites were derivatized 
by methoxyamination and trimethylsilation. Derivatized metabolites were subjected to gas 
chromatography coupled to a quadrupole mass spectrum analyzer. The identities of 
metabolites were determined by comparing spectra to those of a comprehensive metabolite 
library. The abundance of each identified metabolite in each sample was determined as its 
concentration. The results were exported as Microsoft Excel files along with the weight of each 
sample for normalization purposes. The data were loaded into MetaboAnalyst 3.0 
(www.metaboanalyst.ca) where features whose concentrations were significantly altered (p < 
0.05) between scrambled and GAA knockdown cells were determined. The altered metabolites 
were subsequently used for metabolic pathway and metabolite set enrichment analyses.  
 
2.2.10 Magnetic resonance spectroscopy and imaging 
GAA-/- and control mice underwent magnetic resonance spectroscopy, T1 and T2 relaxation 
times of water protons measurements and magnetization transfer ratio determinations of the 
cortex, thalamus, and striatum at 37°C. Magnetic resonance images of the whole brain of mice 
were also obtained. All nuclear magnetic resonance (NMR) experiments were carried out with 
the support of Takashi Watanabe at the Biomedical NMR Department of the Max-Planck 
Institute for Biophysical Chemistry following the protocol described in Watanabe et al. (2016).  
 
2.2.11 Statistical analyses 
Unless otherwise indicated, results were analyzed using Microsoft Excel 2013 and GraphPad 
Prism versions 6 and 7. Graphs were presented as mean values normalized to experimental 
controls and their corresponding standard errors of the mean for at least three biological 
replicates and replicate experiments. Differences of means were considered statistically 
significant if they passed thresholds calculated as Student’s t-test for two-parameter 
comparisons, or as ANOVA for multi-parametric comparisons. These were indicated as p < 
0.05 (*), p < 0.01 (**) or p < 0.001 (***).
  
 
3 Results 
3.1 Impaired sphingosine-1-phosphate signaling in Niemann-Pick 
disease represses mitochondrial biogenesis and function via KLF2 
and ETV1 
 
3.1.1 Lysosomal dysfunction in Niemann-Pick patient fibroblasts 
Although mitochondrial defects have previously been reported in the different types of 
Niemann-Pick diseases (Castillo et al., 2017; Woś et al., 2016), the mechanisms linking 
dysfunctional lysosomes to defective mitochondria remained nevertheless elusive. To address 
this in the context of a lysosomal-mitochondrial crosstalk, Niemann-Pick Type A/B (hereafter 
NP) and age-matched control fibroblasts were obtained from the UMG. The NP fibroblasts 
retained about 15% of acid sphingomyelinase activity and impaired lysosomal function was 
validated by assessing autophagy and lysosomal proteolytic capacity, which were found to be 
compromised (Figure 12). 
 
Figure 12| Lysosomal function is impaired in NP fibroblasts – A NP cells present stalled 
autophagy with accumulation of autophagosomal marker LC3B and autophagic substrate 
SQSTM1. B Lysosomal proteolytic capacity, measured by the Red DQ-BSA assay, is reduced in 
NP fibroblasts. Graphs represent mean ± SD of at least biological triplicates. Differences between 
groups were considered statistically significant based on Student’s t-test at p < 0.01 (**) or p < 
0.001 (***), SD: standard deviation 
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3.1.2 Mitochondrial function is compromised in NP fibroblasts 
Having confirmed lysosomal impairment in NP fibroblasts, mitochondrial function was then 
assessed. To this end, mitochondrial oxygen consumption rate (OCR) was measured under 
basal conditions and upon inhibition or uncoupling of oxidative phosphorylation (maximal 
OCR). The NP fibroblasts presented reduced basal and maximal OCR (Figure 13 A and B). In 
addition, about a two-fold increase in mitochondrial superoxide steady-state levels was 
observed in the NP fibroblast as determined by MitoSox fluorescence (Figure 13C). 
 
Figure 13| Mitochondrial malfunction in NP fibroblasts – A and B Reduced basal and 
maximal mitochondrial OCR in NP fibroblasts as assessed by Real Time respirometry (N = 8).                         
C Increased MitoSox fluorescence in NP fibroblasts, which reflects mitochondrial superoxide 
levels (N = 5). Graphs are mean ± SEM for the indicated number of replicate samples, p < 0.001 
(***); Student’s t-test; SEM: standard error of the mean 
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3.1.3 Repression of mitochondrial biogenesis in NP fibroblasts 
Mitochondrial biogenesis is known to be coupled to oxygen consumption and the production of 
ATP (LeBleu et al., 2014). Given the observed reduced OCR in NP fibroblasts, it was reasoned 
that mitochondrial biogenesis may be repressed. As a result, the expression of several 
 
Figure 14| Mitochondrial biogenesis is repressed in NP fibroblasts – A Reduced 
expression of nuclear-encoded mitochondrial genes in NP. B Transcript levels of regulators of 
mtDNA transcription and mtDNA-encoded respiratory chain genes are reduced in NP.                         
C Reduced mtDNA copy number in NP fibroblasts. D Unlike mitochondrial biogenesis, lysosomal 
biogenesis is up-regulated in NP. Gene expression is depicted as mean ± SEM, N = 8. Based on t-
test, differences were significant at p <0.05 (*) and p < 0.001 (***), SEM: standard error of the 
mean 
Results 
 
 
mitochondrial genes and regulators of transcriptional programs of mitochondrial biogenesis 
was measured. Importantly, the expression of several nuclear-encoded respiratory chain 
subunits including NDUFS3, SDHD, UQCRFS1, COX5A, and COX10 were decreased (Figure 
14A). Furthermore, the transcript levels of essential regulators of mtDNA maintenance and 
transcription (TFAM, POLRMT, and TFB2M) and mtDNA-encoded respiratory chain genes 
(ND6, CYTB) were also downregulated in NP fibroblasts (Figure 14B). Not surprisingly, this 
transcriptional response culminated in a loss of mtDNA copy number in NP (Figure 14C). The 
evidence of repression of mitochondrial biogenesis was further supported by reduced protein 
levels of NRF1, a major transcriptional regulator of mitochondrial biogenesis (Kelly and 
Scarpulla, 2004; Scarpulla, 2008) and its target TFAM, a key regulator of mtDNA maintenance 
and gene expression (Gustafsson et al., 2016), as shown in Figure 15. To rule out bias in the 
measurement of mitochondrial transcript levels that were all decreased in NP, the expression 
of lysosomal genes which are known to be up-regulated in LSDs (Karageorgos et al., 1997) 
was measured.  
 
Figure 15| Levels of regulators of mitochondrial biogenesis – Protein amounts of 
NRF1, NRF2, and TFAM, which are key regulators in coordinating mitochondrial biogenesis 
were measured by WB. Quantifications of bands are depicted as mean ± SD, N = 3. p < 0.01 (**) 
and p <0.001 (***); Student’s t-test; SD: standard deviation 
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3.1.4 Desipramine treatment impairs lysosomal function 
In order to validate these results and to rule out off-target effects of SMPD1 mutations in 
patients, control fibroblasts were treated with desipramine, an inhibitor of acid 
sphingomyelinase (ASM), the affected enzyme in NP. Desipramine treatment has been shown 
to result in a time-dependent loss of ASM activity by targeting the enzyme for proteolysis 
(Jenkins et al., 2011). Following 72 hours of treatment of control fibroblasts with 40µM 
desipramine, impaired lysosomal function, similar to that in NP fibroblasts, was found as 
measured by increased autophagosomal mass and stalled autophagy (Figure 16A) and 
reduced lysosomal proteolytic capacity (Figure 16B). 
 
Figure 16| Lysosomal function is impaired in desipramine-treated cells – A 
Increased levels of LC3B and SQSTM1 reflect stalled autophagy in desipramine-treated 
fibroblasts. B Desipramine treatment impairs lysosomal proteolysis. Graphs are mean ± SEM for 
at least triplicate samples and differences were significant based on the t-test, p < 0.05 (*), p < 
0.01 (**), p <0.00 (***) , SEM: standard error of the mean 
  
3.1.5 Desipramine treatment represses mitochondrial biogenesis and function  
Following confirmation that desipramine treatment in cells affected lysosomes similarly to NP, 
mitochondrial function was assessed. Marked reductions in basal and maximal mitochondrial 
OCR and increased mitochondrial superoxide levels were found (Figure 17 A, B and C). 
Furthermore, like in NP fibroblasts, desipramine treatment resulted in decreased expression of 
several nuclear- and mtDNA-encoded mitochondrial genes (Figure 17D) and increased 
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lysosomal biogenesis (Figure 17E). Altogether, pharmacological ASM inhibition corroborates 
the results obtained in NP fibroblasts, and also rules out SMPD1 mutation-specific effects. 
 
Figure 17| Desipramine treatment represses mitochondrial biogenesis and 
function – A and B Cells treated with desipramine show decreased mitochondrial respiration. 
C Increased mitochondrial superoxide levels in desipramine treated cells. D Treatment with 
desipramine reduces the expression of mitochondrial genes. E Lysosomal biogenesis is 
increased in desipramine-treated cells. Graphs are shown as mean ± SEM, N = 8; p <0.05 (*), p< 
0.01 (**), and p < 0.001 (***); Student’s t-test; SEM: standard error of the mean 
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3.1.6 Transcriptomics reveal global downregulation of mitochondria-related 
genes in NPC1-/- mouse tissues  
Although our results consistently showed that mitochondrial biogenesis was repressed in NP 
patient fibroblasts as well as in desipramine-treated cells, it is noteworthy that only a small 
fraction of mitochondrial genes was studied. We, therefore, set out to corroborate these data 
using groups of mitochondrial or lysosomal genes as comprehensively as possible. To this end, 
bioinformatics approaches developed in the lab were used to analyze publicly available 
transcriptome datasets of NPC1-/- mice, a model of Niemann-Pick type C1 disease. This 
approach is illustrated in Figure 18. A detailed description of the approach and microarray 
dataset can be found in section 2.2.9. 
 
Figure 18| Schematic representation of genomics approach for in silico 
experiments – Differentially-expressed genes (DEGs) were filtered with organelle-specific 
gene lists to obtain  organelle-related DEGs 
 
Lysosomal biogenesis was assessed by measuring the average expression of lysosomal genes 
in NPC1-/- mice relative to their control littermates, which was found to be increased in all tissues 
and ages tested (Figure 19A). This corroborated our results in NP fibroblasts, and have 
validated our transcriptome data analyses approach.  
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Similarly, the average expression of mitochondrial-related genes in the brain and in the liver of 
NPC1-/- mice was measured. While pre-symptomatic mice showed an increase in the 
expression of mitochondrial genes in the brain and no significant change in the liver, 
symptomatic mice, on the other hand, showed a robust downregulation in the average 
expression of mitochondrial genes (Figure 19B). The pattern of expression of OXPHOS-related 
genes in the tissues was similar to the expression of mitochondrial genes albeit with a rather 
larger magnitude (Figure 19C). To exclude the possibility that a few dysregulated genes might 
be driving the pattern of expression of mitochondrial and OXPHOS related genes that were 
observed in the symptomatic mouse tissues, the proportion of organelle-specific DEGs before 
and after the onset of symptoms was assessed. Indeed, the proportion of mitochondrial DEGs 
was increased in the brain and in the liver after disease onset (Figure 20).  
 
Figure 19| Differentially expressed organelle genes in NPC1-/- mice – A Lysosomal 
gene expression is increased in NPC1-/- mice. B and C Mitochondrial and respiratory chain genes 
are decreased with the onset of disease in NPC-/- mice. D Illustration of the correlation of gene 
expression between lysosomes and mitochondria and respiratory chain subunits. Differences in 
organelle expression between wildtype and NPC1-/-.mice passed statistical thresholds 
determined by the Students t-test with Bonferroni post-hoc correction at p < 0.05(*), p < 0.01 
(**), and p < 0.001(***). Graphs represent normalized mean ± SEM, N =6; SEM: standard error 
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Having observed increased expression of lysosomal genes and reduced expression of 
mitochondrial and OXPHOS related genes after disease onset, we sought to establish a tissue-
independent general pattern of gene expression between lysosomes and mitochondria. As a 
result, the level of significance of the negative correlation of gene expression between these 
organelles was tested and found to be significant for both mitochondria and OXPHOS (Figure 
19D). Taken together, these results confirm our findings that lysosomal malfunction 
progressively represses mitochondrial biogenesis. 
 
Figure 20| Disease progression changes in mitochondrial gene expression –                        
A – C Disease progression-dependent increase in mitochondrial DEGs in NPC1-/- mouse brain.                        
D – F NPC1-/- mouse liver shows a five-fold increase in the proportion of mitochondrial DEGs 
with disease progression. Tests for differences in proportions were statistically significant at p 
< 0.001(***) 
 
To verify whether the transcriptional response to lysosomal malfunction was specific to 
mitochondria, the average expression of genes related to peroxisomes, endoplasmic reticulum 
(ER) and Golgi were measured. Irrespective of disease onset, it was found that the average 
expression of peroxisomal-, ER-, and Golgi-related genes was not changed in the brain of 
NPC1-/- mice (Figure 21). 
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While a similar pattern of expression was observed for ER- and Golgi-related genes in the liver, 
peroxisomal related genes were significantly downregulated in the liver (Figure 21). These 
results underscore a specific mitochondrial response to lysosomal malfunction in NPC1-/- mice. 
 
3.1.7 Reduced mitochondrial respiration in NPC1-/- MEFs 
Having demonstrated that mitochondrial biogenesis is repressed in NPC1-/- mouse tissues, 
especially after the onset of disease, we postulated that these deficits will compromise 
mitochondrial respiration, which is tightly linked to mitochondrial biogenesis (LeBleu et al., 
2014). Mitochondrial OCR was therefore assessed in MEFs obtained from NPC1-/- mice under 
basal conditions and upon inhibition or uncoupling of OXPHOS. Not surprisingly, decreased 
basal and maximal mitochondrial respiratory capacities were observed in the NPC1-/- MEFs 
when compared to their wild-type controls (Figure 22 A and B). These findings altogether show 
that lysosomal malfunction in Niemann-Pick disease, irrespective of the type, elicits a 
 
Figure 21| Organelle-specific gene expression changes in NPC1-/- mice – NPC1-/- mice 
show no changes in the expression of ER and Golgi genes. However, peroxisomal genes are 
robustly downregulated in the liver and not altered in the brain. Differences in organelle 
expression between wildtype and NPC1-/-.mice passed statistical thresholds determined by the 
Students t-test with Bonferroni post-hoc correction at p < 0.001(***). Graphs represent 
normalized mean ± SEM, N =6, SEM: standard error 
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transcriptional program of repressed mitochondrial biogenesis in vitro and in vivo, which 
ultimately impairs mitochondrial function. 
 
Figure 22| Mitochondrial respiration is reduced in NPC1-/- MEFs – A Mitochondrial 
respiration profile shows reduced OCR in NPC1-/- MEFs. B Basal and maximal mitochondrial 
respiratory capacity in NPC1-/- cells are decreased to about 50% of wild-type cell levels. Graphs 
represent mean ± SEM for N = 8; p < 0.001 (***); Student’s t-test; SEM: standard error of the 
mean 
 
3.1.8 KLF2 and ETV1 mediate repression of mitochondrial biogenesis in 
Niemann-Pick disease  
In addition to showing that lysosomal malfunction in Niemann-Pick disease specifically 
represses mitochondrial biogenesis, we were further interested in elucidating the 
mechanism(s) which mediate such a response. Additionally, the global decrease in 
mitochondrial gene expression in all conditions tested suggested the involvement of a 
coordinated transcriptional program. To address this, promoter analyses of the respiratory 
chain genes was carried out using the MatInspector software tool (Genomatix). The process is 
described in detail in section 2.2.9.4. Table 15 shows transcription factor families with 
significantly enriched binding sites in the promoters of respiratory chain genes. SP1 and E2F 
transcription factor families were eliminated from further analysis since they were predicted to 
have statistically enriched binding sites in the promoters of lysosomal genes. Given the 
significant negative correlation of gene expression between lysosomes and mitochondria/ 
respiratory chain in Niemann-Pick disease, it was reasoned that it is unlikely that SP1 and E2F 
transcription factor families mediated antagonistic processes. Hence, only the RC gene-
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specific KLF and ETS transcription factor families were subsequently studied in the Niemann-
Pick disease models.   
Table 15: Transcription factors with enriched cis-elements in RC gene promoters 
Transcription factor family p-value (Fisher’s exact test) Transcription factors 
SP1 1.52 x 10-9 SP1, SP4 
E2F 2.79 x 10-8 E2F1, E2F2, E2F3, E2F4 
KLF 0.000265 KLF2, KLF6, KLF7, KLF15 
ETS 0.000796 ELK1, SPI1, ETV1 
 
Since it is unlikely that all transcription factors in these families would be active or repressed at 
the same time to mediate one response in Niemann-Pick disease, the number of transcription 
factors in each family were trimmed using the transcriptome dataset of NPC1-/- mice. Ingenuity 
pathway analyses of the DEGs in the microarray data (described previously see section 2.2.9) 
scored active/repressed TFs in the NPC1-/- mouse tissues. The active/repressed TF dataset 
was crossed with the ones regulating respiratory chain genes, and only KLF2 and SPI1 were 
found to pass the set criteria (Figure 23A). 
 
 
Figure 23| Transcriptional regulation of Respiratory chain genes – A Schematic 
illustration of the TF filtering for those relevant for RC gene expression. B KLF2 and ETV1 are 
significantly induced in NP fibroblasts .Band quantifications are depicted as mean ± SEM, N = 5. 
Differences between means, which passed the statistical threshold of p < 0.01 (**) and p <0.001 
(***) based on the Student’s t-test, were considered significant; SEM: standard error of the mean 
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Furthermore, about 50% increase in the protein amount of KLF2 was found in NP fibroblast 
(Figure 23B). SPI1, either at transcript or at protein levels, could not be detected in NP 
fibroblasts. This is corroborated by reports that SPI1 is expressed in macrophages and not in 
fibroblasts (Feng et al., 2008). The ETS family of TFs have been shown to mostly have 
redundant functions (Maroulakou and Bowe, 2000). To this end, two other commonly 
expressed members of this family were tested. While a two-fold increase in the transcript level 
of ETV1 was observed in NP fibroblasts, ELK1 expression was unaltered (see Appendix Figure 
52). Accordingly, a five-fold increase in ETV1 protein in NP fibroblasts was found (Figure 23B). 
To further validate the results of our promoter analyses, publicly-available ETV1 ChIP-Seq data 
(Baena et al., 2013) were crossed with our mitochondrial gene list, and ETV1 was 
demonstrated to regulate the transcription of several mitochondrial genes (Figure 24). In 
addition, KLF2 and ETV1 were strongly induced in fibroblasts treated with desipramine (see 
Appendix Figure 53). 
 
Figure 24| ETV1 targets mitochondrial genes – Schematic representation of ETV1 ChIP-
Seq data analyses reveals several mitochondrial genes as targets of ETV1  
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We reasoned therefore that KLF2 and ETV1 might be mediating the repression of mitochondrial 
biogenesis, since they were both induced in NP fibroblasts and predicted by promoter analyses 
to target respiratory chain or mitochondrial genes (ChIP-Seq data). To test this hypothesis, 
KLF2 and ETV1 were independently silenced in NP fibroblasts and several mitochondrial 
parameters were tested. At the protein level, it was found that NRF1 and TFAM were restored 
to control levels following KLF2 or ETV1 silencing (Figure 25 A and B). More importantly, 
mitochondrial biogenesis was rescued in KLF2 and ETV1 knockdowns (Figure 25C), which 
ultimately resulted in increased mitochondrial function as assessed by real time respirometry 
(Figure 25D). 
 
Figure 25| KLF2 and ETV1 repress mitochondrial biogenesis and function – 
Silencing of KLF2  or ETV1 rescues NRF1 and TFAM levels (A and B), rescues mitochondrial 
biogenesis (C) and ultimately rescues mitochondrial respiration (D). Graphs depict mean ± SEM 
for at least triplicate; p <0.05 (*), p <0.01(**), and p< 0.001 (***); one-way ANOVA; SEM: 
standard error of the mean. Heatmap represents normalized mean plots of gene expression. 
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Although silencing of either KLF2 or ETV1 improved mitochondrial outcomes in NP fibroblasts, 
it is noteworthy that this response was not due to alleviation of lysosomal stress. This evidence 
stems from the result that KLF2 or ETV1 knockdown had no effect on lysosomal malfunction 
as shown by persistent stalled autophagy in NP fibroblasts despite KLF2 or ETV1 silencing 
(Figure 26).  
 
Figure 26| Autophagy defects in NP are independent of KLF2 and ETV1 – A and B 
Silencing of KLF2 or ETV1 does not alter autophagy defects in NP fibroblasts. Band 
quantifications are depicted as mean ± SD for triplicate samples; p <0.05 (*), p< 0.001 (***), and 
p > 0.05 (ns); one-way ANOVA; SD: standard deviation, ns: not statistically significant 
 
3.1.9 Mechanism of KLF2 and ETV1 regulation in Niemann-Pick disease  
Having shown that KLF2 and ETV1 mediate the repression of mitochondrial biogenesis in 
Niemann-Pick disease, we sought to elucidate how these two TFs were induced in the first 
place. Given that independent silencing of either KLF2 or ETV1 was enough to restore 
mitochondrial biogenesis in NP fibroblasts, it was rational to think that they may be cooperating 
in an epistatic fashion. Accordingly, it was observed that while KLF2 silencing also ablated 
ETV1 levels, ETV1 silencing had no noticeable effect on KLF2 levels (Figure 27A) implying that 
KLF2 regulated ETV1 activity. In addition, several reports have shown that the PI3K-AKT 
signaling pathway negatively regulates KLF2 expression (Sinclair et al., 2008; Skon et al., 
2013) and interestingly, reduced AKT activity was observed in NP fibroblasts (Figure 27B). 
Furthermore, ETV1 has been known for a long time to be regulated by ERK signaling 
(Janknecht, 1996), whose activity was found to be increased in NP fibroblasts (Figure 27B). 
Recently, mTORC1 was found to respond to lysosomal cholesterol (Castellano et al., 2017), 
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which accumulates in Niemann-Pick disease, and accordingly, increased mTORC1 activity was 
also observed, which is independent of its upstream regulator AMPK, the activity of which is 
not affected in NP fibroblasts (Figure 27B).  
 
Figure 27| Mechanism of KLF2 and ETV1 induction – A KLF2 and ETV1 show epistatic 
regulation. Band quantifications are depicted as mean ± Sd for triplicate samples and differences 
between means as based on one-way ANOVA tests with thresholds of p< 0.001 (***) were 
considered significant B NP fibroblasts retain only about 20% of AKT activity while inducing by 
3- and 6-fold the activities of ERK and mTORC1 respectively. AMPK activity is not affected in NP 
fibroblasts. Graph in B represents mean ± SD, N = 3; p<0.01 (**) and p<0.001 (***); Student’s t-
test; SD: standard deviation. 
 
3.1.9.1 KLF2 activates ETV1 in an ERK-dependent manner 
Since ERK levels, a positive regulator of ETV1, were found to be reduced in KLF2 hemizygous 
mice (Das et al., 2012), we reasoned that ERK signaling might also be mediating ETV1 
induction by KLF2. To address this, NP fibroblasts were treated with the ERK inhibitor, U0126. 
Interestingly, pharmacological inhibition of ERK ablated ETV1 levels, although KLF2 levels 
were not affected in NP fibroblasts (Figure 28) suggesting that KLF2 induced ETV1 via an ERK-
dependent pathway. 
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Figure 28| ETV1 induction is ERK dependent – Pharmacological inhibition of ERK activity 
reduces ETV1 levels without affecting KLF2 in NP fibroblasts. p < 0.01 (**) and p < 0.001 (***); 
Student’s test; mean ± SD, N = 3; SD: standard deviation. 
 
3.1.9.2 Impaired sphingosine-1-phosphate signaling activates KLF2 
Thus far, the mechanism driving ETV1 activity in Niemann-Pick disease was demonstrated. It 
remained however unclear how KLF2 was induced, even though reduced AKT activity in NP 
fibroblasts (Figure 27B) might be relevant for any mechanism thereof. Indeed, KLF2 drives the 
expression of S1PR1, which triggers a negative feedback loop targeting KLF2 for degradation 
via an AKT-dependent pathway (Bai et al., 2007; Sinclair et al., 2008; Skon et al., 2013). Given 
that the agonist for S1PR1 signaling, sphingosine-1-phosphate, is reduced in the plasma of 
Niemann-Pick disease patients (Fan et al., 2013), it was reasoned that KLF2 induction might 
be dependent on reduced S1PR1 signaling in Niemann Pick disease to induce the expression 
of S1PR1 as illustrated in Figure 29A. Although reduced AKT activity in NP fibroblasts may 
underlie reduced S1PR1 signaling, S1PR1 expression (a downstream target of KLF2 activity) 
was increased in Niemann-Pick disease (Figure 29B). Conversely, activation of S1PR1 
signaling should reduce KLF2 levels and lower S1PR1 expression. Accordingly, control 
fibroblasts were treated with Sew2871, a potent and specific synthetic agonist of S1PR1 and, 
in agreement with our hypothesis, increased S1PR1 signaling resulted in decreased KLF2 and 
S1PR1 levels (Figure 29C). Having found reduced KLF2 levels following activation of S1PR1 
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signaling, several mitochondrial parameters were tested as well. Importantly, increased levels 
of mitochondrial proteins were found, without any observable effects on lysosomal function as 
assessed by autophagy flux (Figure 29C). Mitochondrial gene expression was also increased 
in Sew2871-treated cells (see Appendix Figure 54). Altogether, these results support the notion 
that impaired sphingosine-1-phosphate signaling in Niemann-Pick disease activates KLF2, 
which represses mitochondrial biogenesis via ERK-dependent ETV1 induction. This pathway 
is independent of defective autophagy, implying that LSDs affect mitochondrial function via 
different mechanisms. 
 
Figure 29| Impaired S1P signaling in NP – A Illustration of the S1PR1 signaling pathway. 
B S1PR1 transcript levels are increased in NP fibroblasts. p <0.0001 (***); Student’s t-test; mean 
± SEM, N = 8 C Induction of S1PR1 signaling lowers KLF2 levels and promotes mitochondrial 
biogenesis. p < 0.05 (*) and p < 0.01 (**); Student’s t-test; mean ± SD, N =3. SD: standard 
deviation, SEM: standard error of the mean 
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3.1.10 Activation of sphingosine 1-phosphate signaling restores mitochondrial 
function in desipramine-treated cells  
We had shown previously that pharmacologic inhibition of ASM in control fibroblasts fully 
replicates mitochondrial deficits in NP fibroblasts with increased KLF2 and ETV1 levels (see 
section 3.1.5 and Appendix Figure 53). Having also shown that S1P signaling promotes 
mitochondrial biogenesis, we reasoned that activating S1P signaling in desipramine-treated 
cells should rescue mitochondrial function in these cells. Accordingly, we treated ASM-inhibited 
control fibroblasts with or without Sew2871 and assessed mitochondrial function by real time 
respirometry. Interestingly, while desipramine alone lowered mitochondrial OCR, coupling ASM 
inhibition with Sew2871 treatment resulted in a partial rescue of both basal and maximal 
mitochondrial respiratory capacity (Figure 30). 
 
Figure 30| S1PR1 signaling rescues mitochondrial function in ASM inhibited cells 
– Activation of S1PR1 signaling by Sew2871 treatment partially rescues basal and maximal 
mitochondrial OCR in desipramine-treated fibroblasts. Graphs represent mean ± SEM, N = 8 
differences between means as based on one-way ANOVA tests with thresholds of p< 0.001 (***) 
were considered significant. SEM: standard error of the mean. 
 
3.1.11 Induction of KLF2 and ETV1 in Niemann-Pick disease is cytoprotective  
Mitochondrial dysfunction is typically associated with the induction of apoptosis. As a result, it 
is reasonable to think that improving mitochondrial biogenesis and function via KLF2 and ETV1 
downregulation in Niemann-Pick disease may be cytoprotective. On the other hand, the anti-
apoptotic role of KLF2 and ETV1 has been known for some time now given their induction in 
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cancers (Alberts-Grill et al., 2016; Chi et al., 2010; Ohguchi et al., 2016). As a result, it was 
unclear to us whether the induction of KLF2 and ETV1 in NP fibroblasts was beneficial or 
detrimental to the cell. To clarify this, KLF2 and ETV1 were downregulated independently in 
NP fibroblasts and their impact on apoptosis was assessed by the Annexin V-Propidium iodide 
assay. While only about background proportion of apoptotic cells was observed in control cells, 
NP fibroblasts had about 10-fold increase in the proportion of apoptotic cells relative to controls. 
This was further increased by 1.4- and 1.5-folds respectively following KLF2 and ETV1 
silencing in NP fibroblasts (Figure 31 A-E). Taken together, these results support the finding 
that KLF2 and ETV1 exert their anti-apoptotic influence in NP fibroblasts with a consequent 
repression of mitochondrial biogenesis 
 
Figure 31| Induction of KLF2 and ETV1 is anti-apoptotic – Proportion of apoptotic cells 
in control (A) and NP (B) fibroblasts, and in NP fibroblasts following KLF2 (C) and ETV1 (D) 
silencing. E Graphical depiction of the increase in apoptosis in NP fibroblasts with/without KLF2 
and ETV1 knockdown. p <0.001 (***); one-way ANOVA; mean ± SD, N = 5; SD: standard deviation 
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3.2 Impaired iron homeostasis due to lysosomal malfunction cause 
mtDNA depletion, which induces TLR9-mediated inflammatory 
signaling. 
 
3.2.1 Cortical mitochondrial defects in Pompe’s disease model 
The different types of Niemann-Pick disease form a spectrum of sphingolipid lysosomal storage 
disorders. The results from this study (section 3.1) and reports of additional studies 
demonstrate that the mechanism(s) underlying the pathogenesis of these diseases in part 
depend on impaired sphingolipid metabolism (Lachmann et al., 2004; Lloyd-Evans et al., 2008; 
Te Vruchte et al., 2004). It seems that mitochondrial dysfunction is a common feature of several 
LSDs and neurodegenerative diseases. However, not all LSDs primarily affect sphingolipid 
metabolism, suggesting that different mechanisms may underlie mitochondrial dysfunction in 
different LSDs. To elucidate some of these mechanisms, we focused on another lysosomal 
disease that affects glycogen storage, Pompe disease, which results from mutations in the acid 
alpha-glucosidase gene, GAA. The GAA protein is an enzyme that catalyzes the reaction of 
glycogen breakdown to glucose as illustrated in Figure 32A. We employed the GAA-/- mice, an 
established mouse model of Pompe’s disease.  
Mitochondrial malfunction was reported in GAA-/- mouse only recently, uncovering altered 
ultrastructural features and dynamics as well as reduced mitochondrial potential (Lim et al., 
2015). We have further found evidence pointing to enhanced glycolysis, a common 
consequence of mitochondrial dysfunction, in GAA-/- MEFs and HeLa cells with shRNA-
mediated silencing of GAA (Figure 40 and Appendix Figure 55). Pompe’s disease literature is 
dominated by studies in cardiac and skeletal muscles, since they are the most affected tissues. 
Nervous system involvement in the Pompe’s disease mechanism has only been recently 
reported in the peripheral nervous system (Falk et al., 2015). It was however unclear whether 
central nervous system (CNS) defects were involved in Pompe’s disease. As a result, we 
sought to find out if, as in Niemann-Pick disease (as shown before), a transcriptional network 
of mitochondrial biogenesis and function was altered in Pompe’s disease. Mitochondrial 
biogenesis was therefore assessed in the cortex of GAA-/- mice by measuring the expression 
of relevant transcriptional regulators of mitochondrial biogenesis and function. 
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Figure 32| Repressed mitochondrial biogenesis in GAA-/- cortex – A Illustration of the 
activity of GAA in healthy (left) and Pompe’s disease lysosomes (right). Lack of GAA activity 
results in intralysosomal glycogen accumulation in Pompe’s disease B Transcript levels of 
mitochondrial biogenesis mediators are reduced in the cortex of GAA-/- mice. C mtDNA 
transcriptional activity is downregulated following reduced expression of mtDNA maintenance 
genes in GAA-/- mice  Gene expression is depicted as mean ± SEM, N = 8; p < 0.05 (*) and p <0.01 
(**); Student’s t-test; SEM: standard error of the mean 
 
The expression of NRF1, NRF2, PPARG, and CREB, which are known transcriptional 
regulators of nuclear-encoded mitochondrial genes, was decreased (Figure 32B). In addition, 
essential factors that regulate the replication and transcription of mtDNA: TFAM, TFB2M, 
POLRMT, and POLG were all reduced in the cortex of GAA-/- mice (Figure 32C). Accordingly, 
reduced NRF1, NRF2, and TFAM protein levels were also observed in the GAA-/- mice (Figure 
33). 
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Figure 33| Reduced transcriptional regulation of mitochondrial biogenesis – 
Mitochondrial biogenesis requires cooperation between two genomes, whose key regulator 
proteins, NRF1, NRF2 and TFAM are less abundant in the cortex of GAA-/- mice. Band 
quantifications are represented as mean ± SEM, N = 8; p < 0.05 (*); Student’s t-test; SEM: 
standard error of the mean. 
 
3.2.2 Progressive cortical mtDNA depletion in GAA-/- mice  
Maintenance of the mitochondrial genome, as well as its transcription and translation, is 
controlled by proteins and enzymes which are encoded in the nucleus (reviewed in Gustafsson 
et al., 2016). Given that reduced amounts of these factors were found in the cortex of GAA-/- 
mice, it was reasoned that mtDNA depletion would likely occur in the brain. To this end, total 
DNA was isolated from cortices of GAA-/- mice and their wild-type littermates at different age 
points and mtDNA copy numbers were measured (relative to a nuclear DNA control). 
Interestingly, progressive decline in mtDNA copy numbers was found in GAA-/- mice culminating 
in a 60% loss at 6 months of age (Figure 34). 
  
Figure 34| Progressive mtDNA copy number depletion in GAA-/- cortex – mtDNA copy 
numbers at 0, 2 and 6 months of age in wild-type and GAA-/- mice cortices show progressive 
mtDNA depletion with age. p <0.001 (***); Student’s t-test; mean ± SEM, N = 8. 
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3.2.3 Cardiac mitochondrial deficits in Pompe’s disease 
Having established that a decreased transcriptional network of mitochondrial biogenesis and 
function ensued in the CNS of GAA-/- mice, it was relevant to determine whether a similar 
response occurred in the heart of GAA-/- mice since cardiomyopathy is a reported phenotype 
of Pompe’s disease. Similarly, mtDNA copy numbers were quantified from total DNA isolated 
from the heart of GAA-/- mice and their control littermates at 2 and 6 months of age. Notably, a 
decline in mtDNA copy numbers was also observed in the heart, albeit not progressive as in 
the CNS, since mtDNA was depleted at 2- and 6-months of age to similar levels (Figure 35).  
 
Figure 35| Cardiac mtDNA copy number declines in GAA loss – Although not 
progressive with age, mtDNA copy number depletion is evident in the heart of GAA-/- mice. p < 
0.001 (***); Student’s t-test; mean ± SEM, N = 8; SEM: standard error of the mean 
 
We hypothesized that a transcriptional component may mediate mtDNA depletion in the heart. 
To verify this, transcript and protein levels of the key regulators of mitochondrial biogenesis 
and function were measured in the heart of GAA-/- mice. Surprisingly, at transcript level, the 
expression of NRF1, NRF2, PPARG, and CREB were markedly increased (Figure 36A). The 
increase in the expression level of genes that regulate mtDNA maintenance (Figure 36B) was 
even more robust. The protein levels of these regulators were not changed consistently, as we 
observed 60% increase in NRF1 levels, unchanged NRF2 levels and a 50% decrease in TFAM 
levels (Figure 36C). Taken together, the results from the cortex and heart of GAA-/- mice implied 
that mtDNA depletion was a common phenotype associated with Pompe’s disease and that 
decline in mtDNA copy numbers was independent of mitochondrial biogenesis. TFAM is known 
to regulate mtDNA transcription and replication, and TFAM haploinsufficiency and 
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overexpression studies suggest that levels of TFAM correlate well with mtDNA copy number 
levels (West et al., 2015; Xu et al., 2009). It has also been shown, conversely, that inhibiting 
mtDNA replication by ethidium bromide treatment results in TFAM degradation without altering 
TFAM mRNA levels (Matsushima et al., 2010). Thus, it remained unclear to us whether mtDNA 
depletion was due to reduced TFAM levels, or whether reduced TFAM levels were a 
consequence of mtDNA depletion. Interestingly, reduced mtDNA copy numbers and TFAM 
levels were also observed in Niemann-Pick disease (Figures 14C and 15). That 
notwithstanding, it was important to understand the mechanism(s) directing mtDNA depletion 
since its copy number variation has been linked to aging and several neurodegenerative 
diseases including AD, PD and ALS (reviewed in Keogh and Chinnery, 2015; Pinto and 
Moraes, 2014). 
 
Figure 36| Increased cardiac mitochondrial biogenesis in GAA-/- mice –                                             
A Transcriptional regulation of mitochondrial biogenesis is increased in the heart. B Cardiac 
mtDNA transcriptional activity is induced in GAA-/-. C Western blot analyses of heart lysates 
show increased NRF1 levels and reduced TFAM protein amounts. NRF2 protein amounts are not 
altered in GAA-/- mice. Gene expression and band quantifications are displayed as mean ± SEM 
for N = 8; p <0.05 (*), p < 0.01 (**), and p< 0.001(***); Student’s tests; SEM: standard error  
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3.2.4 Loss of TFAM but not mtDNA depletion in GAA-/- is dependent on mTORC1  
In order to mechanistically probe mtDNA depletion in lysosomal malfunction, it was necessary 
to employ a model that is amenable to experimental manipulation. As such, it was tested if 
GAA-/- MEFs would replicate the mtDNA defect that was observed in lysosomal malfunction 
models. Figure 38B showed a reduction in mtDNA copy number levels in GAA-/- MEFs. It was 
then tested whether TFAM induction would rescue mtDNA copy numbers. Given that the 
transcript levels of TFAM were only slightly reduced in the brain and increased by fourfold in 
the heart, it was reasoned that enhancing TFAM translation would be a better mechanism of 
TFAM induction. The mechanistic/mammalian target of rapamycin complex 1 (mTORC1) was 
recently shown to specifically direct mitochondrial biogenesis through 4E-BP-dependent 
translational regulation of TFAM and other mitochondrial-related mRNAs (Morita et al., 2013). 
Thus, mTORC1 activity, which was found to be reduced in the cortex (Appendix Figure 56) and 
MEFs, was increased by siRNA-mediated TSC2 silencing in GAA-/- MEFs (Figure 37). 
 
 
Figure 37| Induction of mTORC1 activity in GAA-/- MEFs – siRNA-mediated silencing of 
Tuberin (TSC2), which negatively regulates mTORC1 activity, results in increased mTORC1 
activity as demonstrated by phosphorylation of ribosomal protein S6 at Serine 235/236. Band 
quantifications are depicted as mean ± SD for triplicate samples; p < 0.05 (*) and p < 0.01 (**); 
one-way ANOVA; SD: standard deviation 
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TSC2 silencing, as expected, resulted in increased mTORC1 activity as assessed by the 
phosphorylation of Serine residues 235/236 of the ribosomal protein s6 (Figure 37), which led 
to a robust rescue of TFAM protein amounts to control levels in the GAA-/- MEFs (Figure 38A). 
However, mtDNA copy number levels were affected neither by increased mTORC1 activity nor 
by rescued TFAM levels (Figure 38B). Therefore, this result implied that mtDNA depletion was 
not a consequence of reduced TFAM levels. The reverse, however, may be true given that 
increased mTORC1 activity in GAA-/- MEFs also led to a slight but significant decrease in the 
protein levels of Lon protease, which degrades TFAM (Appendix Figure 57). 
 
Figure 38| Increased mTORC1 activity reverses TFAM loss – A Increased mTORC1 
activity rescues TFAM levels. Band quantifications are depicted as mean ± SD for triplicate 
samples; p < 0.05 (*) and p < 0.001 (***); one-way ANOVA; SD: standard deviation B mtDNA 
depletion is unaffected by mTORC1 activity or TFAM levels in GAA-/- MEFs. Graph 
represents mean ± SEM, N= 8; p > 0.05 (ns) and p< 0.001 (***); one-way ANOVA; SEM: 
standard error of the mean, ns: not statistically significant. 
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3.2.5 Impaired nucleotide metabolism affects mtDNA levels 
Although several nuclear-encoded genes drive mtDNA synthesis and maintenance, a rate-
limiting component of this reaction is the bioavailability of intra-mitochondrial 
deoxyribonucleotide triphosphates (dNTPs) – the pool of building blocks for mtDNA synthesis. 
Furthermore, reduced activity of enzymes and kinases, which regulate the bioavailability of 
dNTPs, is a recognized cause of mtDNA depletion syndromes (El-Hattab et al., 2017). Having 
demonstrated that increasing TFAM levels does not alter mtDNA copy number, it was reasoned 
that impaired nucleotide metabolism may be a culprit in mtDNA depletion in GAA insufficiency.  
  
To address this, GAA-/- MEFs were cultured for 3 days in dividing and non-dividing conditions 
and mtDNA copy number was quantified. The reasoning behind this was that, during cell 
division, de novo biosynthesis of nucleotides is increased to make nucleotides available for 
DNA replication. These nucleotides also become bioavailable for mtDNA synthesis. On the 
other hand, under non-dividing conditions, mtDNA synthesis is markedly dependent on the 
salvage pathway for dNTPs – a mechanism, which is especially relevant for mtDNA 
maintenance in post-mitotic cells. Interestingly, it was found that while mtDNA copy number 
levels were unchanged during dividing conditions, there was a rapid decline in mtDNA copy 
number levels in GAA-/- MEFs when the cells were confluent (Figure 39).  
 
Figure 39| Nucleotide metabolite availability affects mtDNA levels – GAA-/- MEFs 
cultured under dividing and non-dividing conditions show distinct mtDNA copy number 
phenotypes with a decline only under confluent conditions. Graph represents mean ± SEM, 
N= 8; p< 0.001 (***); one-way ANOVA; SEM: standard error of the mean. 
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This result was consistent with our idea of impaired nucleotide metabolism in GAA knockout. 
Interestingly, this result was supported by our data from metabolite profiling of HeLa cells with 
shRNA-mediated silencing of GAA (Figure 40). Nucleotide biosynthetic pathway metabolites 
were decreased while glycolysis intermediates were increased in shGAA cells (Figure 40).  
 
 
 
Figure 40| Metabolite profiling of shGAA HeLa cells – The graph above depicts 
metabolites with significantly altered concentrations following shRNA-mediated silencing of 
GAA in HeLa cells. Graph represents mean ± SEM, n = 10; p< 0.05; Student’s test; SEM: standard 
error of the mean. Glycolysis intermediates (in red) are increased while nucleotide biosynthetic 
components (in green) are reduced in shGAA cells. 
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Table 16: Altered metabolic pathways in shGAA cells 
pathway p-value total expected hits 
Pyrimidine metabolism 0.001255 60 0.49855 4 
Glycolysis 0.002370 21 0.61100 4 
Nitrogen metabolism 0.003707 39 0.32405 3 
Galactose metabolism 0.004278 41 0.34067 3 
Starch and sucrose metabolism 0.007498 50 0.41545 3 
Thiamine metabolism 0.016299 24 0.19942 2 
Purine metabolism 0.038457 92 0.76444 3 
 
In addition, metabolite set enrichment analyses of the altered metabolites revealed the 
metabolic pathways that were significantly affected in GAA knockdown cells (Table 16). It was 
interesting to find that nucleotide metabolism (in red) as well as glycolysis scored as 
significantly affected metabolic pathways in cells with GAA downregulation.  
Further, it was reasoned that enhancing nucleotide metabolism should protect against mtDNA 
depletion. For this purpose, GAA wild type and knockout MEFs were treated with folic acid (or 
NaOH as vehicle control) that regulates nucleotide synthesis through one-carbon metabolism, 
(Nikkanen et al., 2016; Tufi et al., 2014) and mtDNA levels were measured. Notably, folate 
supplementation resulted in enhanced one-carbon metabolism by increasing levels of 
methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) in GAA-/- MEFS (Figure 41A). 
MTHFD2 is an essential and rate-limiting enzyme of the mitochondrial folate metabolic 
pathway, which donates single carbon molecules for nucleotide synthesis (Di Pietro et al., 
2004). Strikingly, mtDNA defects were rescued in GAA-/- MEFs with folate supplementation 
(Figure 41B). Altogether, these results demonstrate that impaired nucleotide metabolism is part 
of the mechanism of mtDNA depletion upon GAA loss, and probably in other lysosomal storage 
diseases too. However, it was still unclear how lysosomal malfunction triggered by GAA 
insufficiency resulted in impaired nucleotide metabolism and, consequently, mtDNA copy 
number loss.  
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3.2.6 Lysosomal malfunction impairs iron homeostasis 
Nucleic acids, like other macromolecules, are degraded continuously in cells. The products of 
such nucleic acid catabolism are either excreted or salvaged as components of new 
nucleotides. In fact, in quiescent cells, the salvage pathway of nucleic acid metabolism is of 
utmost relevance for mtDNA replication requiring the activity of ribonucleotide reductase 
subunit p53R2 (Pontarin et al., 2012) to make dNTPs available. However, no change in the 
levels of ribonucleotide reductase p53R2 was observed in GAA-/- brain or heart (see Appendix 
Figure 58). In addition, ribonucleotide reductase subunit p53R2 harbors an iron-tyrosyl free 
radical center, which is a required co-factor for initiation of nucleotide reduction (Bourdon et al., 
2007; Guittet et al., 2001). Given that the endo-lysosomal system has been known for some 
time now to be central to iron homeostasis (reviewed in Biasiotto et al., 2016; Kurz et al., 2008; 
Rouault, 2013), it was thought that impaired iron homeostasis due to lysosomal malfunction 
might be responsible for reduced ribonucleotide reductase activity, impaired nucleotide 
metabolism and as a consequence, mtDNA instability and depletion.   
 
Figure 41| Enhancing nucleotide synthesis rescues mtDNA depletion – A Folic acid 
supplementation induces folate metabolism in GAA-/- MEFs as shown by increased MTHFD2 
levels. B Induction of folate metabolism via folic acid supplementation reverses mtDNA loss in 
GAA-/- MEFs. Graphs show mean ± SEM of at least triplicate samples; p <0.05 (*), p < 0.01 (**), 
and p< 0.001(***); one-way ANOVA; SEM: standard error of the mean 
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Figure 42| Decreased complex IV activity in GAA-/- cortical mitochondria – A Native 
PAGE and subsequent activity staining of mitochondria purified from GAA-/- mice show 50% 
reduction in complex IV activity. Arrows indicate supercomplexes (top) and complex IV 
monomers (bottom). B Protein amounts of the mtDNA-encoded mitochondrial cytochrome c 
oxidase subunit 1(mtCO1) are increased in the cortex of GAA-/- mice. Quantifications are 
displayed as mean ± SEM for N = 8; p <0.05 (*) and p< 0.001(***); Student’s tests; SEM: standard 
error 
 
Preliminary evidence of such impaired iron handling came from the result that isolated 
mitochondria from the cortex of GAA-/- mice, when subjected to BN-PAGE and subsequent 
activity staining showed about 50% reduction in complex IV activity relative to their littermate 
controls (Figure 42A). However, the steady-state levels of mitochondrial cytochrome c oxidase 
subunit 1 (mtCO1) were not reduced in the cortex of GAA-/- mice (Figure 42B). Since mtCO1 is 
the catalytic enzyme of complex IV of the respiratory chain and displays a steady state-linked 
catalytic activity (D’Aurelio et al., 2001; Varlamov et al., 2002) it was reasoned again that iron 
(a cofactor for complex IV activity) may be mishandled. To further demonstrate iron deficiency 
in GAA-/- mice, levels of transferrin receptor and ferritin were measured in the cortex of GAA-/- 
mice. It is widely known that under conditions of iron deficiency, transferrin receptor levels are 
increased to enhance iron delivery into the cell through endocytosis, and that ferritin amounts 
are reduced to lower sequestration of iron and thus replenish cellular iron content (Rouault, 
2013). Similarly, and consistent with an idea of iron deficiency in GAA-/- mice, increased 
transferrin receptor levels and decreased ferritin amounts were observed in the cortex (Figure 
43A). To confirm these results, iron concentration in the GAA-/- MEFs was measured using an 
iron assay kit (see Methods). Curiously, total iron concentration was not altered but levels of 
ferrous iron were significantly reduced in GAA-/- MEFs, while those of ferric iron were increased 
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(Figure 43B). The relevance of this result stemmed from its consistency with lysosomal 
malfunction: the lysosome harbors the metalloreductase STEAP3, which reduces Fe3+ to Fe2+. 
As such, the results reflect a functional iron pseudo-deficiency state, where Fe2+ levels are 
reduced and thus less available as co-factor for the enzyme activity of ribonucleotide reductase 
or complex IV of the respiratory chain, among other iron-containing proteins. 
 
Figure 43| Impaired iron homeostasis in GAA loss – A Levels of transferrin receptor are 
increased while those of ferritin light chain are reduced in the cortex of GAA-/- mice (N =8).             
B While total iron concentration is not altered by GAA loss, levels of ferrous iron (Fe2+) are 
reduced and those of ferric iron (Fe3+) are rather increased in GAA-/- MEFs (N = 5). Graphs 
represent mean ± SEM for indicated number of samples; p <0.01 (**), p< 0.001(***), and p > 0.05 
(ns); Student’s tests; SEM: standard error of the mean, ns: not statistically significant. 
 
3.2.6 Iron deficiency causes mtDNA depletion  
Although it was shown that lysosomal malfunction due to GAA loss resulted in ferrous iron 
deficiency, it was essential to know whether iron deficiency impacted mtDNA copy numbers. 
To address this, control MEFs were treated with a prescribed iron chelator, deferoxamine 
following which levels of mtDNA copy number were measured. Accordingly, deferoxamine 
treatment resulted in increased TFRC expression and decreased levels of FTH1 and FPN 
(Figure 44A). FPN encodes for the cellular iron exporter ferroportin, whose levels, like those of 
ferritin, are reduced under conditions of iron deficiency. Consistently, mtDNA copy numbers 
were lowered in deferoxamine-treated cells to a degree similar to the GAA-/- MEFs (Figure 44B). 
To exclude drug-specific effects on mtDNA copy number levels, MEFs from IRP1-/- and IRP2-/- 
mice were tested for mtDNA abundance. IRP1 and IRP2 encode for iron-responsive element-
binding proteins, which regulate iron homeostasis. Lack of these proteins impairs iron 
homeostasis leading to reduced bioavailability of Fe2+ (Meyron-Holtz, 2004).  
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Remarkably, mtDNA copy number levels were found to be significantly reduced in IRP1/2-/- 
MEFs (Figure 44C).  
 
Figure 44| Iron deficiency results in mtDNA depletion – A TFRC transcripts are 
increased and FTH1 and FPN mRNAs are reduced following deferoxamine (DFO) treatment.  
B DFO treatment leads to mtDNA copy number loss in control MEFs. C Loss of IRPs, which 
triggers functional iron deficiency, results in mtDNA depletion Gene expression and mtDNA 
copy number are depicted as mean ± SEM, N = 8; p < 0.001(***); Student’s tests; SEM: standard 
error of the mean 
 
More importantly, to show the dependency of mtDNA copy number defects on iron deficiency, 
we were curious to know whether iron supplementation would ameliorate mtDNA copy number 
loss in lysosomal malfunction. To this end, GAA-/- and wild-type MEFs were treated with either 
ferric iron diluted in sodium citrate, or with sodium citrate as a control. In line with our premise, 
iron repletion was enough to rescue mtDNA copy number defects in GAA-/- MEFs (Figure 45). 
These results, altogether, imply that lysosomal malfunction impairs iron homeostasis leading 
to reduced bioavailability of ferrous iron for processes necessary for mtDNA synthesis and 
mitochondrial function. 
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Figure 45| Iron supplementation rescues mtDNA copy number depletion – Repletion 
of iron via iron citrate supplementation rescues mtDNA defects in GAA-/- MEFs. p < 0.001 (***); 
one-way ANOVA; mean ± SEM, N = 8; SEM: standard error of the mean. 
 
3.2.7 mtDNA defects due to iron deficiency trigger the innate immune response  
Next, it was necessary to elucidate the biological relevance of these findings for the health (or 
disease) implications of an organism. As such, we looked for the role of mtDNA defects in 
disease pathogenesis. In addition to its vital role in encoding for key subunits of the respiratory 
chain, it is now appreciated that the mitochondrial genome induces the innate immune 
response through its cooperation with several pattern recognition receptors (Barbalat et al., 
2011; Oka et al., 2012; West et al., 2015). It is thus not a coincidence that a hallmark of LSDs 
and neurodegenerative disorders is the induction of inflammation (reviewed in Bosch and 
Kielian, 2015; Vitner et al., 2015). The endolysosomal system, which degrades mitochondrial 
proteins and mtDNA during mitophagy, has evolved as a platform where pattern-recognition 
receptors like the toll-like receptor 9 (TLR9) sense DNA and subsequently activate the innate 
immune response (Kawai and Akira, 2010).  
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Figure 46| Induction of the innate immune response in the brain – Loss of GAA in the 
cortex triggers a transcriptional response of innate immune response activation. Gene 
expression is depicted as box plots showing minimum, mean and maximum expression levels, 
N =8; p <0.05 (*), p < 0.01 (**), and p< 0.001(***); Student’s t-test 
 
Consistent with these reports, we hypothesized that in lysosomal malfunction, the increased 
retention of agonists of TLR9 like mtDNA or its fragments in the lysosome would enhance the 
activation of the innate immune response pathway typically through increased gene expression 
of type I interferon genes. The expression of such genes was thus measured in the cortex and 
in the heart of GAA-/- mice. Strikingly, the expression of TLR9, its signaling pathway mediators, 
MyD88, IRF7, ISG15 and STAT1, and its downstream effector molecules, CXCL10, IFI44, 
IFIT1, and IFIT3 were all increased in the brain (Figure 46) and in the heart (Figure 47) of GAA-
/- mice. 
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Figure 47| Cardiac innate immune response induction – GAA loss in the heart, like in 
the brain, induces the innate immune response via transcriptional activation of Type I interferon 
genes. Gene expression is depicted as box plots showing minimum, mean and maximum 
expression levels, N =8; p <0.05 (*), p < 0.01 (**), and p< 0.001(***); Student’s t-test 
 
3.2.8 Increased gliosis in the cortex of GAA-/- mice  
The transcriptional induction of the innate immune response (Figures 46 and 47) prompted a 
further probing of markers of inflammation in GAA-/- mice. In the context of neuroinflammation, 
the participation of glial cells is essential. The most abundant cell type in the brain, astrocytes, 
in addition to providing neurotrophic support to neurons, have been known for a long time to 
mediate immune responses in the CNS through chemokine secretion (Persidsky et al., 1999). 
Microglia, the chief immune cells of the CNS, can sense agonists via Toll-like receptors and 
other pattern-recognition receptors (Facci et al., 2014; Yao et al., 2013). When activated, 
microglia release chemokines and cytokines, which respectively recruit and activate peripheral 
immune cells. In support of this, preliminary results from magnetic resonance spectroscopy 
(MRS) of GAA-/- mice at 6 months of age indicated  a significant reduction in T2 relaxation times 
of water protons in the cortex, striatum and thalamus (Table 17), suggesting the infiltration of 
glial cells or macrophages in the brain of GAA-/- mice (Watanabe et al., 2015).  
 
Results 
 
 
Table 17: T2 relaxation times (ms) of water protons 
Brain region Wild-type GAA-/- 
Cerebral cortex 40.3 ± 0.5 38.3 ± 0.8*** 
Striatum 39.7 ± 1.0 37.3 ± 0.8** 
Thalamus 38.4 ± 1.0 35.9 ± 1.1* 
 
 
Figure 48| Glial cell proliferation in the cortex of GAA-/- mice – A Immunoblot analyses 
of whole cortical lysates show a two-fold increase in GFAP, a gliosis marker, levels in GAA-/- mice. 
B Number of GFAP-positive cells is increased in GAA-/- mice as demonstrated by increased GFAP 
immunostaining. Quantifications represent mean ± SEM, N = 8; p <0.01 (**); Student’s tests; 
SEM: standard error of the mean. Scale bars represent 20µM. 
 
This result would later be confirmed by immunoblots and immunostaining for the glial fibrillary 
acidic protein, GFAP, a gliosis marker, in the cortex of GAA-/- mice, where a two-fold increase 
in GFAP was observed (Figure 48A) with an increase in the number of GFAP-positive cells 
(Figure 48B). Thus far, this study showed that lysosomal malfunction triggers the innate 
immune response via a mechanism of mtDNA defects elicited by a pseudo-iron deficiency.  
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3.2.9 Iron supplementation ameliorates brain mtDNA defects and reduces 
innate immune response in GAA-/- mice in vivo. 
the mechanism elucidated in this study would be relevant for lysosomal storage and 
neurodegenerative disorders if it could be targeted to rescue some disease phenotypes, 
especially the inflammatory response. Although the goal of immune response induction is to 
swiftly contain an insult, typically as a protective response, persistent inflammation can exert 
harmful effects on the affected cells or tissues.  
 
Figure 49| Iron supplementation rescues mtDNA defects and down-regulates 
innate immune activation – A In vivo iron supplementation via iron-enriched chow rescues 
mtDNA copy number decline in the cortex of GAA-/- mice at 2 months of age. p <0.01 (**) and p 
< 0.001 (***); one-way ANOVA; mean ± SEM, N = 5; SEM: standard error of the mean. B Iron 
supplementation dampens activated transcripts of innate immune response genes in the cortex 
of GAA-/- mice. Heatmap represents average expression of each gene normalized to the 
expression levels of wildtype mice on standard chow, N = 5. 
 
Given the progressive decline of mtDNA copy numbers in the brain of GAA-/- mice (Figure 34), 
we postulated that persistent mtDNA-induced activation of the immune response would be 
detrimental to the affected tissues. It was also shown previously in cells that iron 
supplementation rescues mtDNA copy number defects (Figure 45). To this end, we were 
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curious to decipher whether iron supplementation would indeed rescue mtDNA defects in vivo 
in GAA-/- mice and consequently ameliorate the induced immune response. Therefore, GAA-/- 
mice and their corresponding wild-type littermates were fed with iron-enriched or standard chow 
ad libitum. The GAA-/- mice were mostly examined at 6 months of age. Nevertheless, we were 
curious about obtaining preliminary results on the iron supplementation experiments. As a 
result, a cohort of the mice was sacrificed at 2 months of age for mtDNA copy number 
measurements as well as gene expression profiling of the innate immune response pathway. 
Remarkably, iron supplementation was found to partially rescue mtDNA copy number levels in 
the cortex of GAA-/- mice already at 2 months (Figure 49A). Consequently, GAA-/- mice, with 
upregulated innate immune response genes, showed a decreasing trend in the expression of 
signaling and effector molecules of the innate immune response pathway following two months 
of iron supplementation (Figure 49B). This result warrants further analyses, which would be 
carried out following the 6 months of iron supplementation. 
  
 
4 Discussion 
 
4.1 Defective lysosomal signaling in Niemann-Pick disease represses 
mitochondrial biogenesis and function 
Mitochondrial dysfunction has been reported in patients and mouse models of the Niemann-
Pick spectrum of lipid disorders, just like in most LSDs (Castillo et al., 2017; Osellame and 
Duchen, 2014). However, the mechanisms governing mitochondrial malfunction in these 
diseases are largely unknown. This study uncovers a novel mechanism that links chronic 
lysosomal malfunction in Niemann-Pick disease to mitochondrial dysfunction. We demonstrate 
unequivocally that the induction of transcriptional regulators KLF2 and ETV1, and their 
cooperation to repress mitochondrial biogenesis and mitochondrial function in Niemann-Pick 
disease. 
 
4.1.1 Mitochondrial biogenesis is repressed in Niemann-Pick disease 
We uncovered reduced mitochondrial respiration and increased levels of mitochondrial 
superoxides in fibroblasts from patients with Niemann-Pick Type A/B (Figure 13). This outcome 
was replicated in human dermal fibroblasts treated with an inhibitor of acid sphingomyelinase, 
the protein deficient in Niemann-Pick Type A/B. In addition, we showed that mitochondrial 
function is compromised in mouse embryonic fibroblasts prepared from NPC1-/- mice, the 
model for Niemann-Pick Type C. Thus far, the mitochondrial impairments in lysosomal 
diseases have been attributed only to defective autophagy (mitophagy) and the consequent 
accumulation of dysfunctional mitochondria (Baulies et al., 2016; Ordonez, 2012).  
However, in addition to defective autophagy, our results indicate that mitochondrial dysfunction 
in Niemann-Pick disease is a consequence of a signaling mechanism that represses 
mitochondrial biogenesis. Interestingly, this transcriptional response was found in cells and 
tissues of Niemann-Pick disease (Figures 14 and 19). Furthermore, repression of mitochondrial 
biogenesis in the brain and liver of NPC1-/- mice was evident in only symptomatic mice (Figure 
19 B, C) probably as an adaptive response to progressive lysosomal malfunction. It is 
noteworthy that lysosomal biogenesis was increased in all models of Niemann-Pick disease 
tested, a response that is usually seen as compensatory in LSDs (Karageorgos et al., 1997). 
Although the etiology is different for the subtypes of Niemann-Pick disease, our results 
underscore a significant overlap in the pathological mechanisms of the syndrome as reported 
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previously (Vanier, 2013). Niemann-Pick Type A/B affects sphingolipid catabolism while 
Niemann-Pick Type C is regarded as a sphingomyelin storage disorder, which mainly affects 
cholesterol efflux from the lysosome (Platt, 2014). However, the only approved therapy for 
Niemann-Pick Type C, miglustat, blocks glycosphingolipid biosynthesis (Patterson et al., 2012), 
suggesting the involvement of sphingolipids in Niemann-Pick Type C. This further underlies the 
mechanistic overlaps in Niemann-Pick disease. 
 
4.1.2 KLF2 and ETV1 mediate repression of mitochondrial biogenesis in 
Niemann-Pick disease  
Beyond reporting mitochondrial defects in Niemann-Pick disease, this study further 
demonstrated that a coordinated transcriptional program mediated by transcriptional 
regulators, KLF2 and ETV1, repressed mitochondrial biogenesis in Niemann-Pick disease. 
Indeed, KLF2 and ETV1, which were induced in Niemann-Pick disease (Figure 23), were 
predicted to target respiratory chain genes by MatInspector analyses of promoters of 
mitochondrial respiratory chain genes. In line with this, genes under ETV1 transcriptional 
regulation were found to include several mitochondrial genes from ETV1 ChIP-Seq data (Figure 
24). Consistently, silencing either KLF2 or ETV1 reversed the repression of mitochondrial 
biogenesis in Niemann-Pick disease and ultimately rescued mitochondrial respiration. 
Strikingly, knockdown of KLF2 or ETV1 was sufficient to rescue the levels of NRF1, a known 
master regulator of mitochondrial biogenesis (Kelly and Scarpulla, 2004). This result implicates 
a potential transcriptional regulatory network involving KLF2, ETV1, and NRF1 in controlling 
mitochondrial biogenesis. In addition, the activated signaling pathway involving KLF2 and ETV1 
is operational in fibroblasts from Niemann-Pick Type A/B patients and in tissues of the 
Niemann-Pick Type C mouse model. This further underlines the biochemical similarities 
between the different variants of Niemann-Pick disease, which all accumulate cholesterol and 
sphingomyelin in the lysosome (Patterson et al., 2012). Previous predictions of the role of KLF2 
and ETV1 in regulating mitochondrial biogenesis or function are worthy of mention. 
Doddaballapur et al. (2015) showed that increased KLF2 activity in endothelial cells is 
associated with decreased mitochondrial content, which can be reversed by KLF2 silencing. 
Interestingly, ETV1, which is highly expressed in cancers, notably prostate cancer, has been 
shown to drive reprogramming of metabolic pathways typically with increased glycolysis and 
reduced mitochondria function (Baena et al., 2013). 
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Furthermore, activities of KLF2 and ETV1 may be associated with other hallmarks of Niemann-
Pick disease. For example, liver disease is a prevalent phenotype of Niemann-Pick disease 
(Patterson et al., 2012). Intriguingly, KLF2 has been shown recently to negatively regulate liver 
regeneration through activin A induction (Manavski et al., 2017). Indeed, overexpressing KLF2 
in liver sinusoidal endothelial cells reduced hepatocyte proliferation. In addition, 
oligodendrocyte differentiation is known to be coordinated by differential transcriptional 
regulation, which includes robust ETV1 downregulation (Dugas et al., 2006). Accordingly, 
hypomyelination and neurodegeneration, which are prevalent in Niemann-Pick disease 
(German et al., 2002; Patterson and Walkley, 2017), maybe to some extent linked to ETV1 
induction. The role of ETV1 and KLF2 in neurodegeneration warrants further investigation.  
4.1.2 Mechanisms of KLF2 and ETV1 induction in Niemann-Pick disease  
Strikingly, silencing KLF2 results in ETV1 depletion and improved mitochondrial biogenesis 
and function, suggesting that KLF2 was potentially upstream of ETV1 (Figure 27 A). In addition, 
ERK activity, a positive regulator of ETV1 (Janknecht, 1996; Janknecht, 2003), was increased 
in Niemann-Pick patient fibroblasts. Indeed, phosphorylation of ETV1 at residues serine-191 
and serine-126 by ERK-dependent signaling drives ETV1 nuclear translocation and 
transcriptional activity (Janknecht, 2003). In line with this, ERK inhibition in Niemann-Pick 
patient cells, like KLF2 silencing, ablated ETV1 protein levels without altering KLF2 amounts 
(Figure 28). Taking also into account the report that KLF2 hemizygous mice present reduced 
ERK activity (Das et al., 2012), these data advocate that KLF2 cooperates with ERK to induce 
ETV1 and drive its transcriptional activation. 
The mechanism mediating KLF2 induction in Niemann-Pick disease seems rather complex but 
we show that it is dependent on reduced sphingosine-1-phosphate (S1P) signaling. KLF2 is a 
known regulator of S1P signaling through the transcriptional activation of S1P receptor 1 
(S1PR1) expression. Interestingly, S1P negative feedback signaling targets KLF2 for 
proteasomal degradation via AKT (Bai et al., 2007; Sinclair et al., 2008; Skon et al., 2013). 
Consistent with reduced S1P signaling due to decreased S1P levels in Niemann-Pick disease 
(Fan et al., 2013), we found reduced AKT activity, induced KLF2 levels and increased S1PR1 
expression in Niemann-Pick patient fibroblasts. Conversely, enhanced agonist-mediated S1P 
signaling facilitated KLF2 downregulation and improved mitochondrial biogenesis and function 
(Figures 29 and 30). Remarkably, increased S1P signaling was recently found to maintain 
mitochondrial content of naïve T cells and promote mitochondrial function (Mendoza et al., 
2017). Although the mechanism was not demonstrated in this report, we propose that it is likely 
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a consequence of KLF2 downregulation following S1P signaling. It is also noteworthy that 
impaired S1P signaling is associated with neurodegeneration, a prevalent phenotype in 
Niemann-Pick disease (German et al., 2002; Hagen et al., 2011). 
Mitochondrial defects have been reported in the most common LSD, Gaucher’s disease 
(Osellame et al., 2013). Mutations in the GBA1 gene, which result in defective lysosomal 
glucocerebrosidase in Gaucher’s disease, have been identified as  genetic rick factors for 
idiopathic Parkinson’s disease (Bultron et al., 2010). It would be particularly interesting to 
understand whether KLF2 and ETV1 mediate mitochondrial defects in Gaucher’s disease, 
given that lysosomal glucocerebrosidase activity is crucial for sphingosine formation. 
Although we have shown that induction of KLF2 and ETV1 in Niemann-Pick disease represses 
mitochondrial biogenesis (Figure 50), it appears that this is an adaptive response to promote 
cell survival. KLF2 and ETV1 are anti-apoptotic, which is illustrated by their crucial role in 
cancers (Alberts-Grill et al., 2016; Chi et al., 2010; Ohguchi et al., 2016). Consequently, KLF2 
and ETV1 induction in response to chronic lysosomal malfunction in Niemann-Pick diseases 
promotes cell survival at the expense of a loss of mitochondrial function. It is imaginable that 
by shutting down mitochondrial respiration and the TCA cycle, for instance, citrate can be 
shuttled into the cytoplasm for fatty acid synthesis. This would be relevant for Niemann-Pick 
disease, given that lipids accumulate in the lysosome and are probably not available to other 
cellular compartments. 
Taken together, this work contributes to our understanding of the interplay between organelles 
by highlighting that mechanisms of communication between lysosomes and mitochondria go 
far beyond metabolic cues and involve complex signaling and transcriptional regulatory 
networks. We uncover a signaling pathway that engages transcriptional regulators, which 
mediate the repression of mitochondrial biogenesis and mitochondrial function in Niemann-
Pick disease. The model for this pathway, as illustrated in Figure 50, shows that S1P, which is 
released from cells, stimulates a family of G protein-coupled receptors, including S1PR1. 
S1PR1 mediates downstream signaling to induce biological processes such as growth and 
differentiation. Importantly, S1PR1 negative feedback signaling targets KLF2 for degradation. 
Owing to the reduced circulating S1P levels in Niemann-Pick disease, our model predicts the 
induction of KFL2 via reduced S1PR1 signaling. KLF2 in turn induces and cooperates with 
ETV1 in an ERK-dependent manner to target and downregulate the expression of 
mitochondrial genes. 
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Interestingly, the model presented in Figure 50, also describes a novel therapeutic target that 
is potentially relevant for Niemann-Pick disease, which involves modulation of S1PR1 
signaling. There is already considerable translational research on the potential of S1PR1 
modulators in human diseases, especially in multiple sclerosis. Although the contribution of this 
work to such clinical investigations is barely relevant, our findings underlie an additional 
mechanism of S1PR1 signaling in regulating cellular functions, which may be useful in 
understanding some clinical outcomes of S1PR1 modulation. 
 
Figure 50| Model of lysosomal and mitochondrial crosstalk in Niemann-Pick 
disease – Niemann-Pick disease is in part caused by decreased circulating S1P levels, 
culminating in its reduced signaling and the induction of ETV1 via ERK and KLF2. Induced KLF2 
and ETV1 engage a transcriptional network that represses mitochondrial biogenesis and 
function in Niemann-Pick disease. (Original illustration, KF Yambire) 
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4.2 Perturbed iron homeostasis links lysosomal malfunction to 
mtDNA depletion and induction of the innate immune response 
 
Sphingolipid metabolism was found to be crucial for the mechanism of crosstalk between 
lysosomes and mitochondria in Niemann-pick disease. Impaired lipid metabolism is not 
implicated in all LSDs, however, suggesting that different mechanisms might mediate interplay 
between organelles in different LSDs. Nevertheless, overlaps in phenotypes between LSDs 
might also suggest common mechanisms which can be attributed to intra-lysosomal steric 
hindrances following substrate accumulation and consequent secondary enzyme deficiencies 
(Platt et al., 2012). This is further demonstrated by our findings in the mouse model of Pompe’s 
disease (GAA-/- mouse). Although Pompe disease is a glycogen storage disorder, we find that 
the Pompe’s disease model shares common features with other LSDs while presenting distinct 
mechanisms and phenotypes of organelle communication. 
 
4.2.1 Mitochondrial genome defects in Pompe’s disease 
It is worthy to underline that this study presents the first line of evidence of cerebral involvement 
in the pathomechanisms of Pompe’s disease. The disease typically causes extensive glycogen 
accumulation with widespread neuromuscular impairments and cardiomyopathy. The only 
other evidence of CNS involvement was demonstrated recently in the spinal cord of GAA-/- mice 
by Fuller and colleagues (Turner et al., 2016). In addition to mitochondrial defects which were 
previously reported in striated muscles of GAA-/- mice (Lim et al., 2015), we report widespread 
mtDNA defects for the first time in brain and heart tissues of GAA-/- mice and in MEFs extracted 
from these mice. Strikingly, the decline in mtDNA copy numbers in the cortex and in the heart 
of GAA-/- mice do not seem to be a consequence of mitochondrial biogenesis, which was 
decreased in the cortex but robustly induced in the heart of GAA-/- mice. The production of 
functional mitochondria requires cooperation between nuclear and mitochondrial genomes. As 
a result, an imbalance between the expression of nuclear- and mtDNA-encoded mitochondrial 
genes has detrimental consequences for cell survival. Larsson et al. (1998) showed that 
oxidative phosphorylation (OXPHOS) is markedly disrupted when mtDNA-encoded respiratory 
chain subunits are not expressed. Interestingly, selective transactivation of nuclear-encoded 
mitochondrial genes via c-myc results in the production of misassembed and defectvie 
OXPHOS complexes and leads to apoptosis induction (Morrish et al., 2003). Evidence of such 
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imbalance may pertain to cardiac tissues (one of the most affected tissues) in Pompe’s disease, 
which show reduced mtDNA copy number and increased mitochondrial biogenesis. It would be 
particularly curious to know whether imbalance between the expression of nuclear and 
mitochondrial genomes contributes to Pompe’s disease pathology in the heart. 
It is noteworthy that mtDNA depletion progressively worsened in the cortex as mice aged 
(Figure 34). Taken into consideration the reports of two independent studies that mtDNA copy 
number is reduced in patients with neurodegenerative disorders (Gui et al., 2015; Pyle et al., 
2015), render our findings more remarkable. In addition, the role of lysosomal and 
mitochondrial crosstalk in neurodegenerative disorders (e.g. PD) has been known for some 
time now (Burbulla et al., 2017; Osellame et al., 2013). It is therefore likely that mtDNA defects 
sit at the crossroads between mitochondrial and lysosomal interplay in LSDs and 
neurodegenerative diseases. 
4.2.2 Mechanisms of mtDNA depletion in Pompe’s disease 
Similarly to mtDNA depletion, TFAM protein amounts were decreased in all examined tissues 
and in MEFs of GAA-/- mice. Although this result initially presented a ‘chicken-and-egg’ problem, 
given that TFAM and mtDNA regulate the levels of each other, we demonstrated that mtDNA 
copy number decline was not a consequence of TFAM depletion. Indeed, restoring TFAM 
amounts to control levels by increasing mTORC1 activity had no noticeable impact on mtDNA 
copy number levels. As demonstrated by Matsushima et al. (2010), when not bound to mtDNA, 
TFAM is targeted for degradation by Lon proteases. This might account for the loss of TFAM 
in GAA-/- mice, especially since restored TFAM levels coincided with reduced Lon protease 
levels (Appendix Figure 57). 
mtDNA depletion syndromes are not restricted only to mutations in genes that regulate mtDNA 
maintenance. Indeed, mutations in genes that regulate components of nucleotide metabolism 
have been implicated in mtDNA depletion syndromes (reviewed in El-Hattab et al., 2017), 
suggesting that nucleotide availability is crucial for mtDNA maintenance and stability, especially 
in post-mitotic cells like neurons. This study demonstrated that mtDNA defects were prevalent 
only under conditions where cell division was slowed down or halted. Subsequent metabolite 
profiling of cells with downregulated GAA levels showed impaired nucleotide metabolism with 
reduced concentrations of intermediates of purine and pyrimidine metabolic pathways. 
Metabolic profiling of Pompe’s disease cells was recently published (Sato et al., 2016), and 
findings like increased glycolysis and increased nitrogen metabolism were corroborated by our 
study. Contrary to our findings, purine metabolism was found in this report to be increased in 
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Pompe’s disease cardiomyocytes. Given that the cardiomyocytes used in Sato et al. (2016) 
were derived from induced pluripotent stem cells prior to metabolomic profiling, it is likely that 
metabolic reprogramming during differentiation influenced some of the outcomes in this study. 
Nevertheless, we enhanced nucleotide metabolism via folic acid supplementation. The folate 
cycle shuttles one-carbon units to specific biosynthetic enzymes, which are involved, for 
example, in purine and in deoxythymidine monophosphate synthesis (Nilsson et al., 2014). 
Folate supplementation induced the levels of MTHFD2, whose bi-functional activity in folate 
metabolism is crucial also for nucleotide biosynthesis (Di Pietro et al., 2004). Remarkably, 
mtDNA defects in GAA-/- MEFs were rescued following folate supplementation. Interestingly, in 
the “Deletor” mouse, a model for adult-onset mitochondrial myopathy, Nikkanen et al. (2016) 
showed that mtDNA maintenance defects resulted in increased demand for one-carbon units 
for purine and methionine synthesis. The increased demand for nucleotides ultimately 
remodeled cytoplasmic metabolic pathways and contributed to myopathy. Intriguingly, 
myopathy is a hallmark of Pompe’s disease. Therefore, it is plausible that the beneficial effects 
of folate supplementation in mtDNA defects stem from a negative feedback loop, where folate 
rapidly makes nucleotide available, lowers the excessive demand for one-carbon metabolism 
and dampen metabolic remodeling. It is noteworthy that folate supplementation had previously 
been shown to ameliorate mitochondrial and mtDNA defects in a Drosophila model of 
Parkinson’s disease (Tufi et al., 2014). It would be particularly relevant to study the role of 
deoxyribonucleotide (dNTP) supplementation in reversing mtDNA depletion in Pompe’s 
disease. This is especially interesting, since dNTP supplementation bypasses the need for 
folate metabolism and nucleotide biosynthesis.  
 
4.2.3 Lysosomal malfunction impairs iron homeostasis 
Although the activity of ribonucleotide reductases is crucial for nucleotide metabolism, 
especially for mtDNA replication in quiescent cells (Pontarin et al., 2012), no differences in the 
levels of ribonucleotide reductase subunit p53R2 were found in GAA-/- mice and their wild-type 
littermates. Nevertheless, the activity of ribonucleotide reductases depends largely on iron 
bioavailability, a required co-factor for initiation of nucleotide reduction (Bourdon et al., 2007; 
Guittet et al., 2001). In line with this, results from two independent experiments suggested iron 
deficiency in GAA-/- mice. Despite retaining increased levels of the catalytic subunit of 
respiratory chain complex IV, cortical mitochondria from GAA-/- mice showed about 50% 
reduction in complex IV activity staining. The most likely basis for this observation is reduced 
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bioavailability of iron, which is an essential component of heme, a required protein for electron 
transfer to molecular O2. Furthermore, the typical cellular response to iron deficiency, increased 
transferrin receptor levels and decreased ferritin levels were observed in the cortex and in 
MEFs of GAA-/- mice. In addition, functional iron deficiency was confirmed in GAA-/- MEFs by 
the findings that cellular ferrous iron (Fe2+) concentrations were decreased while total iron 
concentrations were unchanged in GAA-/- cells. Altogether, these results implicate lysosomal 
dysfunction in impaired iron homeostasis since the reduction of Fe3+ to Fe2+ occurs in the 
lysosome, and lysosomal activity mediates the release of free iron to the cytoplasm (Rouault, 
2013). 
Iron, which forms part of heme and iron-sulfur clusters, is an indispensable trace element for 
mammalian metabolism, and functions as a cofactor in several metabolic reactions. 
Interestingly, iron deficiency and iron overload have detrimental consequences for cellular 
metabolism and survival. Iron deficiency was recently demonstrated to cause dopaminergic 
neurodegeneration in mice (Matak et al., 2016), while the role iron overload, in oxidative stress 
via the Fenton reaction has been well described (Winterbourn, 1995). As a result, 
understanding iron metabolism and the mechanisms of iron homeostasis, especially in LSDs, 
is becoming increasingly relevant, since mounting evidence suggests impaired iron handling in 
the pathogenesis of some LSDs. For instance, clinical manifestations of most LSDs in the 
newborn include anemias, which are dependent on iron availability (Staretz-Chacham et al., 
2009). In addition, impaired myelination was recently associated with functional iron deficiency 
in a mouse model of mucolipidosis type IV (Grishchuk et al., 2015). The lysosomal lumen 
serves as a major catabolic hub for several macromolecules, including iron-containing proteins, 
such as ferritin and OXPHOS complexes. Owing to this role, impaired lysosomal iron handling 
in LSDs is now recognized as a ‘double-edged sword’ (Kurz et al., 2008). On one hand, 
accumulation of iron in the lysosome compounds lysosomal deficits in LSDs and has been 
shown to initiate apoptosis or necrosis through lysosomal membrane permeabilization (Kurz et 
al., 2008; Zhao et al., 2003). On the other hand, lysosomal build-up of iron makes it less 
available to be incorporated into the several iron-containing proteins and as a cofactor in 
metabolic reactions (Kurz et al., 2008). It is therefore plausible that lysosomal mishandling of 
iron in GAA-/- mice contributes to the reduced activity of complex IV of the respiratory chain and 
mitochondrial dysfunction, as well as reduced ribonucleotide reductase activity and impaired 
nucleotide metabolism. Although our findings highlight a role of iron in linking lysosomal 
malfunction to mitochondrial dysfunction in Pompe’s disease, the mechanism involved 
warrants further investigation. 
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 4.2.4 Cellular iron levels impact mtDNA copy numbers 
In addition, the implications of the role of iron in ribonucleotide reductase activity suggest that 
modulating iron levels in cells should be sufficient to impact mtDNA copy numbers. In line with 
this reasoning, deferoxamine-mediated iron deficiency resulted in a robust decline in mtDNA 
copy numbers in control cells. Interestingly, deferoxamine, which is a prescribed iron chelator 
for iron overload in humans, has been shown to mainly act by chelating lysosomal iron (Doulias 
et al., 2003). This further illustrates the role of lysosomal iron in mtDNA defects in GAA-/- mice. 
Likewise, MEFs extracted from IRP1-/- and IRP2-/- mice that specifically present functional iron 
deficiency had decreased mtDNA copies, thereby confirming the role of iron in mtDNA stability. 
Conversely, iron repletion, like folate supplementation, rescues mtDNA defects in GAA-/- MEFs. 
mtDNA maintenance is a tightly regulated process and defects in mtDNA have been linked to 
several human mitochondrial diseases (DiMauro and Davidzon, 2005). It is therefore striking 
how iron levels adequately play such a crucial role in regulating mtDNA copy number level, 
given that modulation of iron levels is common in clinical practice. Our findings in Pompe’s 
disease implicate iron and folate metabolism in mtDNA defects. It would be particularly 
interesting to understand the mechanistic connection between iron and folate metabolism. 
 
4.2.5 Induction of innate immune response in GAA-/- mice 
mtDNA was first demonstrated by Zhang et al. (2010) to contain damage-associated molecular 
patterns (DAMPs) which are sensed by TLR9 with a subsequent induction of the innate immune 
response. Accordingly, it is expected that mtDNA defects would trigger the innate immunity. 
Consistently, this study demonstrates by three independent experiments that innate immune 
response induction is prevalent in GAA-/- mice. We found increased gene expression of all 
components of the TLR9-mediated pathway of innate immune response activation in the brain 
and in the heart of GAA-/- mice. Interestingly, this response was found to be likely dependent 
on TLR9 (and its agonist, mtDNA), because GAA-/- MEFs, which poorly express functional 
TLR9 (Ewald et al., 2008), did not show induction of the immune response, despite displaying 
mtDNA defects. Increased expression of cytokines and chemokines following TRL9 signaling 
serve to recruit immune cells to the site of DAMPs. This was supported by evidence of immune 
cell infiltration in the CNS by magnetic resonance spectroscopy. Indeed T2 relaxation time of 
water protons was decreased in the cortex, striatum, and thalamus of GAA-/- mice (Table 16). 
Reduced T2 relaxation time of water protons has previously been shown to be a reliable in vivo 
index of macrophage or glial cell infiltration in the brain (Watanabe et al., 2015).  
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In addition, gliosis was confirmed in GAA-/- mice, which showed an increase in the number of 
GFAP positive cells in the cortex. Given that distinct cell populations are implicated in the 
induction of gliosis, including microglia and astrocytes, it is of utmost priority to identify which 
glial cell type is activated in the cortex of GAA-/- mice. After demonstrating mtDNA defects in a 
lysosomal storage disorder, and taking into account other reports, which show mtDNA defects 
in neurodegenerative diseases (Gui et al., 2015; Keogh and Chinnery, 2015; Pyle et al., 2015), 
it is not surprising that induction of the inflammatory response is a hallmark of most LSDs and 
neurodegenerative diseases (reviewed in Bosch and Kielian, 2015; Vitner et al., 2015). 
 
4.2.6 Iron rescues mtDNA defects and induced immune responses 
We demonstrate that the mechanism of mtDNA copy number decline and its consequences in 
GAA-/- mice could be targeted to ameliorate the observed defects. We showed by preliminary 
evidence in GAA-/- mice at 2 months of age that in vivo dietary iron supplementation rescues 
mtDNA defects in the cortex. Interestingly, reversing mtDNA defects in GAA-/- mice also 
decreased the previously induced innate immune response, further validating the mechanism 
of mtDNA defects that we uncover in this study. In addition, the persistence of lysosomal 
malfunction implies that if not modulated, mtDNA defects would continually trigger the immune 
response resulting potentially in chronic inflammation, which is known to be deleterious for 
affected tissues and cells (Oka et al., 2012). Although remarkable, it must be emphasized that 
these results are preliminary since all in vivo experiments in this study were carried out with 
mice at 6 months of age. Results at 6 months following dietary iron supplementation in GAA-/- 
mice will be communicated in due course. 
Taken together, the results of this study establish that mtDNA intersects both mitochondria and 
lysosomes and that iron plays a crucial in linking lysosomal dysfunction to mtDNA defects as 
illustrated in Figure 51. This model posits that impaired iron homeostasis, due to lysosomal 
malfunction in Pompe’s disease, results in reduced bioavailability of iron, which affects the 
function of iron-containing proteins, including respiratory chain complexes and ribonucleotide 
reductases. The ensuing mitochondrial stress due to respiratory chain malfunction, and 
reduced activity of ribonucleotide reductases, ultimately affect mtDNA maintenance leading to 
its loss. Circulating mtDNA reaches the lysosome via the endocytic pathway, while mtDNA 
contained in mitochondria reaches the lysosome via mitophagy. Within the lysosome, mtDNA 
acts as agonist of the TLR9 signaling pathway to induce innate immunity. Based on the findings 
of this study and other reports, we propose that modulating mtDNA defects using iron levels 
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may provide crucial therapeutic avenues for LSDs and probably neurodegenerative diseases. 
The results of this study show the potential of modulating iron levels to enhance nucleotide 
metabolism and reverse mtDNA defects, and improve mitochondrial respiratory chain function. 
This study also uncovers the mechanism by which iron plays a crucial role in signaling between 
mitochondria and lysosomes through the tightly regulated mtDNA molecule. 
 
Figure 51| Mechanism of lysosomal-mitochondrial crosstalk in Pompe’s disease – 
Chronic lysosomal malfunction impairs iron homeostasis resulting in functional iron deficiency, 
which impairs mitochondrial function and nucleotide bioavailability for mtDNA synthesis in 
quiescent cells. This results in mtDNA instability and depletion. mtDNA consequently reaches 
the lysosome, via the endocytic and/or autophagy pathways, where it acts as DAMPs to trigger 
TLR9-MYD88-IRF7 pro-inflammatory signaling.( Original illustration, KF Yambire) 
 
  
 
5 Summary and conclusion 
Distribution of cellular functions in membrane-bound organelles such as the nucleus, 
mitochondrion, and lysosome is a hallmark of eukaryotic life. Contrary to earlier views that 
organelles were functionally isolated from each other, unequivocal evidence nowadays 
suggests the existence of interdependent networks between these membrane-limited cellular 
compartments. It is therefore likely that the interplay between these organelles plays a crucial 
role in maintaining organelle homeostasis and contributes to pathologies that arise due to 
organelle dysfunction. As a result, understanding the crosstalk between organelles has become 
of utmost priority to cell biology. 
The findings of this thesis deepen our understanding of the mechanisms of communication 
between lysosomes and mitochondria, and illustrates further that disease pathogenesis that 
arise due to organelle dysfunction engages the crosstalk between organelles as well. Based 
on two different and etiologically distinct LSDs (lipid storage disorder and glycogen storage 
disorder), this study established that lysosomal dysfunction affects mitochondrial homeostasis 
and function at several levels including transcriptional, mtDNA maintenance and ultimately 
functional levels. Interestingly, we had shown previously that mitochondrial malfunction affects 
transcriptional programs of lysosomal biogenesis (Fernández-Mosquera et al., 2017), further 
illustrating that organelle crosstalk via transcriptional regulation may be a widespread 
mechanism. The study further elucidates the underlying mechanisms that link the different LSD 
models to mitochondrial deficits. 
In the context of Niemann-Pick diseases, the findings of this study established how impaired 
sphingosine-1-phosphate signaling, which arises primarily due to impaired catabolic activity of 
lysosomal sphingomyelinases, engages transcriptional repressors of mitochondrial biogenesis, 
KLF2, and ETV1. In addition, the mechanisms of KLF2 and ETV1 induction were demonstrated, 
and these mechanisms highlighted the therapeutic potential of sphingosine-1-phosphate 
modulation in ameliorating features of Niemann-Pick diseases. Interestingly, modulators of 
sphingosine-1-phosphate signaling have been the subject of phase III clinical trials in multiple 
sclerosis, which exacerbates some features of Niemann-Pick disease. In closing, our data 
establish the contribution of lysosomal and mitochondrial crosstalk in Niemann-Pick diseases 
and underscore the role of sphingosine-1-phosphate signaling in modulating the pathogenesis 
of Niemann-Pick disease. 
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Importantly, this work also provides the first line of evidence of encephalic involvement in 
Pompe’s disease pathology. In Pompe’s disease, mtDNA defects were the most predominant 
mitochondrial phenotype, although increased glycolysis also suggested reduced mitochondrial 
function. Our data established that impaired iron homeostasis due to lysosomal malfunction 
was the main culprit of mtDNA defects in Pompe’s disease. In addition, mtDNA defects are 
associated with prevalent phenotypes of LSDs. Consistent with this, it was demonstrated that 
mtDNA defects promoted pro-inflammatory signaling via TLR9-mediated induction of the innate 
immune response, which subsequently resulted in gliosis in the cortex. Remarkably, the 
mechanisms elucidated in this study were valid in vivo since modulating iron levels was 
sufficient to reverse phenotypes of mtDNA defects and dampen the activated innate immunity 
in Pompe’s disease. This study provides evidence that supports modulation of Pompe’s 
disease pathology through dietary iron supplementation by reversing mitochondrial defects. 
Iron is a safe and prescribed dietary supplement in humans, which based on our findings, might 
be beneficial to Pompe’s disease patients. 
 
5.1 Perspectives 
As with most scientific endeavors, this work has contributed to broadening our knowledge and 
understanding of the concepts of organelle interdependence, but more importantly, it raises a 
wealth of new questions to be addressed in subsequent studies. In line with this, it would be of 
utmost interest to explore the KLF2-ETV1-NRF1 network of transcriptional regulation of 
mitochondrial biogenesis in the context of other lysosomal malfunction states. It must be 
emphasized that signaling pathways between organelles go beyond transcriptional networks 
and these signaling routes require further investigation to enhance our understanding. The 
concept of organelle interplay is increasingly becoming clearer; however, its role in the 
pathogenesis of various diseases is not yet appreciated. Our evidence of CNS involvement in 
Pompe’s disease is interesting since it presents a slower progression of the disease, whose 
molecular mechanisms we hope to investigate. mtDNA copy number loss has been proposed 
as a biomarker for neurodegenerative diseases, suggesting that it is worth investigating the 
mechanisms of mtDNA maintenance in the CNS. 
Although this work was primarily aimed at understanding some of the mechanisms of crosstalk 
between lysosomes and mitochondria, the findings of the study delineated mechanisms that 
underpin human disease. To this end, the therapeutic avenues that were elucidated in this 
study warrant further exploration to understand their potential in protecting against diseases. 
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Specifically, our findings establish that Pompe’s disease shares some common features with 
other neurodegenerative diseases (e.g., Parkinson’s disease), including mtDNA defects and 
impaired iron homeostasis. It would be interesting to know whether the same mechanism 
mediates the mtDNA defects in neurodegenerative disorders, and whether modulating iron 
levels could be beneficial.  
This work does not exhaust the subject of organelle crosstalk. We have only elucidated some 
mechanisms of communication between lysosomes and mitochondria. However, mitochondria 
are known to contact other organelles, including the ER and peroxisomes, physically or via 
signaling pathways. For example, the mitochondria-ER contact sites have been the subject of 
intense research. It is particularly interesting to understand whether mitochondrial crosstalk 
with ER influences lysosomal function, and the mechanisms of communication between 
lysosomes and mitochondria. The interplay between mitochondria and peroxisomes has partly 
been established. These organelles are known to share important metabolic functions, as well 
as proteins that regulate their function. It is particularly thought-provoking to know whether a 
functional interdependent network exists between lysosomes, mitochondria and peroxisomes. 
Understanding how metabolic cues from organelle crosstalk are integrated by the nucleus in 
driving cellular functions through gene expression would be especially interesting. 
Finally, understanding nature has been the ultimate quest of scientific endeavors. Despite 
considerable efforts along these lines, nature continually outpaces science and leaves us 
always with a wealth of questions to be addressed. For instance, eukaryotes are thought to 
have acquired membrane-bound compartments more than a billion years ago. Although there 
is an enormous wealth of knowledge on the basic role that these organelles play in ensuring 
cell survival, and the cooperation between multiple organelles in the execution of some cellular 
functions, our understanding of the mechanisms that regulate organelle function and interplay 
are still limited. It is my hope that this work, which sought to uncover some of the mechanisms 
of interdependence between lysosomes and mitochondria, has contributed, though 
insignificant, to our understanding of the functions of these subcellular compartments.  
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Figure 52| Expression levels of ETS transcription factors in NP patient cells – 
Transcript levels of ETV1 are increased by about two-fold in NP fibroblasts while ELK1 levels 
are unchanged. p < 0.001 (***); Student’s t-test; mean ± SEM, N = 8; SEM: standard error of the 
mean 
 
 
Figure 53| KLF2, ETV1 and TFAM protein levels in desipramine-treated cells – 
Desipramine-treated human fibroblasts, like NP fibroblasts, showed increased KLF2 and ETV1 
protein levels, and reduced TFAM protein levels. Graphs are mean ± SD, N = 3; p < 0.05 (*) and 
p <0.00 (***); Student’s t-test; SD: standard deviation 
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Figure 55| Increased glycolysis in GAA-/- MEFs – Extracellular acidification rate 
measurements showed increased basal and maximal glycolytic capacities in GAA-/- MEFs. p < 
0.001 (***); Student’s t-test; mean ± SEM, N = 8; SEM: standard error of the mean  
 
 
Figure 54| Enhanced S1P signaling induces mitochondrial gene expression – 
Treatment of control human fibroblasts with Sew2871 (S1P receptor agonist) results in 
increased mitochondrial transcript levels. 
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Figure 56| mTORC1 activity in GAA-/- cortex – mTORC1 activity in the cortex of GAA-/- mice 
is reduced. This is demonstrated by decreased phosphorylation of ribosomal protein S6 at 
Serine 235/236. Band quantifications are represented as mean ± SEM, N = 8; p < 0.01 (**); 
Student’s t-test; SEM: standard error of the mean 
 
 
Figure 57| LONP1 levels are partly dependent on mTORC1 activity in GAA-/- MEFs 
– LONP1 protein levels in GAA-/- MEFs are partially reduced following siTSC2-mediated 
induction of mTORC1 activity. Band quantifications are depicted as mean ± SD for triplicate 
samples; p < 0.05 (*); Student’s t-test; SD: standard deviation 
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Figure 58| RRM2B gene expression in GAA-/- mice – RRM2B transcript levels in the cortex 
(A) and in the heart (B) of GAA-/- mice. Gene expression levels of RRM2B are unchanged based 
on p > 0.05; Student’s t-test. Graphs represent mean ± SEM, N = 8; SEM: standard error of the 
mean 
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